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Abstract	
	Introduction	Ischemia	Reperfusion	 Injury	 (IRI)	 has	 a	 significant	 influence	 on	 patient	 outcomes	after	renal	transplantation.		The	role	of	Nitric	Oxide	(NO)	in	IRI	is	controversial	with	evidence	for	both	protective	and	deleterious	effects.		The	aim	of	this	project	was	to	investigate	 NO	 in	 recipients	 of	 Donation	 After	 Cardiac	 Death	 (DCD)	 renal	transplants,	who	are	expected	to	have	high	rates	of	Delayed	Graft	Function	(DGF)	as	a	result	of	IRI,	and	to	correlate	this	with	their	inflammatory	response	and	induction	immunosuppression.			Methods	Plasma	samples	were	collected	from	35	recipients	of	DCD	renal	transplants	around	the	time	of	transplantation.		NO2-	and	NO3-	were	measured	using	the	Griess	reaction	and	Ozone	chemiluminescence	and	cytokines	were	measured	using	Luminex.		Results	At	2	and	8	hours	post	reperfusion	of	the	transplanted	kidney	changes	in	NO2-	were	associate	with	 the	 age	of	 the	 recipient	 (p	 =	 0.05	 and	0.001	 respectively)	 and	 at	 8	hours	very	strongly	related	to	the	warm	ischemic	time	(p	<	0.0005).		At	8	hours	post	reperfusion	there	was	a	strong	negative	correlation	between	the	age	of	the	recipient	and	the	change	of	NO3-	(p	=	0.002).		IL-6	and	IL-10	were	found	to	increase	significantly	at	30	minutes	and	2	hours	after	reperfusion	(p	<	0.0005).		IL-6,	IL-10	and	TNF-α	were	all	influenced	significantly	by	induction	immunosuppression	and	at	30	minutes	post	reperfusion	changes	in	NO2-	were	also	affected	by	the	induction.					
		 IV	
Conclusion	Changes	in	NO2-	were	influenced	by	factors	effecting	renal	IRI	and	also	by	induction	immunosuppression.	 	 Increasing	 age	 was	 associated	 with	 dampening	 of	 the	 NO2-	and	NO3-	response.	 	Cytokines	levels	rose	after	reperfusion	of	the	kidney	and	their	changes	were	modified	by	induction	immunosuppression.																										
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1.1.		The	History	of	Renal	Transplantation	
	Transplantation	is	a	comparatively	new	surgical	specialty,	despite	this,	in	just	a	few	decades	it	has	become	the	gold	standard	of	treatment	for	patients	with	end	stage	 renal	 failure.	 	 The	 following	 paragraphs	 are	 a	 summary	 of	 the	 pivotal	discoveries	that	have	shaped	the	field	of	clinical	transplantation.			
	
1.1.1.		Surgical	technique	
	The	 first	 successful	 human	 renal	 transplant	was	 performed	 in	 1954,	 however	this	 was	 preceded	 by	 half	 a	 century	 of	 experimental	 work.	 	 During	 the	 first	decade	 of	 the	 20th	 century	 experiments	were	 conducted	 in	Austria	 and	 France	using	 animal	 models	 (1).	 	 Alexis	 Carrel	 worked	 particularly	 on	 improving	methods	of	vascular	anastomosis	and	 is	 credited	with	establishing	 the	modern	method	of	vascular	suturing.	 	As	well	as	his	contribution	to	the	technicalities	of	transplantation	 he	 considered	 the	 conditions	 that	 the	 donor	 kidney	 should	 be	kept	 in	 prior	 to	 implantation	 concluding	 that;	 “the	 blood	 supply	 of	 the	
transplanted	 kidney	 should	 not	 be	 occluded	 for	 more	 than	 50	 to	 60	 minutes	
without	consequences	to	its	subsequent	function”.		He	also	suggested	that	cooling	may	have	some	value	(2).		Today	the	warm	and	cold	ischemic	times,	to	which	he	was	eluding,	are	known	to	be	pivotal	in	transplant	outcomes	and	as	we	will	see	later	 in	 the	 text,	 are	 particularly	 important	 to	 this	 project	 in	 the	 context	 of	Ischemia	Reperfusion	Injury	(IRI).		By	the	start	of	the	First	World	War	technical	aspects	 of	 renal	 transplantation	 had	 been	 established,	 however,	 despite	 the	improvements	 in	 surgical	 technique	 the	 grafts	 all	 failed.	 	 Although	 it	 was	acknowledged	 that	 the	 recipient	 was	 likely	 to	 be	 “rejecting”	 the	 organ,	 the	mechanism	 was	 uncertain	 and	 as	 a	 result	 interest	 in	 organ	 transplantation	diminished	(1).		
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1.1.2.		The	immune	system	
	The	 next	 real	 period	 of	 progression	 in	 transplantation	 was	 the	 1950’s	 when	Peter	Medawar	defined	the	biological	features	of	graft	rejection	and	showed	it	to	be	an	immunological	process	(3).		Medawar	also	contributed	to	the	work	which	lead	 to	 the	 proposal	 that	 immunological	 tolerance	 may	 be	 induced	 by	suppression	of	 the	 immune	system	(4).	 	 Initially	 this	was	attempted	using	total	body	irradiation	followed	by	concurrent	renal	and	bone	marrow	transplantation.	However,	 this	 practice	 had	 an	 unacceptably	 high	 mortality	 and	 with	 the	introduction	 of	 chemical	 immunosuppression	was	 abandoned	 (5).	 	 	 Following	the	discovery	of	HLA	(Human	Leucocyte	Antigens)	in	1952	by	Jean	Dausset	there	was	a	rapid	expansion	in	knowledge	about	the	human	immune	system	leading	to	the	concepts	of	tissue	typing,	histocompatibility	and	cross-matching	(6).		
	
1.1.3.		Clinical	application	
	Dr.	 Joseph	 Murray	 performed	 the	 first	 successful	 renal	 transplant	 between	identical	 twins	 in	Boston	on	December	23rd	1954.	 	 It	was	preceded	by	years	of	experimental	work	on	dogs	and	was	the	beginning	of	live	donation	of	organs	as	well	 as	 solid	 organ	 transplantation.	 	 Murray	 pioneered	 the	 field	 of	 transplant	immunology	and	indeed	transplant	surgery.		In	1990	he	was	awarded	the	Nobel	prize	 for	 Medicine	 for	 the	 first	 successful	 transplantation	 of	 kidneys	 from	 a	genetically	identical	twin,	from	a	non	identical	twin	and	from	a	cadaveric	donor.			
	
1.1.4.		Organ	donation	
	Murray	 is	well	known	for	his	work	in	renal	 transplant	surgery.	 	However,	he	is	less	renowned	for	his	contribution	to	the	development	of	brain	death	status	and	organ	recovery,	which	was	an	essential	step	for	the	expansion	of	deceased	donor	organ	 transplantation.	 	 In	 1967	 a	 committee,	 including	 Murray,	 set	 out	 to	objectively	 define	 criteria	 for	 death	 in	 the	 context	 of	 an	 irreversibly	 comatose	
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patient;	 they	 concluded	 “the	 time	honored	 criteria	 of	 stoppage	 of	 the	 heartbeat	
and	circulation	are	indicative	of	death	only	when	they	persist	long	enough	for	the	
brain	 to	 die”.	 	 This	 definition	 allows	 the	 medical	 profession	 to	 legally	 obtain	organs	from	a	deceased	donor,	in	the	UK	cadaveric	organs	make	up	over	half	of	those	used	for	renal	transplantation	(7).			
1.1.5.		Immunosuppression	
	By	the	1960’s	foundations	were	in	place	for	the	topic	of	transplant	immunology	to	 develop	 into	 clinical	 practice;	 the	 concept	 of	 chemical	 immunosuppression	had	 been	 introduced,	 initially,	with	 6-mercaptopurine	 (Purinethol)	 and	 its	 less	toxic	derivative	Azathioprine.	Azathioprine	later	proved	to	be	the	more	effective	of	 the	 two	 drugs	 by	 permitting	 survival	 of	 the	 graft	 whilst	 maintaining	 other	protective	 immune	responses	 in	 the	recipient.	It	was	 later	discovered	that	dual	therapy	with	 steroids	produced	a	 synergistic	effect	 (1).	 	 In	 the	 first	half	of	 the	1960’s	transplants	were	performed	from	cadaveric	and	live	donors	with	success	using	 dual	 therapy.	 	 In	 1966	 a	 triple	 drug	 program	was	 introduced	 by	 adding	antilymphocyte	globulin	(ALG)	(8).				As	 the	 specialty	grew,	 so	did	 its	 infrastructure;	 societies	were	 formed	 to	 share	information	on	evolving	HLA	typing	methods,	organ	sharing	schemes	and	organ	procurement.		Governments	became	involved	and	public	awareness	increased;	in	1971	 the	 Kidney	 Donor	 Card	was	 introduced	 in	 Britain	 to	 be	 replaced	 by	 the	Multi-Organ	 Donor	 Card	 10	 years	 later.	 	 HLA	 matching	 as	 well	 as	 the	introduction	of	a	new	immunosuppressant	called	Cyclosporine	improved	results	of	 organ	 transplantation.	 	 It	 also	 provided	 sufficient	 immunosuppression	 to	permit	successful	liver,	pancreas,	heart	and	lung	transplant	and	remained	within	the	 drug	 regimen	 until	 the	 1990’s	 when	 drugs	 such	 as	 Tacrolimus	 and	Mycophenolic	 acid	 were	 introduced	 (5).	 	 Induction	 therapies	 with	 polyclonal	antibodies	 (ALG	 and	 antithymocyte	 globulin	 (ATG))	 were	 superseded	 by	monoclonal	 therapies;	 OKT3,	 Basiliximab	 and	 Alemtuzumab.	 	 Although,	
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depending	 upon	 the	 clinical	 factors,	 both	 polyclonal	 antibodies	 are	 still	 used	today.		
	
	
1.1.6.		Transplantation	today	
	Renal	transplantation	is	firmly	established	as	the	gold	standard	of	treatment	for	end	 stage	 renal	 failure	and	 it	 is	 an	expanding	area	of	both	 clinical	 activity	and	research	 in	 the	 UK.	 	 One-year	 graft	 survival	 rates	 now	 range	 from	 92-97%,	depending	on	the	type	of	donation	with	patient	survival	at	one	year	between	95-99%.	 	Nationally,	 a	 total	of	4753	organ	 transplants	were	performed	 in	 the	 last	year,	3348	of	which	were	kidney	transplants.		Despite	this,	the	organ	waiting	list	in	the	UK	currently	stands	at	around	6388	patients,	with	5233	patients	waiting	for	 kidney	 transplants.	 	 In	 the	 last	 year	 470	patients	 died	whilst	 active	 on	 the	transplant	 waiting	 list	 and	 a	 further	 875	 were	 removed	 due	 to	 deteriorating	health.	 	 All	 of	 the	 above	 figures	 are	 taken	 from	 the	 Organ	 Donation	 and	
Transplantation	Activity	Report	2016/17	produced	by	NHSBT.		In	order	 to	address	 the	gap	between	supply	and	demand	of	organs,	 transplant	physicians	are	constantly	on	the	look	out	for	ways	to	expand	the	donor	pool	and	improve	 the	 longevity	 of	 grafts.	 	 One	 approach	 to	 this	 is	 the	 use	 of	 extended	criteria	donors	 (ECD)	and	 increased	use	of	donation	after	 cardiac	death	 (DCD)	organs.		DCD	and	ECDs	would	have	previously	been	thought	to	be	unusable	due	to	donor	characteristics	and	long	ischemic	times	and	are	now	being	considered	for	 transplantation	 into	 appropriate	 recipients.	 	 The	 consequence	 of	 this	 for	transplant	 recipients	 is	 that	 these	 organs	 are	prone	 to	higher	 rates	 of	 delayed	graft	 function	 (DGF)	 as	 a	 result	 of	 increased	 ischemic	 injury.	 	 Despite	 the	expected	 difficulties	 that	 come	 with	 use	 of	 marginal	 organs	 the	 prognosis	 for	patients	with	end	stage	renal	failure	who	receive	a	transplant	remains	preferable	to	 spending	 time	on	dialysis.	 	 It	 is	 therefore	 important	 for	patient	outcomes	 to	understand	the	mechanisms	of	injury	that	 these	organs	are	subjected	to	and	to	develop	means	of	reducing	the	injury	sustained.				
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In	 this	project	we	hope	 to	 contribute	 to	 this	 field	of	 research	by	 studying	DCD	kidneys	where	we	would	expect	 to	 find	 rates	 of	delayed	graft	 function	around	50%.		We	will	be	investigating	Nitric	Oxide	(NO)	production,	which	is	one	of	the	pathways	 which	 influences	 ischemic	 injury	 in	 transplanted	 organs	 and	correlating	our	findings	with	clinical	outcomes.		
	
1.2.	Ischemia	Reperfusion	Injury	
1.2.1.		Introduction	
	Ischemia	 reperfusion	 injury	 is	 a	 pathological	 condition	 characterized	 by	 initial	restriction	 of	 blood	 supply	 to	 an	 organ	 followed	 by	 subsequent	 restoration	 of	perfusion	 and	 oxygenation.	 	 IRI	 contributes	 to	 a	 range	 of	 pathology	 including	myocardial	 infarction,	cerebrovascular	accident	(ischemic	stroke),	acute	kidney	injury,	 trauma	 and	 circulatory	 arrest.	 	 It	 also	 presents	 a	 major	 challenge	 for	surgical	specialties	including	organ	transplantation,	cardiothoracic,	vascular	and	general	 surgery.	 	 IRI	 is	 a	 mechanism	 by	 which	 damage	 to	 solid	 transplanted	organs	 occurs	 as	 a	 consequence	 of	 the	 process	 of	 retrieval	 and	 organ	implantation	and	contributes	significantly	to	the	morbidity	and	mortality	rates	in	clinical	 transplantation	 (9).	 	 As	 the	 name	 suggests	 it	 is	 a	 biphasic	 process;	 the	initial	 hypoxia	 deprives	 cells	 of	 the	 energy	 needed	 to	 maintain	 their	 ionic	gradients	 and	 homeostasis.	 	 This	damage	 is	 exacerbated	 on	 reperfusion	of	 the	organ	 when	 an	 inflammatory	 reaction	 is	 triggered	 (10).	 	 The	 result	 of	 this	process	is	endothelial	dysfunction	(9).		Renal	 IRI	 is	 a	 complex	 phenomenon	 with	 many	 variables	 but	 one	 that	 may	significantly	 affect	 patient	 outcomes	 following	 transplantation.	 	 In	 this	 text	we	will	first	explore	the	clinical	consequences	for	the	renal	transplant	patient	of	the	damage	 sustained	 as	 a	 result	 of	 IRI.	 	 We	 will	 then	 consider	 the	pathophysiological	mechanisms	behind	this	damage	and	look	at	the	cellular	and	molecular	reactions	behind	them.		There	are	many	mediators	of	this	process	but	the	focus	of	this	work	is	the	significance	and	effects	of	Nitric	Oxide	(NO)	on	the	endothelium.	 	 As	 part	 of	 our	 investigation	 we	 will	 also	 look	 at	 the	 effect	 that	
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endothelial	 activation	 has	 on	 the	 production	 of	 NO	 and	 the	 cytokines	 that	mediate	this	in	the	context	of	renal	transplantation.				
	
1.2.2.	 	 Clinical	 consequences	 of	 renal	 IRI	 during	 kidney	 transplantation–	
Delayed	Graft	Function		IRI	is	an	inevitable	consequence	of	organ	transplantation;	the	clinical	sequelae	of	IRI	 for	 the	renal	 transplant	recipient	 include	primary	non-function	of	 the	graft,	long-term	 graft	 dysfunction	 and	 DGF.	 	 DGF	 is	 a	 clinical	manifestation	 of	 acute	kidney	 injury	 in	 the	 immediate	 postoperative	 period	 and	 may	 result	 in	 the	recipient	 requiring	 temporary	 dialysis.	 	 The	 prevalence	 of	 DGF	 after	 deceased	donor	 transplants	 is	 reported	 with	 wide	 variability	 (between	 25	 and	 75%).		Shortage	 of	 donors	 has	 resulted	 in	 increased	 use	 of	 DCD,	 as	 well	 as	 use	 of	marginal	 organs	 from	ECDs.	 	 As	 both	 groups	demonstrate	 higher	 rates	 of	DGF	than	donation	after	brain	death	(DBD)	or	living	donor	kidneys,	IRI	and	DGF	are	becoming	increasingly	relevant	subjects	in	the	field	of	transplantation.		The	exact	definition	of	DGF	is	debated	with	18	different	definitions	identifiable	in	the	literature	(11)!		This	is	problematic	when	comparing	studies	that	use	DGF	as	an	 endpoint	 and	 explains,	 partly,	 the	wide	 variation	 in	 its	 reported	 incidence.		The	most	widely	used	definition	 is	 the	use	of	dialysis	within	the	first	week	after	
transplantation	 (12).	 	 Failure	 of	 a	 fall	 in	 serum	 creatinine	 of	 10%	 on	 two	
consecutive	 days	 in	 the	 first	 postoperative	 week	 is	 an	 alternative	 popular	definition	 as	 it	 is	 a	 more	 objectively	 delineated;	 the	 dialysis	 definition	 is	criticized	because	it	is	subjective	to	clinician	or	unit	practice.		Irrespective	of	how	DGF	 is	 defined	 it	 is	 significantly	 more	 prevalent	 in	 DCD	 transplants	 with	 the	incidence	being	double	that	found	among	DBD	transplants.	 	Interestingly,	when	DGF	 does	 occur,	 it	 translates	 to	 poorer	 graft	 function	 at	 one	 year	 after	transplantation	 in	 kidneys	 from	DBD	but	 not	 from	DCD	donors	 (12,	 13).	 	 This	implies	 a	 different	 pathophysiological	 process	 between	 the	 two	 groups.	 	 To	further	support	this,	the	duration	of	cold	ischemic	time	does	not	appear	to	have	an	effect	on	DBD	kidneys	however	 is	 associated	with	 reduced	graft	 survival	 in	
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DCD	transplants	(14).		The	consequences	of	DGF,	regardless	of	donor	group,	are	clinically	significant	and	include	an	increased	potential	for	early	graft	loss,	acute	and	chronic	rejection	and	patient	mortality	(15-18).	 	We	can	see	therefore	that	IRI	 carries	 a	 significant	 risk	 of	 morbidity	 and	 mortality	 for	 the	 recipients	 of	kidney	transplants	and	as	such	is	the	focus	of	multiple	avenues	of	investigation;	this	study	aims	to	explore	the	impact	of	nitric	oxide	on	this	injury.	
	
	
1.2.3.	Pathophysiology	of	renal	IRI		
	Historically	DGF	was	thought	 to	be	due	to	kidney	tubular	damage	secondary	to	ischemia	 and	 hypoxia	 sustained	 during	 organ	 retrieval.	 	 It	 is	 now	 thought	 to	represent	the	tissue	damage	sustained	from	ischemic	reperfusion	injury.		In	the	preceding	discussion	we	can	see	that	there	are	differences	between	donor	types	in	 renal	 transplantation;	 the	 patient	 group	 studied	 in	 this	 work	 is	 the	 cohort	receiving	 renal	 transplants	 from	DCD	donors;	 therefore	we	shall	now	consider	the	 pathological	 changes	 that	 occur	 during	 the	 ischemic	 phase	 and	 on	reperfusion	within	 the	 kidney	 as	well	 as	 the	 resultant	 IRI	 and	 the	 differences	between	donor	groups.		1.2.3.1.	Ischemia		As	part	of	 the	process	of	organ	 retrieval	 and	 storage	prior	 to	 implantation	 the	oxygen	supply	to	the	organ	is	suspended.	 	This	causes	a	switch	from	aerobic	to	anaerobic	metabolism	 and	 consequentially	 a	 fall	 in	 intracellular	 adenosine	 tri-phosphate	(ATP)	levels	and	lactic	acidosis.		Tissue	hypoxia	causes	destabilization	of	 the	 cellular	 structure	 with	 leakage	 of	 lysosomes,	 dysfunction	 of	 the	 Na+	/K+/ATPase	and	Ca2+	pumps	and	consequent	 intracellular	oedema	(19).	 	These	changes	 are	 accompanied	 by	 opening	 of	 the	 mitochondrial	 permeability	transition	pore	which	disrupts	the	membrane	potential	of	the	mitrochondria	and	further	attenuates	ATP	production.		Within	the	kidney,	afferent	arterioles	act	as	baro-receptors	and	trigger	activation	of	renin	 synthesis	 in	 the	macula	densa	 in	an	attempt	to	maintain	the	perfusion	pressure.	 	As	anaerobic	metabolism	takes	over,	 oxygen	 free	 radicals	 accumulate,	 disrupting	 intracellular	 metabolic	
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processes	 and	 trans-cellular	 solute	 gradients.	 	 This	 ultimately	 damages	 the	proximal	tubular	cell	structure	(20).		1.2.3.2.	Reperfusion	On	reperfusion	with	oxygenated	blood	tissue	hypoxia	is	relieved	and	pH	returns	to	 normal,	 however	 cellular	 injury	 is	 exacerbated;	 increased	 production	 of	reactive	oxygen	species	(ROS)	and	reactive	nitrogen	species	(RNS)	such	as	super	oxide	radicle	(O2-)	and	peroxynitirite	(ONOO-)	occur.		These	free	radicals	disrupt	cellular	membranes	and	the	cytoskeleton	and	affect	signal	 transduction	 in	post	hypoxic	cells	resulting	in	the	initiation	of	cell	death	programs	(19-21).	 	Later	in	the	chapter	we	will	see	the	conflicting	interactions	of	NO	with	ROS	and	RNS	that	forms	part	of	the	premise	of	this	project.		In	the	kidney	the	proximal	tubular	cells	produce	 ROS	 and	 the	 injury	 sustained	 as	 a	 result	 of	 hypoxia	 and	 reperfusion	causes	 acute	 tubular	 necrosis	 (ATN),	 leading	 to	 DGF.	 	 These	 processes	 are	common	to	both	types	of	deceased	donation	however	there	are	some	differences	between	DBD	and	DCD	organs.		
DBD	organs	Upon	 brain	 death	 the	 sympathetic	 nervous	 system	 induces	 an	 inflammatory	state	 and	 this	 process	 may	 commence	 long	 before	 organ	 recovery	 (22).	Complement	activation	is	triggered	as	well	as	endothelial	cell	activation	with	up	regulation	of	cell	adhesion	molecules	(intracellular	adhesion	molecule-1	(ICAM-1)	 and	 P-selectin),	 which	 facilitate	 immune	 cell	 localization	 (23-25).	 	 In	 the	kidney,	P-selectin	 in	particular	has	been	associated	with	neutrophil	 infiltration	and	 DGF	 (26).	 	 Endothelial	 activation	 and	 inflammatory	 cell	 accumulation	 is	exacerbated	 by	 thrombin	 (released	 from	 injured	 tissues)	 binding	 to	 the	endothelial	 surface	 causing	 enhanced	 neutrophil	 localization	 (27),	 ultimately	leading	to	endothelial	dysfunction	and	ATN	of	the	kidney.		The	duration	of	brain	death	and	the	time	spent	in	the	intensive	care	unit	(prior	to	organ	retrieval)	are	both	associated	with	DGF	(28,	29).	
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DCD	organs	Although	DCDs	 are	 not	 subject	 to	 the	 physiologic	 effects	 of	 a	 sustained	 period	post	brain	death	prior	to	organ	retrieval,	the	rates	of	DGF	are	highest	in	patients	receiving	organs	 from	DCD	donors.	 	This	 is	attributed	to	the	perfused	 ischemic	time	between	withdrawal	of	treatment	and	asystole	known	as	1st	warm	ischemic	time	(1st	WIT)	(30).		If	the	warm	ischemic	time	is	prolonged	it	results	in	greater	risk	 of	 primary	 non-function	 (31)	 as	well	 as	 increased	 rates	 of	 DGF.	 	 For	 this	reason	there	are	procurement	protocols	(variable	for	each	organ)	that	limit	the	time	 of	 warm	 ischemia	 accepted	 prior	 to	 DCD	 organ	 retrieval.	 	 Although	 in	kidney	 transplantation	 the	 rates	 of	 DGF	 are	 significantly	 higher	 in	 patients	receiving	organs	from	DCD	donors,	the	long-term	outcomes	are	comparable	(32)	and	 DCD	 organs	 seem	 to	 have	 a	 better	 outcome	 after	 DGF	when	 compared	 to	DBD	organs	(33)	implying	underlying	differences	in	the	pathophysiology	of	DGF	between	 the	 groups.	 	 This	 study	 primarily	 investigates	 DCD	 renal	 transplants	due	to	their	higher	incidence	of	DGF.		1.2.3.3.	IRI	in	the	transplanted	kidney	IRI	is	a	dynamic	process	that	may	persist	for	days	after	reperfusion	(34).	 	Once	transplantation	is	complete	the	kidney	responds	to	reperfusion	in	several	ways.		Damaged	vascular	endothelium	releases	endothelin	(ET	1)	causing	pathological	vasoconstriction	 (35).	 	 To	 counteract	 this	 effect,	 renal	 NO	 concentration	increases.	 	 NO,	 which	 is	 produced	 by	 Nitric	 oxide	 synthases	 (NOS),	 at	 low	concentrations	 causes	 vasodilation.	 	 However,	 when	 present	 in	 higher	concentrations	 it	reacts	with	superoxide	to	produce	peroxynitrite	(36).	 	One	of	the	 aims	 of	 this	 study	 will	 be	 to	 attempt	 to	 clarify	 the	 role	 of	 NO	 and	 its	metabolites	 in	 IRI;	 currently	 it	 is	 not	 clear	 whether	 it	 is	 protective	 or	detrimental.	 It	 might	 be	 that	 at	 different	 times	 and	 concentrations	 it	 plays	different	roles.		The	 innate	 immune	 system	 propagates	 the	 inflammatory	 reaction	 in	 IRI;	migration	of	neutrophils	and	macrophages	 into	the	transplanted	kidney	 is	seen	within	6	hours	of	reperfusion	(37).		Macrophages	stimulate	chemokine	synthesis	in	dendritic	cells	which	in	turn	activate	T	lymphocytes	(38).		The	proximal	tubule	
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cells	 secrete	 Tumor	 necrosis	 factor	 alpha	 (TNF-α),	 Interleukin–6	 (IL-6)	 and	(Interlukin-1	 beta)	 IL-1β	 (all	 pro-inflammatory	 cytokines)	 and	 up-regulate	 the	Cxc3	receptor	on	their	basement	membranes.		This	allows	inflammatory	cells	to	breach	the	microvascular	cuff	(39).		Within	the	kidney,	ischemic	injury	results	in	expression	of	toll-like	receptors	(TLRs),	by	tubular	epithelial	and	mesangial	cells,	which	 are	 involved	 in	 regulating	 T	 cell	 activity	 and	 have	 also	 been	 associated	with	acute	rejection(40).		Reperfusion	activates	the	compliment	cascade	causing	cell	lysis	within	the	graft;	in	an	animal	model	C3	has	been	found	to	prime	a	T-cell	mediated	response	contributing	to	acute	rejection	(41).		Part	of	this	project	will	look	at	 the	levels	of	 inflammatory	cytokines	around	the	time	of	 transplantation	and	correlate	this	data	with	other	markers	of	injury.		The	 donors’	 immune	 system	 is	 also	 relevant	 after	 reperfusion;	 the	 donors’	adaptive	immune	response	can	up-regulate	major	histocompatibility	complexes	(MHC)	 (42)	 and	 is	 involved	 directly	 with	 allorecognition.	 	 This	 response	 is	greater	 in	 organs	 from	 older	 donors;	 it	 seems	 that	 there	 is	 an	 age	 associated	increase	 in	 graft	 immunogenicity	 with	 increased	 inflammation,	 immune	recognition	 and	 consequential	 functional	 loss	 (43).	 	 Thus	 donor	 age	 is	 an	important	predictor	of	long-term	outcome	in	organ	transplantation	and	a	factor	we	will	evaluate	in	our	results		To	 summarize,	 IRI	 causes	activation	of	 the	endothelium	and	 inflammation	 that	stimulates	innate	and	adaptive	immune	responses,	leading	to	injury	of	the	graft	kidney.	 	 The	 products	 of	 these	 processes	 are	 associated	 with	 the	 clinical	syndrome	of	DGF.		As	we	have	seen	above,	in	transplantation,	these	mechanisms	are	also	affected	by	donor	factors.	
	
	
1.2.4.	The	cellular	changes	of	IRI	
	IRI	may	cause	cellular	injury	through	several	different	processes,	some	of	which	occur	 synchronously,	 leading	 to	 damage	 of	 the	 endothelium	 and	 consequently	
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the	transplanted	organ.	 	There	are	two	distinct	phases	to	 the	 injury	with	some	pathological	processes	being	attributable	primarily	to	one	rather	than	the	other.				The	 ischemic	 period	 is	 particularly	 associated	 with	 weakening	 of	 the	 barrier	function	 of	 the	 endothelium.	 	 Hypoxia	 causes	 reduced	 levels	 of	 intracellular	cyclic	adenosine	monophosphate	(cAMP)	and	adenylate	cyclase	activity	and	this	results	in	increased	vascular	permeability	and	 leakage	of	the	endothelium	(44).		The	 ischemic	 period	 is	 also	 associated	 with	 alterations	 in	 the	 transcriptional	control	 of	 gene	 expression	 (transcriptional	 reprogramming)(45).	 	 Even	 after	successful	 return	 of	 vascular	 supply	 to	 an	 ischemic	 organ,	 perfusion	 of	 the	tissues	 may	 not	 in	 fact	 be	 restored	 immediately	 due	 to	 persistent	 endothelial	dysfunction;	this	is	known	as	no	reflow	phenomenon	and	is	a	further	extension	to	the	 period	of	 ischemic	 insult	 (9).	 	 It	 is	 caused	 by	 interstitial	 inflammation	 and	endothelial	 swelling	 leading	 to	 obstructive	 micro-vasculopathy	 and	 thus	prolonged	ischemia	(46).		The	 reperfusion	 injury	 phase	 is	 characterized	by	 the	 autoimmune	 response;	 it	involves	 antibody	 recognition	 of	 neoantigens	 (i.e.	 byproducts	 of	 metabolic	pathways)	 and	 subsequent	 activation	 of	 the	 complement	 system	 (47).	 	 In	addition	to	these	processes	occurring,	with	the	appropriate	physiological	stimuli	ischemia	and	reperfusion	together	lead	to	the	activation	of	cell	death	programs	(apoptosis,	 nuclear	 fragmentation,	 plasma	membrane	 blebbing,	 cell	 shrinkage,	and	 loss	 of	 mitochondrial	 membrane	 potential	 and	 integrity),	 autophagy-associated	 cell	 death	 (cytoplasmic	 vacuolization,	 loss	 of	 organelles	 and	accumulation	of	vacuoles)	and	necrosis	(progressive	cell	and	organelle	swelling,	plasma	 membrane	 rupture	 and	 leakage	 of	 proteases	 and	 lysosomes	 into	 the	extracellular	 compartment)(48).	 	 	 Ultimately	 the	 end	 result	 of	 these	 injuries	 is	endothelial	 dysfunction;	 the	 endothelium	 is	 the	 primary	 site	 of	NO	production	and	will	be	considered	in	more	detail	in	the	following	paragraphs.		
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1.2.5.	The	Endothelium	
	The	endothelium	is	the	layer	of	cells	that	line	the	blood	and	lymphatic	vessels,	it	regulates	 vascular	 permeability	 and	 modulates	 vasomotor,	 hemostatic	 and	inflammatory	 responses	 (49).	 	 Its	 relevance	 to	 this	 study	 is	 as	 a	 site	 of	 NO	production	and	one	that	 is	damaged	during	IRI.	 	The	 following	paragraphs	will	explore	 the	 normal	 endothelial	 physiology	 and	 the	 mechanisms	 behind	 its	dysfunction	 following	 IRI.	 	 In	 the	 resting	 state	 the	 endothelium	 is	 inactive,	 its	primary	 function	 being	 to	 facilitate	 blood	 flow	by	 providing	 an	 antithrombotic	surface.	 	However,	 it	 is	 also	vital	 for	maintenance	of	vascular	homeostasis	 and	therefore	is	has	the	capacity	to	alter	its	structure	and	function	accordingly	(50).		1.2.5.1.	Endothelial	activation	The	 vascular	 endothelium	 is	 activated	 in	 response	 to	 adverse	 stimuli	 such	 as	ischemia,	 reperfusion,	 sheer	 stress	 or	 inflammation;	 the	 process	 of	 organ	transplantation	and	therefore	IRI	encompasses	all	of	these	stimuli.		Activation	of	the	 endothelium	 initiates	 a	 cascade	 of	 events	 leading	 to	 increased	 endothelial	permeability	and	dysfunction.		In	response	to	ischemia,	endothelial	cells	express	P-	 selectin,	L-selectin,	platelet-endothelial	 and	 intercellular	adhesion	molecules	which	are	all	involved	in	leucocyte	adhesion.	 	They	also	secrete	cytokines,	such	as	TNF-α	and	IL-1,	6	and	8	and	vasoactive	agents	endothelin	and	thromboxane	A2.		These	substances	induce	other	pro-inflammatory	cytokines	and	promote	the	inflammatory	 responses	 that	 occur	 on	 reperfusion	 (51,	 52).	 	 On	 reperfusion	aerobic	metabolism	is	re-established	and,	at	a	cellular	level,	 the	tissue	starts	 to	recover.	 	 However,	 the	 endothelial	 functions	 of	 vascular	 permeability	 and	vasomotricity	remain	affected.			Endothelial	 dysfunction	 is	 characterized	 by	 impaired	 release	 of	 vasoactive	chemicals	 such	 as	 NO,	 endothelium-derived	 contracting	 factors	 (such	 as	 ET-1	and	angiotensin),	pro-inflammatory,	prothombolytic	and	growth	factors.		During	a	period	of	 ischemia,	vascular	hypoxia	 leads	to	 increased	vascular	permeability	caused	 by	 low	 cAMP	 levels	 (44).	 	 Locally,	 microvascular	 dysfunction	 may	 be	exacerbated	 upon	 reperfusion	 by	 complement	 activation,	 leucocyte-endothelial	
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cell	 adhesion	 and	 platelet-leucocyte	 aggregation	 (53).	 	 However	 distant	physiological	effects	may	also	be	seen;	an	animal	model	study	found	that	4-8h	of	ambient	hypoxia	(8%	oxygen)	caused	pulmonary	oedema,	albumin	leakage	into	multiple	 organs	 and	 elevated	 systemic	 cytokine	 levels	 (9).	 	 In	 humans,	 micro	vascular	 dysfunction	 following	 IRI	 may	 lead	 to	 distant	 events	 such	 as	 non-cardiogenic	pulmonary	oedema	and	 respiratory	 failure,	 this	 is	 caused	again	by	increased	 micro-vascular	 permeability	 resulting	 in	 disruption	 of	 the	 alveolar	capillary	 barrier	 function	 (54).	 	 We	 can	 see	 that	 although	 the	 injury	 occurs	locally	 the	 effects	 of	 IRI	 are	 systemic	 and	 cause	 significant	 morbidity	 for	transplant	recipients.			As	 touched	 upon	 earlier,	 dysfunction	 of	 the	 endothelium	 that	 persists	 after	reperfusion	 is	known	as	 ‘no	reflow	phenomenon’.	 	Failure	of	vascular	relaxation	after	 reperfusion	 causes	 obstruction	 of	 blood	 flow	 and	 is	 associated	with	 poor	clinical	 outcomes.	 	 The	 reduction	 in	 blood	 flow	 seen	 is	 related	 directly	 to	 the	duration	of	 ischemia	(55).	 	 In	animal	models	sustained	contraction	of	pericytes	on	 micro-vessels	 even	 after	 resolution	 of	 hypoxia	 has	 been	 demonstrated.	Furthermore,	 suppression	 of	 oxidative/nitrative	 stress	 relieves	 pericyte	contraction.	 	 This	 indicates	 that	 the	 micro-vessel	wall	 is	 a	 source	 of	 ROS	 and	nitrogen	 radicals	 and	 that	 these	 radicals	 are	 influencing	 IRI-induced	 micro-vascular	dysfunction	(56).		One	of	the	aims	of	this	study	is	to	see	if	these	findings	in	 an	 animal	 model	 correlate	 with	 clinical	 outcomes	 in	 renal	 transplant	recipients	 by	 measuring	 metabolites	 of	 NO	 in	 the	 plasma	 around	 the	 time	 of	transplantation.		1.2.5.2.	Endothelium	derived	relaxing	factor	Endothelium	 derived	 relaxing	 factor	 (EDRF)	 is	 now	 known	 to	 be	 NO	 and	 is	involved	in	the	regulation	of	vascular	tone	in	both	the	arteries	and	the	veins	(57).		The	 endothelial	 cells	 are	 mechanosensors;	 they	 transduce	 physical	 forces	exerted	 on	 the	 vessel	wall	 by	 blood	 flow	 into	a	 chemical	 signal.	 	 As	 is	 evident	from	 its	 previous	 name,	NO	 is	 one	of	 these	 biologically	 active	 chemical	 signals	(58).	 	NO	mediates	relaxation	of	vascular	smooth	muscle	by	stimulating	soluble	guanylate	cyclase	resulting	in	the	formation	of	cyclic	guanosine	monophosphate	
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(cGMP).		Smooth	muscle	relaxation	is	seen	as	a	result	of	protein	phosphorylation	by	cGMP	dependent	kinases	(59).		Changes	seen	in	the	compliance	of	the	vessel	wall	 are	 mediated	 by	 changes	 in	 NO	 levels	 that	 are	 controlled	 by	 the	endothelium.		1.2.5.3.	Endothelial	dysfunction	and	nitric	oxide	At	times	of	endothelial	dysfunction,	production	of	NO	by	endothelial	nitric	oxide	synthase	 (eNOS)	 is	 reduced	 (60).	 	 The	 fall	 in	 NO	 production	 is	 due	 to	“uncoupling”	of	eNOS;	this	not	only	attenuates	NO	production	but	also	results	in	increased	 levels	 of	 superoxide	 and	 ultimately	 leads	 to	 the	 formation	 of	peroxynitrite	(both	free	radicals	have	been	discussed	previously	as	propagators	of	IRI).		Uncoupling	of	NOS	occurs	when	either	l-arginine	or	tetrahdyrobiopterin	are	not	available.		Their	absence	causes	electron	flow	through	the	enzyme	to	be	disrupted	and	results	 in	reduction	of	oxygen	rather	than	formation	of	NO	(61).		Animal	 studies	 have	 shown	 that	 ROS	 generation	 is	 maximal	 15	 minutes	 after	reperfusion	of	tissues	(62);	this	increase	in	ROS	coincides	with	the	development	of	 endothelial	dysfunction	and	 is	 associated	with	a	decreased	bioavailability	of	NO	due	to	eNOS	deactivation	(63).		This	has	lead	to	several	areas	of	research	into	therapeutic	possibilities	 to	reduce	IRI,	 including	modulation	of	NOS	uncoupling	and	 NO	 supplementation	 around	 the	 time	 of	 reperfusion	 in	 an	 attempt	 to	preserve	endothelial	function.		In	rat	kidney	models,	nitrite	supplementation	has	been	 shown	 to	 attenuate	 IRI	 when	 administered	 locally	 (64)	 but	 not	 when	administered	systemically	(65).		In	this	respect	the	kidney	is	different	to	both	the	liver	 and	 the	 heart,	 which	 are	 protected	 from	 IRI	 by	 systemic	 nitrite	administration	(66).		It	has	been	further	demonstrated	that	the	attenuation	effect	is	mediated	by	conversion	of	nitrite	to	NO	as	opposed	to	by	the	nitrite	itself	(67).		We	 know	 that	 increased	 NO	 leads	 to	 elevated	 peroxynitrite	 levels	 (due	 to	 its	interaction	with	superoxide)	and	that	peroxynitrite	promotes	the	inflammatory	response	 leading	 to	 acute	 kidney	 injury.	 	 It	 is	 therefore	 surprising	 that	 NO	appears	 to	 exert	 a	 protective	 effect	 against	 IRI	 in	 some	 organs.	 	 It	 has	 been	hypothesized	that	this	effect	is	seen	due	to	the	reduction	of	nitrite	to	NO	at	the	molybdenum	site	of	 the	xanthine	oxidoreductase	enzyme	(XOR);	 this	results	 in	
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competition	for	electrons	and	therefore	limits	the	rate	of	oxygen	reduction	at	the	flavin	adenine	dinucleotide	site	of	the	same	enzyme.	 	Consequently	superoxide,	and	therefore	harmful	peroxynitrite	levels,	do	not	rise	with	NO	generation	(64)	allowing	 the	 protective	 effects	 of	 vasodilation	 and	 inhibition	 of	 leucocyte	adhesion	and	platelet	aggregation	to	prevail.			The	seemingly	conflicting	roles	of	NO	in	 IRI	 is	a	 topic	which	we	aim	to	explore	with	 this	 study.	 	 Our	 chosen	 cohort,	 i.e.	 patients	 receiving	 kidney	 grafts	 from	donation	after	circulatory	death	(DCD)	donors,	are	expected	to	undergo	a	more	severe	IRI	than	patients	receiving	grafts	from	other	donor	groups	for	the	reasons	referred	 to	 earlier	 in	 this	 chapter.	 	 This	 is	 translated	 clinically	 into	 the	 higher	rates	of	delayed	graft	function	(DGF)	seen	in	this	group	and	is	attributable	to	the	warm	ischemic	and	often	prolonged	cold	ischemic	times	that	are	inevitable	with	this	mode	of	organ	donation.				
	
1.3.		Nitric	Oxide	
1.3.1.		NO	–	Overview	and	discovery	
	Nitric	 oxide	 is	 a	 free	 radical	 gas	 and	 the	 first	 that	 was	 recognized	 to	 have	signaling	 properties.	 	 It	 has	 an	 unpaired	 electron	 and	 is	 therefore	 extremely	reactive;	 in	 the	 presence	 of	 oxygen	 it	 exists	 only	 transiently	 before	 being	oxidized	into	nitrite	(NO2-)	and	nitrate	(NO3-)	(68).	 	 	The	classical	production	of	NO	(there	is	also	an	alternative	pathway)	is	by	conversion	of	L-arginine	into		L-citrulline	 under	 the	 control	 of	 a	 group	 of	 enzymes	 known	 as	 nitric	 oxide	synthases	 (69).	 	Unlike	 the	majority	of	bioactive	molecules	 it	 is	not	 stored	and	does	not	require	exocytosis	to	leave	a	cell.		It	is	formed	endogenously	at	a	basal	rate	that	may	be	augmented	by	external	stimuli	such	as	cytokines.		NO	acts	intra-cellularly	by	binding	to	the	iron	molecule	of	haem	containing	proteins.		Many	of	its	 effects	 are	 as	 a	 result	 of	 its	 activation	 of	 soluble	 guanylate	 cyclase	 which	produces	3’5’-cGMP	(59);	the	contribution	of	NO	to	cGMP	production	explains,	in	part,	 its	wide	 spectrum	of	 effects	as	 cGMP	 is	 a	 common	physiological	signaling	molecule.	
	 17	
1.3.2.		Production	of	NO	
	Until	 recently	 it	 was	 believed	 that	 NO	 was	 produced	 endogenously	 and	 that	although	its	end	products,	nitrite	and	nitrate,	could	be	acquired	from	the	diet	the	reaction	 did	 not	 occur	 in	 reverse.	 	 However,	 it	 now	 appears	 that	 there	 is	 an	alternative	to	 the	classical	 “L	arginine	NOS”	pathway	(70).	 	Both	sources	of	NO	will	be	discussed	in	the	following	paragraphs.		1.3.2.1.		Classical	L-arginine	pathway		The	classical	pathway	involves	production	of	NO	by	a	five-electron	oxidation	of	a	guanidine	 nitrogen	 atom	 of	 L-arginine	 under	 the	 control	 of	 NOS	 (71).		Nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH),	 tetrahydrobiopterin	and	 oxygen	 are	 cofactors	 (72)	 and	 therefore	we	 would	 expect	 NO	 production	during	times	of	ischemia	or	hypoxia	to	be	diminished.		The	reaction	results	in	the	production	of	L-citrulline	and	equal	 amounts	of	NO	and	superoxide	 (O2-).	 	The	NOS	 enzymes	 can	 be	 classified	 into	 constitutive	 (cNOS)	 and	 inducible	 (iNOS),	with	 further	 sub	 classification	 of	 cNOS	 in	 to	 endothelial	 (eNOS)	 and	 neuronal	(nNOS).	 	 The	 constitutive	 forms	 are	 responsible	 for	 maintaining	 a	 continuous	basal	 level	of	NO	and	are	dependent	on	calmodulin	and	calcium	binding.	 	They	are,	 therefore,	potentially	affected	by	 calcineurin	 inhibitors;	 although	 the	exact	physiology	 of	 this	 is	 debated	 it	 appears	 that	 production	 of	 NO	 by	 eNOS	 is	attenuated	by	these	medications	(73).		Inducible	NOS	is	a	cytosolic	enzyme	that	remains	quiescent	unless	stimulated	by	cytokines	or	endotoxins.		Once	induced	it	remains	active	for	around	24h	and	it	produces	NO	in	concentrations	1000	times	greater	than	cNOS	(69).		cNOS	 is	 a	 dimer	 with	 each	 unit	 containing	 two	 identical	 subunits.	 	 iNOS	 is	 a	tetrameric	complex,	again	with	each	unit	containing	two	identical	subunits.		Each	subunit	 has	 a	 flavin	 adenine	 dinucleotide,	 a	 flavin	 mononucleotide,	 a	tetrahydrobiopterin	and	a	haem	group.	 	 Importantly,	each	unit	has	a	reductase	and	an	oxidase	domain	linked	by	a	calmodulin	binding	site;	it	is	this	calmodulin	binding	 site	 that	 activates	 the	 enzyme	 when	 a	 calcium-calmodulin	 complex	 is	
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bound.	 	 This	 process	 is	 dependent	 on	 an	 increase	 in	 intracellular	 calcium	concentration	which	may	stimulated	by	a	variety	of	agonists	(59).		In	whole	blood	NO	is	an	unstable	molecule	and	exists	only	transiently	before	it	is	metabolized	in	one	of	three	ways:	- Oxidized	 to	 nitrite	 (NO2-)	 or	 nitrate	 (NO3-);	 NO2-	 is	 produced	 by	oxidization	 of	 NO	 in	 plasma.	 	 This	 reaction	 is	 catalyzed	 by	 the	 plasma	copper	protein	ceruloplasmin	(74).		NO3-	is	formed	when	NO	reacts	with	oxyhaemoglobin,	a	byproduct	of	which	is	methaemoglobin.	- Quenched	with	a	superoxide	molecule.	- Bound	to	haem	containing	proteins	such	as	oxyhaemoglobin	(75).		1.3.2.2.		Alternative	pathway	NO2-	was	once	 considered	 to	be	an	 inactive	end	product	of	NO	however	 this	 is	now	thought	to	be	inaccurate.		Reduction	of	NO2-	to	NO	under	anoxic	conditions	was	 proposed	 by	 Zhang	 et	 al	 in	 1998	 (76)	 however,	 it	 was	 believed	 that	 this	could	only	take	place	in	conditions	incompatible	with	life.	 	More	recently	it	has	become	 apparent	 that	 this	 reduction	 can	 occur	 in	 conditions	 that	 span	 the	pathophysiological	 spectrum	 although	 still	 outside	 the	 normal	 physiological	oxygen	 tension	 and	 pH	 (77).	 	 This	 raises	 the	 question	 of	 whether	 NO2-	supplementation	 could	 replenish	 NO	 signaling	 and	 prevent	 ischemic	 tissue	injury	during	times	of	hypoxia	when	the	NOS	pathway	is	diminished	(78).				Sources	 of	 NO2-	 other	 than	 the	 previously	 discussed	 classical	 L	 arginine	 NOS	pathway	 include:	 reduction	 of	 salivary	 nitrate	 by	 commensal	 bacteria	 in	 the	mouth	 and	gastrointestinal	 tract	 and	 dietary	 intake	 from	meat,	 vegetables	 and	drinking	water	 (77).	 	 Four	different	 reactions,	 each	of	 them	requiring	different	physiological	conditions	and	substrates,	have	described	reduction	of	NO2-	to	NO.	These	 pathways	 respectively	 involve	 the	 mitochondrial	 electron	 transport	system,	protonation,	haemoglobin	and	xanthine	oxidase.		1. NO2-	 reductase	 activity	 has	 been	 found	 in	 the	 mitochondrial	 electron	transport	 system	 resulting	 in	 reversible	 inhibition	 of	 mitochondrial	respiration	(79).			
	 19	
2. Acidic	reduction	of	NO2-	requires	protonation	and	one-electron	reduction,	it	 will	 only	 occur	 in	 very	 acidic	 environments,	 e.g.	 in	 the	 stomach	 or	during	ischemic	events	when	the	pH	falls	(80).			3. Haemoglobin	may	function	as	NO2-	reductase,	although	the	haemoglobin	saturation	rate	must	be	40-50%,	 this	 contributes	 to	 the	phenomenon	of	hypoxic	vasodilatation	(81)	as	NO	is	a	potent	vasodilator.		Interestingly	if	NO2-	reacts	with	oxygenated	haemoglobin	then	oxidation	of	NO2-	to	NO3-	occurs	(82).		4. The	 final	 substrate	 is	 xanthine	 oxidase,	which,	 at	 low	O2	tensions	 and	 a	low	 pH	 is	 capable	 of	 NO2-	 reduction.	 	 This	 reduction	 reaction	 also	produces	 superoxide	 and	 therefore	 to	 produce	 meaningful	 NO	concentrations	would	 require	an	abundance	of	 superoxide	dismutase	 to	be	 present	 to	 scavenge	 the	 superoxide	 before	 it	 goes	 on	 to	 react	 with	generated	NO,	forming	peroxynitrite	(83).				It	 is	 expected	 that	 each	 sub-pathway	 becomes	 relevant	 at	 different	 times	depending	on	the	environment.	 	The	NO	produced	by	both	the	classical	and	the	alternative	pathways	is	identical	and	both	are	biologically	active.			1.3.2.3.		Nitrate	–	Nitrite	–	Nitric	Oxide	axis	The	 preceding	 paragraphs	 have	 demonstrated	 the	 many	 reactions	 that	 may	occur	as	a	result	of	NO	production	and	metabolism.		This	may	be	thought	of	as	a	dynamic	 axis	 between	 NO3-,	 NO2-	 and	 NO	 as,	 depending	 on	 the	 physiological	conditions	at	the	time,	Nitrogen	and	Oxygen	may	be	present	in	any	one	of	these	three	forms.		The	normal	plasma	concentrations	of	nitrate	are	20-40μM	whereas	nitrite	 is	 much	 lower	 at	 50-300nM	 (84)	 the	 relevance	 of	 this	 will	 become	apparent	when	 considering	 the	methodology	 and	 results	 chapters	 later	 in	 the	text.	 	 	 	 As	 discussed	 previously,	NO	 only	 exists	 for	 a	 few	 seconds	 in	 the	 blood	before	reacting	and	forming	either	NO2-	or	NO3-	therefore	in	this	study	we	will	be	measuring	both	molecules.	 	Blood	samples	will	be	taken	at	various	time	points	throughout	 the	 perioperative	 period	 from	 patients	 receiving	 DCD	 renal	transplants,	the	samples	will	be	centrifuged	immediately	to	separate	the	plasma	component	of	the	blood	and	frozen	to	-80	degrees	Celsius.	 	Although	we	will	be	
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processing	 the	 samples	 as	 quickly	 as	 possible	 oxidation	 of	 NO	 will	 still	 have	taken	place	and	therefore	we	will	need	to	use	both	NO2-	and	NO3-	as	indicators	of	NO	production.			
1.3.3.		NO	in	physiology	
	NO	affects	many	biological	systems	 in	both	normal	physiology	and	pathological	conditions.	The	following	text	will	consider	the	systems	in	turn	and	then	review	its	role	in	common	pathophysiology.	The	cardiovascular	and	renal	systems	are	of	obvious	connection	to	this	study	whereas	other	systems	will	be	referred	to	only	briefly	for	completion.			
Cardiovascular	system	and	thrombus	formation	Endothelium	derived	NO	 is	 involved	 in	 the	 regulation	 of	 vascular	 tone	 in	 both	arteries	 and	 veins,	 although	 it	 acts	 differently	 on	 each	 vessel	with	 veins	 being	affected	to	a	greater	extent	than	arteries	(57).	 	 	As	already	described	in	section	1.2.5.	 (and	 therefore	 not	 repeated	 in	 detail)	 NO	 mediates	 the	 relaxation	 of	vascular	smooth	muscle	by	stimulating	soluble	guanylate	cyclase	resulting	in	the	formation	of	cGMP.		Protein	phosphorylation	by	cGMP	dependent	kinases	causes	relaxation	of	vascular	smooth	muscle	and	therefore	vasodilation	(59).		Within	 the	 myocardium	 NO	 influences	 contractility,	 it	 is	 known	 to	 be	 a	 key	regulator	of	myocardial	excitation-contraction	coupling	(ECC)(85).		NO	signaling	in	the	heart	may	be	either	cGMP	dependent,	cGMP	independent	or	as	a	result	of	metabolites	of	NO.	 	The	effect	on	 the	myocardium	appears	 to	be	dependent	on	the	concentration	of	NO	seen	which	in	turn	is	dependent	on	the	isoform	of	NOS	producing	 it.	 	 At	 low	 concentrations,	 such	 as	 those	 produced	 constitutively	 by	eNOS	 and	 nNOS,	 NO	 exerts	 a	 positive	 inotropic	 effect	 by	 increasing	 ECC	 and	therefore	contractility.		At	the	higher	concentrations	produced	by	iNOS,	negative	inotropic	 effects	 are	 seen.	 	 This	 is	 not	 thought	 to	 be	 due	 to	 the	 NO	 itself	 but	rather	 to	 the	 toxic	peroxynitrite	 that	 is	 formed	as	a	 consequence	 (86,	87).	 	We	expect	 that	 the	 contradictory	 concentration	 dependent	 effects	 of	 NO	 may	 be	
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relevant	 to	 the	 potential	 findings	 of	 this	 study,	 as	 both	 IRI	 and	immunosuppression	 will	 stimulate	 the	 cytokines	 that	 cause	 up-regulation	 of	iNOS.		NO	 also	 plays	 a	 role	 in	 thrombus	 formation;	 it	 causes	 a	 reduction	 in	 platelet	adhesion,	 activation	 and	 recruitment	 onto	 the	 endothelial	 cell	 surface.	 	 Again,	these	 actions	 are	mediated	 by	 the	 ability	 of	NO	 to	 stimulate	 guanylate	 cyclase	and	 also	 by	 reducing	 platelet	 intracellular	 calcium	 levels	 (88).	 	 	 NO,	 in	combination	 with	 prostacycline,	 causes	 platelet	 disaggregation	 from	 collagen	fibers	 and	 inhibits	 platelet	 adhesion.	 	 Platelets	 produce	 NO	 as	 a	 negative	feedback	mechanism	via	 the	 classical	L-arginine	pathway,	 thus	 regulating	 their	own	aggregation	(89).			
Renal	and	genitourinary	system	Within	the	kidney	NO	effects	vascular	tone,	renin	release	and	influences	sodium	and	 water	 excretion	 (59).	 	 As	 seen	 elsewhere	 in	 the	 body,	 the	 renal	 vascular	endothelium	 synthesizes	 NO	 inducing	 vasodilation.	 This	 leads	 to	 increased	diuresis	 and	 sodium	 excretion	 (90).	 	 Renin	 secretion	 is	 affected	 in	 a	 time	dependent	 fashion;	 initially	renin	 release	 is	 inhibited,	however	after	prolonged	exposure	 to	 NO	 stimulation	 of	 renin	 secretion	 occurs	 (91).	 	 In	 chronic	 renal	failure,	dimethylamine	(DMA),	which	is	produced	as	a	consequence	of	increasing	creatinine,	 inhibits	 NO	 synthesis	 (92).	 	 This	 reduction	 in	 NO	 synthesis	contributes	to	the	hypertension	seen	in	chronic	renal	impairment	(59).				
Respiratory	system	NO	is	released	within	the	airways	by	NOS	and	 it	 is	protective	against	excessive	bronchoconstriction.	 	 NO	 has	 bronchodilatory	 effects	 as	 a	 result	 of	 increased	cGMP	production;	by	facilitating	the	production	of	bronchodilatory	nitrosothiols	(RSNO)	 and	 by	 its	 action	 as	 a	 neurotransmitter	 of	 the	 non	 adrenergic	 non	cholinergic	nervous	system	(NANC)	causing	relaxation	of	the	airway	vessels	and	smooth	muscle	(93-95).		
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Neurological	system	In	the	brain,	inhibition	of	NO	is	associated	with	impaired	learning	ability,	vision,	feeding,	nociception	and	olfaction	(96).		Its	release	causes	an	increase	in	synaptic	activity	via	increased	production	of	cGMP	(97).		NOS	is	found	in	the	cerebellum,	hippocampus,	medulla,	cerebral	cortex	and	corpus	striatum	(98).			
Gastro-intestinal	system	In	 the	 gastro-intestinal	 system	 NO	 mediates	 relaxation	 of	 longitudinal	 and	circular	muscle	 in	 the	 lower	oesophageal	 sphincter,	 stomach,	duodenum,	 small	intestine	 and	 internal	 anal	 sphincter	 (99).	 	 It	 affects	 pancreatic	 function	 by	regulating	 sphincter	 of	 Oddi	 tone	 (100)	 and	 release	 of	 insulin	 (101)	 and	 also	plays	 a	 role	 in	 mucosal	 integrity	 within	 the	 gut;	 NO	 production	 increases	mucosal	blood	 flow	by	 causing	vasodilatation,	while	 inhibition	of	NO	synthesis	restricts	 it.	Mucosal	 integrity	 is	dependent	on	adequate	mucosal	perfusion	and	therefore,	NO	production	(102).			
1.3.4.		NO	in	pathophysiology	
	
Atherosclerosis	and	vascular	dysfunction.		The	development	of	atherosclerosis	commences	with	endothelial	cell	injury	and	gives	 rise	 to	occlusive	plaques	within	 the	arterial	wall	 and	 lumen.	 	Animal	and	human	 studies	 have	 shown	 that	 early	 on	 in	 this	 process	 there	 is	 loss	 of	 NO	mediated	 vasodilation	 and	 that	 this	 may	 occur	 before	 any	 of	 the	 structural	changes	are	seen	(103).	 	The	importance	of	NO	mediated	vasodilation	has	been	confirmed	 in	 therapeutic	 studies	where	 L-arginine	 supplements	 are	 associated	with	a	reduction	 in	atherosclerosis	 in	major	vessels	(104).	 	 	Dysfunction	of	 the	endothelium,	 associated	 with	 a	 reduction	 in	 basal	 NO	 production,	 is	 found	 in	myocardial	 infarction,	 angina,	 coronary	 artery	 stenosis	 and	 hypertension,	particularly	in	diabetic	patients.(105,	106).		
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Intimal	hyperplasia	Intimal	hyperplasia	may	occur	as	a	result	of	 the	therapeutic	 interventions	used	to	treat	occlusive	arterial	disease	i.e.	angioplasty	or	bypass	grafting	(107).		In	the	early	 stages	 post	 angioplasty	 the	 endothelium	 has	 an	 attenuated	 ability	 to	mediate	 vasodilation,	 loss	 of	 NO	 synthesis	 contributes	 to	 this	 endothelial	dysfunction	(59)	and	this	is	thought	to	lead	to	formation	of	a	fibro-cellular	lesion	in	 the	overlying	endothelium	(58).	 	Autologous	vein	bypass	grafts	 can	develop	stenosis	over	 time,	which	may	 lead	 to	 failure	of	 the	graft	 (108),	dysfunction	of	NO	mediated	relaxation	is	found	within	the	endothelium	of	the	graft	and	this	is	believed	to	contribute	to	the	generation	of	stenosis	(109).		In	humans,	use	of	the	internal	mammary	artery	 for	coronary	artery	bypass,	as	opposed	to	a	reversed	vein	 graft,	 is	 associated	with	 better	 long-term	outcomes;	 these	 grafts	maintain	production	 of	 NO	 and	 endothelial	 derived	 vasodilatory	 function	 during	 the	grafting	process,	which	is	thought,	in	part,	to	explain	its	superior	outcome	(110).	
	
Inflammation	and	sepsis	NO	 is	 involved	 in	 the	 process	 of	 inflammation	 and	 in	 the	 clinical	 syndrome	 of	sepsis.	During	an	inflammatory	response	NO	enhances	vasodilation,	formation	of	oedema	 and	 modulation	 of	 sensory	 nerve	 endings	 (111).	 	 Inhibition	 of	 NO	reduces	 the	 magnitude	 of	 the	 inflammation	 as	 seen	 when	 NOS	 inhibitors	 or	glucocorticoids	 are	 given	 (112).	 	 In	 the	 context	 of	 sepsis,	 bacterial	 endotoxins	induce	 iNOS	 in	vascular	smooth	muscle,	 cardiomyocytes	and	 the	endocardium.		At	the	high	concentrations	produced	by	iNOS,	NO	causes	reduced	vascular	tone	leading	 to	 venous	 pooling	 and	 cardiac	 dysfunction	 (113)	 and	 is	 therefore	 a	negative	inotrope.		On	one	hand,	inhibition	of	NO	maintains	blood	pressure	and	prevents	hypotension	(114)	but	on	the	other	it	reduces	cardiac	output	and	raises	pulmonary	vascular	resistance	(115)	this	is	another	example	of	the	dichotomous	effects	of	NO	when	it	is	produced	by	iNOS	in	high	concentrations.		Macrophages	that	are	stimulated	by	the	pro-inflammatory	cytokine	Interferon	gamma	(IFN-g)	also	 synthesize	NO	 in	high	 concentrations,	 this	 time	with	 protective	 effects;	 at	these	concentrations	NO	interferes	with	deoxyribonucleic	acid	(DNA)	synthesis	by	interacting	with	iron	containing	enzymes,	causing	cytotoxicity	to	bacteria	and	
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therefore	assisting	the	host	 immune	system	to	eliminate	the	bacterial	 infection	(116).		NO	affects	every	 system	within	 the	body	and	has	a	broad	 spectrum	of	 actions.		However	common	themes	are	seen	within	each	system	and	they	are:	vasomotor	effects,	 effects	 on	 the	 immune	 system	 and	 its	 role	 in	 inflammation.	 	 Ischemic	reperfusion	 injury	 is	 a	 condition	 involving	 all	 of	 these	 processes	 and	 it	 is	therefore	 logical	 that	 NO	 should	 play	 a	 significant	 role	 within	 it.	 	 We	 will	 be	studying	the	levels	of	the	metabolites	of	NO	found	after	the	IRI	that	occurs	as	a	result	 of	 organ	 transplantation.	 	 In	 the	 following	 text	 we	 will	 look	 at	 what	 is	known	currently	about	NO	in	the	context	of	IRI.			
1.4.	Nitric	Oxide	and	IRI	
	As	 we	 have	 already	 explored,	 IRI	 is	 an	 important	 consideration	 in	 organ	transplantation.	However,	the	consequences	of	NO	release	in	IRI	are	debated,	as	there	 is	 evidence	 of	 both	 protective	 and	 deleterious	 effects.	 	 The	 interplay	between	 NO	 and	 ROS	 is	 thought	 to	 be	 pivotal	 to	 clarifying	 the	 answer	 to	 this	question,	 however,	 in-vitro	 and	 in-vivo	 studies	 contradict	 one	 another	 and	 it	remains	unresolved.	 	There	 is	robust	evidence	that	NOS	activity	 is	 increased	 in	the	early	 ischemic	phase.	 	On	 reperfusion,	ROS	are	generated	which	may	 react	with	NO.		This	results	in	both	molecules	either	quenching	each	other	or	acting	as	a	substrate	for	further	ROS	production.	 	NO	and	the	toxic	ROS,	superoxide	(02-)	react	 rapidly,	 eliminating	 them	 both	 and	 therefore	 exerting	 a	 cyto-protective	effect.	 	 The	 product	 of	 this	 reaction	 however,	 is	 the	 highly	 toxic	 radical,	peroxynitrite	 (ONOO-)	 (117).	 	 The	 following	 paragraphs	 will	 explore	 the	mechanisms	 by	which	 NO	may	 be	 playing	 a	 cyto-protective	 role	 and	 illustrate	why	it	is	important	to	study	its	role	within	this	investigation.		
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1.4.1.		Cyto-protective	effects	of	NO	
	During	the	ischemic	phase	of	IRI	NO	is	generated	which,	in-vitro,	has	been	shown	to	damage	DNA	and	inhibit	its	repair	(118).		In	ischemic	conditions	NO	has	also	been	 shown	 to	damage	 the	 actin	 cytoskeleton,	 altering	 renal	 tubular	 epithelial	function	 (119).	 	 However	 in	 post-ischemic	 conditions,	 as	 those	 occurring	 in	transplantation,	NO	does	not	appear	 to	be	purely	 cytotoxic,	 as	 it	 also	 seems	 to	have	a	variety	of	cyto-protective	effects.	
	
Antioxidant	There	are	two	proposed	mechanisms	by	which	NO	acts	as	an	antioxidant.	 	 	The	first	 is	 related	 to	 its	 reaction	 with	 superoxide	 during	 which	 peroxynitrite	 is	formed;	peroxinitrite	 then	goes	on	to	act	as	a	superoxide	scavenger	preventing	the	 formation	 of	 other	 free	 radicals	 such	 as	 hydrogen	 peroxide	 (H2O2)	 and	hydroxide	 (120)	 (despite	 this	 seemingly	 protective	 effect,	 peroxynitrite	 itself,	particularly	in	high	levels,	is	toxic	causing	DNA	damage,	cellular	injury	and	death	(85,	121)).				Secondly,	 NO	 inhibits	 mitochondrial	 respiration	 and	 therefore	 reduces	 the	formation	 of	 ROS	which	would	 otherwise	 be	 produced	 during	 ischemic	 injury	(122);	 NO	 modulates	 mitochondrial	 respiration	 by	 competing	 with	 O2	 for	cytochrome-c	oxidase	binding.	During	ischemia,	as	pO2	falls,	a	higher	proportion	of	 cytochrome-c	 oxidase	 is	 therefore,	 bound	 by	 NO.	 	 During	 reperfusion	 as	 O2	becomes	available	again,	because	of	its	competitive	binding,	NO	prevents	abrupt	resumption	 of	 the	 electron	 transport	 chain	 and	 therefore	 attenuates	 the	formation	of	ROS	(123).		Thus	in	the	context	of	IRI	is	seems	that	NO	may	have	a	protective	effect	by	reducing	ROS	production.		
Anti-inflammatory	–	Anti-TNF-α	+	Anti-IL-1	NO	is	known	to	inhibit	neutrophil	infiltration	and	reduce	the	production	of	pro-inflammatory	 cytokines	 (124)	 despite	 its	 production	 being	 promoted	 by	 them.	TNF-α	induces	the	accumulation	of	neutrophils	and	the	production	of	other	pro-inflammatory	cytokines.	 	Studies	have	shown	that	administration	of	NO	donors	
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such	as	molsidomine	and	nitroprusside	reduce	TNF-α	and	IL-1	production	(125,	126)	and	therefore	inflammation	and	tissue	injury.		In	an	animal	model	this	was	associated	with	improved	renal	function	and	a	decreased	inflammatory	response	after	renal	ischemia	(125).		Both	TNF-α	and	IL-1	may	be	up-regulated	as	part	of	the	 inflammatory	 response	 to	 IRI	 in	 the	 context	 of	 organ	 transplantation,	 NO	may	 be	 attenuating	 this	 and	 therefore	 providing	 a	 protective	 role	 by	 reducing	inflammation.	
	
Anti-adhesion	molecule	After	 ischemic	 reperfusion	 injury	 cellular	 adhesion	 molecules	 (CAMs)	 are	 up-regulated.	 CAMs	 such	 as	 selectins	 are	 mediators	 of	 the	 initial	 attachment	between	 polymorphonuclear	 neutrophils	 and	 activated	 endothelium	 and	therefore	 play	 a	 critical	 step	 in	 reperfusion	 injury	 (127).	 	 It	 has	 been	demonstrated	 that	 infusion	 of	 an	 NO	 donor	 prevents	 P-selectin	 expression	 on	endothelial	surfaces	 (128)	and	 that	other	CAMs,	 such	as	vascular	 cell	 adhesion	molecule-1	 (VCAM-1),	 ICAM-1	 and	 endothelial-leucocyte	 adhesion	 molecule-1	(E-selectin)	are	also	inhibited	(129).	 	Thus,	 in	this	context,	NO	seems	to	 inhibit	binding	 of	 neutrophils	 with	 activated	 endothelium	 thereby	 preventing	progression	of	IRI.		
Apoptotic	effect	NO	may	act	in	both	a	pro-apoptotic	and	anti-apoptotic	manner.	 	TNF-α	induced	apoptosis	of	endothelial	cells	caused	by	oxidative	stresses	(including	IRI)	may	be	reduced	 by	 NO	 administration	 however	 this	 effect	 is	 only	 seen	 at	 low	concentrations;	at	higher	concentrations	necrosis	and	apoptosis	still	occur.		The	same	 study	 also	 looked	 at	 the	 role	 of	 cGMP	 in	 this	 pathway;	 it	 seems	 that	NO	reduced	 cGMP	 dependent	 apoptosis	 at	 low	 concentrations	 however	 in	 higher	doses	cGMP	independent	apoptosis	was	induced	(130).	 	This	study	implies	that	at	 low	 levels,	 such	 as	 those	 produced	 constitutively	 in	 physiology,	 NO	 is	protective	but	at	higher	concentrations,	such	as	those	produced	in	the	context	of	ischemia	or	 inflammation,	 it	was	detrimental.	 	This	 is	contradicted	however	by	more	 recent	work	 in	which	 an	 animal	model	of	 renal	 IRI	was	 used;	 this	 study	found	that	decreased	apoptosis	was	seen	after	administration	of	exogenous	NO	
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and	 this	 also	 correlated	with	down	 regulation	 of	 the	 p53	 gene	 (131).	 	 Further	work	on	NO	and	p53	has	shown	that	NO	inhibits	a	 family	of	cysteine	proteases	called	caspases.		Caspase	activation	is	required	for	p53-dependent	apoptosis	and	therefore	 explains	 the	 reduction	 in	 apoptosis	 found	when	 NO	 is	 administered	(132).	 	NO	clearly	plays	a	role	in	apoptosis	however	whether	that	role	is	pro	or	anti	 –	 apoptotic	 seems	 to	 be	 dependent	 on	 the	 concentration	 and	 also	 the	mechanism	of	apoptosis	that	is	prevalent	i.e.	TNF-α,	cGMP	or	p53.		
NO	as	a	therapeutic	target.	We	 have	 seen	 that	 NO	 is	 important	 in	many	 biological	 systems	 and	 therefore	therapies	 that	 either	 regulate	 NOS	 activity	 or	 produce	 NO	 exogenously	 have	become	 an	 expanding	 area	 of	 research.	 Despite	many	 investigations	 into	 their	therapeutic	role,	very	few	have	made	it	into	clinical	practice.		Organic	nitrites	are	the	obvious	exception	to	this;	 isosorbide	mononitrite	and	glyceryl	 trinitrite	are	extensively	used	for	their	vasodilatory	properties	to	treat	angina,	cardiac	failure,	pulmonary	oedema	and	anal	 fissure	however	 their	use	 is	 accompanied	by	 side	effects	such	as	hypotension,	headaches	and	evolving	tolerance	(77).		
	
1.4.2.		NO	concentration;	iNOS	and	eNOS	
	Resultant	 NO	 concentration	 is	 emerging	 as	 a	 recurring	 theme	 that	 appears	 to	influence	 the	 consequences	 of	 its	 production.	 	 The	 concentration	 produced	 is	dependent	on	the	isoform	of	NOS	that	is	activated;	in	IRI	NO	is	produced	by	both	constitutive	 and	 inducible	 NOS,	 however	 the	 majority	 is	 by	 iNOS	 (with	concentrations	of	1000	times	greater	then	eNOS).		The	renal	expression	of	eNOS	and	 iNOS	 occurs	 in	 different	 parts	 of	 the	 kidney	 and	 varies	 in	 response	 to	ischemia	(133);	eNOS	is	found	in	the	vasa	recta,	inner	medullary	collecting	duct	and	 glomeruli	 (134)	 whereas	 iNOS	 is	 expressed	 by	 vascular	 smooth	 muscle,	renal	 tubular	 cells	 and	 immune	 cells	 such	 as	 monocytes,	 macrophages	 and	neutrophils	 (135,	 136).	 Inducible	 NOS	 expression	 in	 the	 nephron	 has	 been	shown	to	increase	by	up	to	30	times	during	IRI,	its	peak	being	at	one-hour	post	reperfusion.	 	 In	 contrast,	 eNOS	 expression	 diminishes	 in	 response	 to	 either	
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ischemia	 alone	 or	 to	 IRI,	 an	 effect	 that	 is	 not	 neutralized	 until	 3	 hours	 after	reperfusion	(60).		Although	the	NO	produced	by	the	different	isoforms	of	NOS	is	identical,	 its	effects	on	the	kidney	are	contradictory;	NO	produced	by	eNOS	up-regulation	 appears	 to	 prevent	 vascular	 dysfunction	 (by	 preventing	 platelet	aggregation	 and	 leucocyte	 activation)	 (137)	 and	 also	 to	 promote	 vasodilation	(138),	 thus	 having	 a	 protective	 role	 in	 IRI.	 Furthermore,	 inhibition	 of	 eNOS	worsens	cortical	and	medullary	blood	flow	and	oxygenation	(139).		INOS-derived	NO	 however,	 seems	 to	 contribute	 to	 vascular	 dysfunction	 (140)	 as	 a	 result	 of	increased	production	of	peroxynitrite	and	inhibition	of	protective	eNOS-derived	NO.		Several	studies	have	reported	that	inhibition	of	iNOS	attenuates	renal	injury	in	IRI	(141-145).		The	conflicting	effects	of	NO	are	demonstrated	effectively	by	Yates	et	al;	using	an	ex	vivo	porcine	model	and	NO	supplementation	they	found	a	biphasic	response	to	NO	donation	that	initially	resulted	in	increased	renal	blood	flow	in	the	treated	group.		However,	this	effect	was	not	sustained	and	between	30	and	180	minutes	the	renal	blood	flow	in	the	control	and	treatment	groups	converged.		Intra-renal	resistance,	 unsurprisingly,	 demonstrated	 a	 reciprocal	 relationship.	 	 The	 initial	increase	 in	 flow	 is	 thought	 to	be	due	 to	 the	vasodilatory	effects	of	NO	 that	are	well	documented.		However	it	is	the	fall	in	blood	flow	between	30-180	min	that	highlights	 the	 conflicting	 functions	 of	 NO.	 	 The	 authors	 of	 the	 study	 proposed	that	rising	levels	of	peroxynitrite	and	superoxide	caused	endothelial	dysfunction	thus	preventing	vasodilation	(146).		This	inconsistent	response	is	not	just	limited	to	NO	as	peroxynitrite	also	has	conflicting	properties;	 in	 low	doses	 it	 increases	renal	blood	flow	due	to	indirect	vasodilation	however	at	higher	doses	this	effect	is	not	only	 lost	but	vasoconstriction	occurs.	 	 If	NOS	activation	 is	also	 inhibited,	further	 vasoconstriction	 and	 reduction	 in	 renal	 blood	 flow	 occurs	 (147)	 it	 is	thought	 that	 at	 low	 concentrations	 and	 in	 the	 presence	 of	 activated	 NOS,	peroxynitrite	 may	 be	 reduced	 back	 to	 NO	 and/or	 NO2-	 hence	 the	 vasodilator	effects	seen.			Concentration	appears	to	be	emerging	as	significant	in	the	interpretation	of	the	NO:superoxide	 axis.	 	 The	 complex	 and	 varied	 reactions	 of	 these	ROS	 that	may	
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occur,	 depending	 upon	 the	 physiological	 conditions	 at	 the	 time,	 make	 IRI	 an	interesting	 and	 challenging	 environment	 in	 which	 to	 investigate	 them.	 	 This	study	will	attempt	to	explore	further	the	questions	that	remain	unanswered	with	regards	 to	 NO	 and	 IRI	 by	measuring	 concentrations	 of	 nitrite	 and	 nitrate	 at	 a	various	time	points	during	reperfusion	of	kidney	transplants	and	by	relating	this	to	physiological	inflammatory	reactions	occurring	concurrently.			
1.5.	Cytokines	
1.5.1.		Cytokines	–	Overview	and	discovery	
	The	 simplest	 definition	 of	 a	 cytokine	 this	 author	 has	 encountered	 is	 the	description	of	them	as	a	“chemical	messengers”,	however	Jan	Vilcek	proposes	a	more	comprehensive	definition:	(148)	“Cytokines	are	regulatory	proteins	secreted	
by	white	blood	cells	and	a	variety	of	other	cells	in	the	body;	the	pleiotropic	actions	
of	 cytokines	 include	 numerous	 effects	 on	 cells	 of	 the	 immune	 system	 and	
modulation	of	inflammatory	responses”.		No	short	description	exists	to	encompass	all	 of	 the	 defining	 features	 of	 a	 cytokine	 however	 there	 are	 characteristic	properties	that	can	be	explained	to	help	understand	their	function	and	purpose.		It	should	be	noted	that	these	properties	are	not	exclusive	to	cytokines.			Features	of	cytokines	include:	- They	are	soluble	proteins	or	glycoproteins,	most	being	≤	30	kDa	in	size.	- Their	 production	 and	 release	 are	 often	 described	 as	 ‘burst	 like’,	 i.e.	transient	 and	 in	 response	 to	 a	 stimulus,	 rather	 than	 at	 a	 constant	background	rate.	- Their	actions	are	mediated	by	binding	to	specific	cell	surface	receptors.	- Their	actions	are	usually	caused	by	modification	of	gene	expression	in	the	target	 cell	 and	 may	 lead	 to	 changes	 in	 the	 rate	 of	 cell	 proliferation	 or	differentiation	of	the	cell.			- Their	actions	are	varied	and	diverse	but	each	one	has	some	effect	on	cells	within	the	haematopoietic	system	(148).	
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1.5.2.		Structure,	function	and	family	groups	
	Cytokines	may	be	grouped	into	six	distinct	“families”	according	to	the	structure	of	 their	 receptors	 (149),	 see	 appendix	 1.	 The	 question	 of	 “What	 does	 an	
individual	cytokine	do?”	is	a	difficult	one	to	answer	succinctly.		Cytokine	function	is	highly	contextual;	its	actions	on	a	cell	depend	upon	the	conditions	that	the	cell	is	 exposed	 to	 at	 the	 time.	 	 The	 interactions	 of	 cytokines	 are	 described	 as	synergistic	and	antagonistic;	cells	exposed	to	different	combinations	of	multiple	cytokines	may	have	completely	different	responses	and	those	responses	may	be	greater	than	those	produced	by	an	individual	cytokine.		An	example	of	this	may	be	seen	in	the	reaction	of	damaged	epithelial	cells	in	the	colons	of	patients	with	inflammatory	 bowel	 disease;	 stimulation	 of	 HT-29	 cells	 with	 IFN-γ	 or	 TNF-α	alone	induces	production	of	IL-8.	However	in	combination,	they	cause	apoptosis	(150).		Transforming	growth	factor	(TGF-β)	in	the	liver	provides	a	good	example	of	another	cytokine	property	known	as	pleiotropy.		In	chronic	liver	disease	TGF-β	is	 involved	with	 regulation	of	proliferation	of	hepatic	progenitor	 cells	 (thereby	preventing	 hepatocellular	 carcinoma).	 It	 also	 plays	 a	 role	 in	 blunting	inflammatory	responses	within	the	liver	as	well	as	mediating	wound	healing	and	immune	responses	(151).		Pleiotropy	describes	the	multiple	actions	and	multiple	cell	 targets	 that	 individual	 cytokines	 may	 influence.	 	 Conversely	 different	cytokines	may	have	similar	actions	and	this	is	termed	redundancy.			One	 cytokine	 may	 stimulate	 or	 inhibit	 the	 production	 of	 another.	 When	 this	action	 is	 stimulatory	 it	 may	 involve	 multiple	 cytokines	 and	 is	 known	 as	 a	
cytokine	cascade.		A	well	described	example	of	this	is	IL-1,	which,	exerts	its	action	on	 T	 cell	 proliferation	 by	 stimulating	 IL-2	 (152).	 	 Two	 further	 important	functions	of	cytokines	are	their	ability	modulate	cytokine	receptor	activity;	this	may	be	through	receptor	transmodulation	 (when	a	cytokine	 influences	receptor	expression	of	a	different	cytokine)	or	receptor	trans-signaling,	where	a	cytokine	may	interfere	with	the	signaling	properties	of	a	receptor.			The	 clinical	 effects	 of	 cytokines	 include;	 regulation	 of	 the	 immune	 system	 and	inflammation	 by	 their	 influence	 on	 leucocyte	 migration;	 haematopoietic	 cell	
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proliferation;	 the	 systemic	 inflammatory	 response;	 temperature	 regulation;	tissue	 remodeling	 and	 cell	 survival.	 	 As	 previously	 discussed	 these	 actions	 are	the	result	of	the	pattern	of	release	of	multiple	cytokines	and	rarely	attributable	to	a	single	cytokine	(149).		As	part	of	this	study	on	NO	and	IRI	we	will	measure	some	of	 the	cytokines	we	believe	may	be	 influential	around	the	time	of	kidney	transplantation.	 We	 will	 also	 look	 for	 relationships	 between	 cytokines	 and	induction	 immunosuppression	 as	 this	 may	 cause	 an	 overriding	 effect	 in	 the	context	 of	 this	 project.	 	 The	 following	 paragraphs	will	 review	what	 is	 already	known	about	cytokines	in	transplantation	and	specifically	that	which	is	relevant	to	this	study.	
	
	
1.5.3.		Cytokines	in	transplantation	
	T-cells	play	a	crucial	role	in	transplant	immunology;	CD4+	helper	T-cells	secrete	IL-2,	IL-4,	IL-5	and	IFN-γ.		Graft	damage	is	caused	by	cytotoxic	T-cell	responses,	antibody	mediated	responses	and	delayed-type	hypersensitivity	reactions;	all	of	which	are	modulated	by	these	cytokines	(153).	 	IL-2,	released	directly	by	CD4+	cells,	causes	CD8+	T-cells	(in	turn	activated	by	recognition	of	donor	MHC	class	1	antigens)	 to	 differentiate	 further	 into	 cytotoxic	 T-cells	 (154).	 	 CD4+	 T-cells	initiate	 a	 delayed-type	 hypersensitivity	 reaction	 and	 release	 INF-γ	 and	 TNF-α,	which	causes	recruitment	of	macrophages	and	monocytes	(155).		The	patterns	of	cytokine	 release	 in	 relation	 to	 CD4+	 (T-helper)	 cells	 have	 been	 simplified	 into	two	groups;	T-helper	1	and	T-helper	2	(156).	 	T-helper	1	lymphocytes	produce	IL-2,	IFN-γ	and	TNFβ;	the	differentiation	of	T-cells	into	T-helper	1	lymphocytes	is	controlled	 by	 IL-12	 and	 IFN-γ.	 	 In	 contrast,	 IL-4	 and	 IL-13	 promote	 the	generation	of	T-helper	2	lymphocytes	(157),	which	then	produce	IL-5,	IL-6,	IL-9,	IL-10	and	IL-13.		Broadly	speaking,	T-helper	1	cytokines	are	thought	to	promote	rejection	 (158),	 where	 as	 T-helper	 2	 cytokines	 are	 believed	 to	 be	 protective	against	 it	 and	 to	encourage	allograft	 acceptance	or	 tolerance	 (159).	 	They	also	stimulate	 antibody	 production	 by	 B-cells.	 	 Multiple	 cytokines	 regulate	 B-cell	behavior	including	IL-4,	IL-5,	IL-6,	IL-10	and	IL-13	(160).		
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1.5.4.		Cytokines	effecting	NO	production	
	IFN-γ,	 in	 combination	 with	 either	 TNF-α	 or	 IL-1,	 activates	 the	 transcription	factor	 nuclear	 factor	 -	 κβ	 (NF-κβ).	 	 NF-κβ	 results	 in	 up-regulation	 of	 iNOS	 in	activated	 macrophages,	 therefore	 causing	 increased	 NO	 production	 (161).		However	as	we	have	previously	discussed,	the	nature	of	cytokines,	the	immune	system	 and	 IRI	 are	 such	 that	 in	 order	 to	 account	 for	 the	multiple	 actions	 and	reactions	occurring	simultaneously,	it	is	prudent	to	consider	a	panel	of	cytokines	to	look	for	changes	and	associations.	 	For	the	purposes	of	this	study	we	will	be	looking	at	IFN-γ,	IL-2,	IL-6,	IL-10,	IL-17a	and	TNF-α;	all	of	which	are	involved	in	the	 immune	 response	 to	 organ	 transplantation.	 	 Each	will	 be	 discussed	 in	 the	following	paragraphs.		1.5.4.1.		IFN-γ	IFN-γ	(also	known	as	Macrophage	Activating	Factor	(MAF))	is	produced	by	CD8+	and	CD4+	T-cells	as	well	as	Natural	Killer	(NK)	T-cells.		IFN-γ	is	involved	in	many	of	 the	 process	 of	 the	 inflammatory	 and	 immune	 responses	 including	proliferation	 and	 differentiation	 of	 T-cells,	 B-cells,	 macrophages,	 NK-cells,	endothelial	 cells	 and	 fibroblasts	 (162).	 	 It	 acts	 on	 antigen	 presentation	 cells	(APCs)	 to	enhance	HLA	expression	and	also	has	antiviral	 and	anti-proliferative	actions	 (163,	 164).	 	 As	 mentioned	 previously,	 IFN-γ	 is	 involved	 in	 the	 up	regulation	 of	 iNOS	 (and	 therefore	 NO	 production)	 and	 also	 the	 host’s	 T-cell	response	to	the	graft,	it	is	also	likely	to	be	affected	by	immunosuppressive	agents	(as	described	 later	 in	 this	chapter).	 	By	measuring	 it	at	specific	 time	points	we	hope	 to	 see	 what	 effects	 are	 most	 influential	 in	 the	 context	 of	 renal	transplantation;	 is	 its	 concentration	 in	 plasma	 linked	 to	NO	production,	 or	 are	the	 known	 responses	 overshadowed	 by	 the	 effect	 of	 induction	immunosuppression?		1.5.4.2.		IL-2	Initially	known	as	T-cell	 growth	 factor,	 it	 is	not	 surprising	 that	 IL-2	 stimulates	growth	and	differentiation	of	T	cells.		It	is	produced	by	T-cells	and	also	influences	the	behavior	of	many	other	 immunological	cell	 lines	 including	B-cells,	NK-cells,	
	 33	
Lymphokine-activated	 killer	 (LAK)	 cells,	 monocytes,	 macrophages	 and	oligodendrocytes	 (165).	 	 It	 can	 induce	 production	of	 other	 cytokines	 including	TNF-α	and	 IFN-γ	and	broadly	may	be	 considered	a	pro-inflammatory	 cytokine.		In	 the	 context	of	 this	 study,	 Simulect,	 one	of	 the	 induction	 immunosuppressive	therapies,	 is	 an	 antibody	 that	 specifically	 targets	 the	 IL-2	 receptor.	 	 We	 will	therefore	be	looking	to	see	of	this	translates	into	a	detectable	effect	in	the	plasma	samples.		1.5.4.3.		IL-6	IL-6	has	also	been	known	by	the	name	IFN-β2	and	B-cell	stimulatory	factor	2;	it	is	produced	by	both	T	and	B-cells,	as	well	as	macrophages,	bone	marrow	stromal	cells,	fibroblasts,	keratinocytes	and	endothelial	cells.	It	acts	to	regulate	function	of	T	and	B-cells,	haematopoiesis	and	acute	phase	responses	(149).		In	the	kidney,	IL-6	appears	to	have	both	protective	and	detrimental	effects;	 it	 is	released	as	a	pro-inflammatory	mediator	as	part	of	 the	T-cell	 immune	response	and	 is	 found	to	be	elevated	early	after	reperfusion	(166).		However	it	also	plays	a	role	in	the	repair	 of	 the	 tissues	 via	 a	 trans-signaling	mechanism	 that	 attenuates	 oxidative	stress,	 limiting	 further	 tissue	 damage	 and	 activating	 signal	 transducer	 and	activator	of	transcription	(STAT)	3	in	the	epithelial	cells	to	promote	resolution	of	the	injury	(167,	168).				Once	 again	 we	 see	 that	 the	 mediators	 and	 products	 of	 IRI	 have	 dichotomous	functions	 in	 renal	 transplantation	and	 in	 the	 context	of	 this	 study	we	may	 find	that	 precise	 roles	 are	 difficult	 to	 define.	 	 In	 order	 to	 correct	 for	 this	 we	 are	measuring	 multiple	 cytokines	 and	 will	 be	 looking	 for	 changes	 as	 opposed	 to	absolute	values.		1.5.4.4.		IL-10	Although	IL-10	has	both	inhibitory	and	stimulatory	effects,	on	the	whole	 in	 the	context	 of	 transplantation	 it	 is	 considered	 an	 immunosuppressive	 cytokine;	 it	inhibits	 the	 maturation	 of	 dendritic	 cells	 (preventing	 T-cell	 activation	 and	recruitment	of	NK	cells	 (169))	and	has	an	 inhibitory	action	on	T-helper	1	 cells	where	 it	 blocks	 cytokine	 synthesis	 (including	 IFN-γ	 and	 TNF-	 α	 (170)).	 	 Its	
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stimulatory	effects	include	roles	in	B-cells,	thymocyte	and	mast	cell	proliferation	(149).		Its	relevance	to	this	study	is	to	see	if	IL-10	production	differs	in	any	way	from	the	other	pro-inflammatory	cytokines	and	also	to	see	if	it	has	any	detectable	relationship	with	IFN-γ	or	TNF-α.		1.5.4.5.		IL-17	IL-17	is	a	stimulatory	and	pro-inflammatory	cytokine;	it	is	produced	by	CD4+	T-cells,	mast	cells,	neutrophils	and	macrophages	and	its	effects	include	recruitment	of	neutrophils	and	monocytes	and	production	of	IL-6,	IL-8	and	TNF-α	(171-173).		In	the	kidney,	IL-17	producing	T-cells	have	been	found	to	promote	inflammation	and	 induce	 production	 of	 IFN-γ	 and	 TNF-α	 (174).	 	 Furthermore	 IL-17,	 in	combination	with	IFN-γ,	 is	 thought	 to	be	 important	 in	renal	 IRI	(175).	 	 IL-17	 is	intimately	 linked	with	the	 cytokines	we	are	measuring,	 in	particular	 IFN-γ	and	TNF-α,	which	are	important	for	NO	production.		1.5.4.6.		TNF-α	TNF-α	 has	 a	 varied	 role	 in	 inflammation	 and	 immunity	 regulating	 growth	 and	differentiation	 of	many	 cell	 lines.	 	 It	 acts	 synergistically	with	 IFN-γ	 and	many	other	cytokines.		Secretion	is	primarily	by	activated	monocytes	and	macrophages	although	it	may	also	be	produced	by	T-cells,	B-cells	and	fibroblasts.		Its	receptors	are	found	on	most	cell	types	with	the	exceptions	of	erythrocytes	and	inactive	T-cells	 (149).	 	 TNF-α	 is	 released	 from	 the	 kidney	 in	 response	 to	 IRI;	 it	 causes	 a	reduction	 in	 glomerular	 filtration	 rate	 (GFR)	 via	 glomerular	 fibrin	 deposition,	cellular	 infiltration	 and	 vasoconstriction.	 	 In	 the	 kidney,	 binding	 at	 the	 TNF	receptor	may	induce	cell	apoptosis	(176,	177),	which	is	one	of	the	hallmarks	of	IRI.	 	As	previously	mentioned	TNF-α	and	 IFN-γ	act	 synergistically	 to	 cause	up-regulation	of	iNOS	and	are	therefore	linked	directly	to	NO	production.	
	
	
1.5.5.	Cytokines	–	NO;	Inflammatory	axis		As	we	 have	 already	 discussed,	 the	 production	 of	 NO	 by	 iNOS	 is	 stimulated	 by	pro-inflammatory	cytokines	via	their	effect	on	NF-κβ.	 	The	resultant	increase	in	
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NO	 concentration	 further	 perpetuates	 the	 inflammatory	 process	 resulting	 in	ongoing	production	of	pro-inflammatory	cytokines	and	increased	inflammation.		This	 effect	 is	 seen	 due	 to	 the	 production	 of	 free	 radicals	 (peroxynitrite	 and	superoxide)	 which	 occurs	 as	 a	 result	 of	 the	 reactivity	 of	 NO	 and	 the	 high	concentrations	of	NO	that	are	produced	by	iNOS	(178).		One	of	the	challenges	of	interpreting	 the	 results	 of	 this	 study	will	 be	 the	many	 concurrent	 process	 and	influences	 that	 may	 affect	 our	 analytes;	 we	 anticipate	 that	 the	 induction	immunosuppressant	may	be	particularly	influential.	 	The	following	chapter	will	consider	the	immunosuppressive	drugs	that	are	of	relevance	to	this	project	and	discuss	 their	mechanisms	of	 action,	with	particular	 reference	 to	 their	 effect	on	cytokines,	 which	may	 be	 important	 in	 the	 interpretation	 of	 the	 results	 of	 this	study.			
	
	
1.6.		Immunosuppression		The	 introduction	 and	 development	 of	 immunosuppressive	 agents	 for	transplantation	was	 a	 breakthrough	 in	 the	 field	 of	 transplant	 surgery	 and	 it	 is	therefore	 reasonable	 to	 say	 that	 without	 immune	 manipulation,	 organ	transplantation	would	 not	 be	 possible.	 	 Today,	 immunosuppressive	 agents	 are	used	around	the	day	of	 transplantation	(induction),	 for	maintenance	and	 in	the	event	 of	 episodes	 of	 rejection	 (rescue	 therapy).	 	 The	 exact	 regimen	 will	 vary	between	transplant	units	depending	upon	local	policy	but	the	purpose	of	each	is	set	out	below.		For	the	purposes	of	this	project	we	will	only	explore	in	detail	the	medications	 which	 may	 exert	 an	 effect	 on	 our	 results	 i.e.	 those	 administered	around	 the	 time	 of	 surgery;	 other	 medications	 will	 be	 mentioned	 but	 not	described	in	detail.		Induction	 immunosuppression	 is	 an	 intense,	 upfront	 treatment	 that	 aims	 to	inhibit	 the	 immune	 response	 at	 the	 time	 of	 transplantation;	 it	 might	 affect	various	aspects	of	the	immune	response	not	necessarily	targeting	rejection.		It	is	important	 to	 note	 that	 its	 prolonged	 use	 is	 unsustainable	 due	 to	 its	 toxicity.		Maintenance	 immunosuppression	 is	 used	 for	 the	 life	 of	 the	 graft	 and	 is	 often	
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comprised	 of	 two	 or	 three	 agents;	 it	must	 therefore	 be	 tolerable	 for	 sustained	use.	 	Rescue	therapy	is	comparable	to	induction	therapy	and	indeed,	the	agents	used	 may	 be	 the	 same.	 	 It	 is	 an	 intensive	 regimen	 designed	 to	 treat	 allograft	rejection.		Figure	1.1	below	depicts	the	cellular	mechanism	of	both	the	induction	and	the	maintenance	agents	used	by	our	unit.		Immunosuppression	–	Mechanism	of	action	
													 	
Figure	 1.1:	 	 Immunosuppression	 –	Mechanism	 of	 action.	 	Demonstrating	 the	
sites	of	action	of	commonly	used	immunosuppressants	in	their	prevention	of	T-cell	
activation	and	proliferation.		
(APC:	 Antigen	 presentation	 cell.	 	 TCR:	 T-cell	 receptor.	 	 NFAT:	 Nuclear	 factor	 of	
activated	T	cells.	MMF:	Mycophenalate	mofetil)	(179).			
1.6.1.		Induction	therapy	
	On	 the	 day	 of	 transplantation,	 both	 pre	 and	 intra-operatively,	 an	 intense	prophylactic	 immunosuppressive	 therapy	 is	 administered	 to	 reduce	 the	 risk	of	early	acute	rejection	and	graft	 loss.	 	Regimens	vary	between	transplant	centers	but	 broadly	 they	 consist	 of	 a	 combination	 of	 biological	 agents	 and	corticosteroids.	
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1.6.1.1.		Biological	agents	Biological	 agents	 act	 to	 target	 particular	 cell	 surface	 receptors	 (including	antibodies)	resulting	in	a	clinical	effect.		Within	the	field	of	organ	transplantation	biologics	are	used	in	the	form	of	either	polyclonal	or	monoclonal	antibodies	for	induction	immunosuppression.			
Polyclonal	antibodies;	ATG	Polyclonal	antibodies	are	derived	from	animals,	usually	rabbits	or	horses.	 	The	preparation	used	by	the	Cardiff	Transplant	Unit	and	many	others,	particularly	in	USA	 and	 France,	 is	 ATG;	when	 administered	 to	 the	 patient	 it	 causes	 profound	lymphopoenia	via	a	variety	of	mechanisms.		T-cell	depletion	is	caused	primarily	by	complement	mediated	cell	lysis	although	antibody	mediated	cytotoxicity	and	activation	of	cell	death	programs	both	contribute	(180).		B-cell	depletion	occurs	by	 induction	 of	 apoptosis	 in	 immature	 B-cells,	 activated	 B-cells	 and	 mature	plasma	cells	within	the	bone	marrow.		As	well	as	its	effects	on	T	and	B-cells,	ATG	may	also	cause	alteration	in	function	of	dendritic	and	NK	T-cells	(181).				Side	effects	of	polyclonal	antibodies	may	be	acute	or	delayed.	 	Acutely,	cytokine	release	 syndrome	 (a	 dose	 dependent	 effect,	 experienced	most	 commonly	 after	the	 first	 exposure)	 may	 cause	 febrile	 episodes,	 rigors,	 nausea,	 vomiting,	diarrhoea,	dyspnea,	headaches,	 skin	 rashes,	hypotension	and	even	anaphalaxis.		Cytokine	 release	 occurs	 as	 a	 result	 of	 cell	 surface	 receptor	 engagement,	 in	particular	TNF-α,	 IL-1	and	 IL-6	 (182);	 stopping	 the	 infusion	and	administering	steroids	 is	 used	 to	 treat	 the	 syndrome.	 	 More	 severe	 reactions	 have	 been	reported	 with	 ATG	 use,	 including	 myocardial	 infarctions,	 pulmonary	 oedema,	tachy-arrhythmias	 and	 death	 (54).	 	 In	 our	 unit	 because	 of	 the	 risk	 of	 severe	reactions,	 anti-histamines	 and	 steroids	 are	 given	 routinely	 prior	 to	 infusion	 of	polyclonal	antibody.				Delayed	 effects	 include	 pancytopenia,	 serum	 sickness	 and	 infections.	 	 Another	important	side	effect	of	biological	therapies	is	the	significantly	increased	risk	of	developing	post	transplant	lymphoproliferative	disease	(PTLD).	This	is	due	to	a	combined	increased	intensity	of	immunosuppression	as	opposed	to	use	of	a	sole	
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agent	(1).		Despite	the	extensive	list	of	side	effects,	ATG	is	still	used	routinely	in	transplant	 recipients	 as	 studies	 show	 significantly	 reduced	 rates	 of	 acute	rejection	 when	 compared	 with	 a	 group	 receiving	 no	 induction	immunosuppression	(183).		Long-term	graft	and	patient	survival	rates	and	renal	function	 are	 not	 found	 to	 be	 significantly	 different	 between	 the	 two	 groups	(184).	
	
Monoclonal	antibodies	Monoclonal	antibody	preparations	contain	a	single	antibody	type	that	binds	to	a	single	 cell	 surface	 antigen,	 thereby	 limiting	 their	 spectrum	 of	 action	 but	increasing	 their	 specificity	 and	 reducing	 the	 incidence	 of	 unwanted	 effects.		There	are	many	different	monoclonal	antibodies	available	and	they	are	used	to	treat	 a	 variety	 of	 conditions	 including	malignancies	 and	 autoimmune	diseases.		We	 will	 be	 considering	 two	 such	 antibodies	 that	 are	 used	 for	 induction	immunosuppression	in	solid	organ	transplantation.				Monoclonal	 antibodies	 bind	 to	 specific	 cell	 surface	 epitopes;	 Campath	(Alemtuzumab)	 is	 a	 humanized	 monoclonal	 antibody	 against	 CD52.	 	 Binding	causes	complement	fixation	and	destruction	of	the	target	cell	by	apoptosis.		CD52	is	predominantly	expressed	on	T	and	B-lymphocytes	although	it	is	also	found	to	a	 lesser	 extent	 on	 NK	 T-cells,	monocytes	 and	macrophages	 (185).	 	 Studies	 on	Campath	 have	 found	 that	 it	 reprograms	 the	 immune	 system,	 suppressing	production	 of	 pro-inflammatory	 IFN-γ	 and	 IL-17	 and	 increasing	 anti-
inflammatory	cytokines	such	as	IL-4	and	IL-10	(186).		It	was	initially	licensed	for	use	in	lymphoma,	however	it	has	been	investigated	in	renal	transplantation	with	satisfactory	short-term	outcomes;	long-term	results	are	still	unknown.	 	It	is	not	routinely	 used	 in	 our	 unit,	 however	 as	 part	 of	 a	 concurrently	 running	 multi-center	 randomized	 control	 trial,	 some	 of	 the	 subjects	 of	 this	 study	 did	 receive	Campath.		Side	effects	include	cytokine	release	syndrome	although	this	is	usually	mild,	 particularly	 when	 compared	 with	 the	 effects	 of	 ATG.	 Rare	 anaphylactic	reactions	 have	 been	 reported	 and	 other	 effects	 include	 neutropenia,	 anemia,	thrombocytopenia	and	autoimmune	thyroid	disease	(187).		
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The	use	of	Simulect	(Basiliximab)	is	more	wide	spread.		Simulect	is	an	anti	CD25	antibody	 (Fig.	 1),	 CD25	 is	 found	 on	 the	 IL-2	 receptor	 and	 is	 expressed	 by	activated	T-cells	 and	mature	dendritic	 cells.	The	 clinical	 effects	of	 Simulect	 are	caused	by	inhibition	of	T-cell	activation	and	proliferation.		The	antibodies	remain	in	 the	 patient’s	 system	 for	 up	 to	 3	months,	 causing	 destruction	of	 activated	T-cells	during	this	period.	 	Unlike	ATG,	Simulect	does	not	typically	produce	a	first	dose	 reaction	 (although	 it	 is	 possible	 to	 have	 anaphylactic	 responses)	 and	 is	relatively	 free	of	other	side	effects.	 	 In	renal	 transplantation	Simulect	 induction	significantly	 reduced	 episodes	 of	 acute	 rejection	 when	 compared	 with	 no	induction	immunosuppression.		However,	although	historically	the	occurrence	of	rejection	 predicts	 graft	 loss,	 no	 benefit	 in	 five-year	 graft	 survival	 has	 been	demonstrated	(188-190).	 	These	 findings	have	been	echoed	 in	the	 field	of	 liver	transplantation	in	a	recent	systematic	review	(191).		A	number	of	studies	have	compared	ATG	with	Simulect;	the	evidence	is	slightly	conflicted,	 but	 suggests	 overall	 that	 ATG	 is	 of	 benefit	 in	 moderate	 to	 high	immunological	 risk	 deceased	 donor	 recipients	 (192-194);	 this	 is	 the	 strategy	adopted	by	our	unit.	 	No	demonstrable	benefit	of	ATG	has	been	detected	in	the	low	immunological	risk	group	(195)	and	therefore	Simulect	is	used	in	this	group	by	our	unit	due	 to	 its	 favourable	 side-effect	profile.	 	During	part	of	 the	 subject	recruitment	 and	 sample	 collection	 phases	 for	 this	 project,	 our	 unit	 was	participating	 in	 a	 national	 multi-center	 trial	 that	 involved	 randomization	 to	receive	 either	 Campath	 or	 Simulect	 induction.	 	 Therefore	 when	 we	 come	 to	explore	 the	 results	 we	 have	 three	 different	 induction	 immunosuppression	groups	to	consider	(those	who	were	not	enrolled	in	the	national	study	received	the	standard	departmental	induction,	which	at	that	time	was	ATG).		1.6.1.2.		Corticosteroids	Corticosteroids	are	used	for	induction,	maintenance	and	rescue	therapy	in	renal	transplantation.	 	 They	 are	 anti-inflammatory	 as	 well	 as	 immunosuppressive	drugs	 and	 have	 a	 therapeutic	 role	 in	 a	 variety	 of	 conditions.	 	 In	 renal	transplantation,	 intravenous	 methylprednisolone	 is	 used	 at	 a	 high	 dose	 at	induction	 and	 may	 also	 be	 used	 in	 the	 treatment	 of	 acute	 rejection.	 	 Oral	
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prednisolone	is	used	for	maintenance;	the	dose	starts	initially	at	20mg	daily	and	is	weaned	over	a	period	of	time	depending	upon	clinical	and	patient	factors.		The	effects	of	prednisolone	are	predominantly	glucocorticoid	although	 it	does	have	some	mineralocorticoid	activity.				Corticosteroids	 influence	the	gene	transcription	of	pro-inflammatory	cytokines,	particularly	 IL-1	 IL-2,	 IL-6,	TNF-α	and	 IFN-γ.	 	A	 reduction	 in	 the	production	of	these	 cytokines	 (Fig.	1)	 results	 in	 a	 blunting	of	 the	 inflammatory	 response	 but	perhaps	more	importantly,	impairs	the	function	of	circulating	macrophages	and	CD4+	T-cells.	 	Other	 important	effects	of	 corticosteroids	 include	a	 reduction	 in	prostaglandin,	 histamine	 and	 bradykinin	 release	 and	 decreased	 capillary	permeability	(196).			
1.6.2.		Maintenance	therapy	
	Maintenance	 immunosuppression	 is	 used	 for	 the	 life	 of	 the	 graft	 to	 prevent	rejection;	 it	 is	 comprised	of	 a	 combination	of	 two	or	 three	agents	and	 is	 taken	daily.		Maintenance	therapy	is	usually	started	on	the	first	post-operative	day;	it	is	therefore	not	relevant	to	the	main	focus	of	this	study,	which	is	in	the	few	hours	following	 reperfusion	 of	 the	 graft.	 	 The	 agents	 used	 include	 Cyclosporine	 and	Tacrolimus	 (both	 calcineurin	 inhibitors);	 mycophenolate	 mofetil	 (MMF)	 and	mycophelolate	 sodium	 (Myfortic)	 (both	 inhibitors	of	 nucleotide	 synthesis)	 and	Sirolimus,	which	is	a	mammalian	target	of	rapamycin	(mTOR)	inhibitor.		The	3C	trial	 (which	was	recruiting	at	 the	same	time	as	 this	study	and	 in	which	several	 of	 our	 subjects	 were	 also	 participating)	 comprised	 2	 treatment	 arms.		The	 first	 group	 received	Campath	 induction,	Myfortic	 and	calcineurin	 inhibitor	(CNI)	 maintenance,	 switching	 to	 Sirolimus	 at	 6	 months.	 	 The	 second	 group	received	Simulect	induction	and	standard	maintenance	(CNI	and	Prednisolone).		Initial	results	have	a	reduction	in	acute	rejection	in	the	group	receiving	Campath	induction	followed	by	low	dose	CNI,	Myfortic	and	steroid	avoidance	(197).		The	
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long-term	results	of	 the	 trial,	 including	 those	 from	 the	 group	who	 switched	 to	mTOR	inhibitors	at	6	months,	are	awaited.		The	 preceding	 text	 has	 highlighted	 the	 likely	 importance	 of	 the	immunosuppression	 on	 the	 results	 of	 this	 study	 via	 their	 effects	 on	 cytokine	release.	 One	 of	 the	 aims	 of	 this	 project	 is	 to	 look	 at	 the	 effect	 different	immunosuppression	 regimens	 have	 on	 cytokines	 and	 how	 this	may	 affect	 NO	levels.			
1.7.		Therapeutic	Approach	to	IRI	and	Clinical	Implications	of	DGF	
	We	have	seen	how	IRI	results	in	damage	to	grafts	used	for	organ	transplantation	as	 well	 as	 to	 other	 organs	 in	 vivo	 after	 ischemic	 events	 such	 cerebrovascular	accident	 or	 myocardial	 infarction.	 	 Therapeutic	 approaches	 to	 attenuate	 the	injury	have	therefore	been	studied	widely.		In	organ	transplantation,	the	clinical	manifestation	 of	 IRI	 is	 DGF	 and	 this	may	 be	 reviewed	 by	 considering	 the	 risk	factors	 that	 predict	 injury	 as	 well	 as	 interventions	 in	 the	 recipient,	 organ	preservation	and	interventions	in	the	donor.		
	
1.7.1.		Risk	factors	for	DGF		The	most	important	epidemiological	associations	for	DGF	are	cold	ischemic	time;	DCD	 kidneys;	 donor	 age;	 donor	 body	 mass	 index	 (BMI)	 and	 donor	 creatinine	levels	 (198).	 	Many	 attempts	have	 been	made	 to	 develop	 scoring	 systems	 that	quantify	an	individual’s	risk	for	DGF,	however	they	have	thus	far	been	unreliable	or	 impractical.	 	 Experimentally,	 levels	 of	 urinary	 IL-18	 and	 NGAL	 (neutrophil	gelatinase-associated	lipocalin)	at	day	zero	may	be	predictors	of	DGF	(C	statistic	=	 0.9)	 (199).	 	 Biomarkers	 in	 machine	 perfusate	 (taken	 from	 hypothermic	machine	 perfusion)	 have	 also	 showed	 associations	with	DGF	 (200).	 Our	 group	has	a	strong	interest	in	this	area.		
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Recipient	characteristics	Certain	patient	characteristics	in	the	recipient	may	also	place	them	at	increased	risk	 of	 DGF,	 with	 maintenance	 dialysis	 prior	 to	 transplant	 being	 the	 single	greatest	 influence	 (201).	 	 Other	 factors	 including	 high	BMI,	 diabetes,	 age	 >	 55	years,	 male	 sex,	 African	 American	 race,	 prolonged	 waiting	 period,	 immune	sensitizing	events	and	small	for	size	organs	(198).	
	
	
1.7.2.		Prevention	and	treatment	targets	
	1.7.2.1.		Recipient	Identification	 of	 those	 at	 high	 risk	 of	 DGF	 through	 the	 use	 of	 biomarkers	 and	genomic	 studies	 preoperatively	 may	 facilitate	 targeted	 interventions	 with	pharmacological	agents.		Single	nucleotide	polymorphisms	(SNP)	for	TLR3	have	been	 identified,	 as	 well	 as	 a	 polymorphism	 in	 the	 TNF	 gene;	 these	polymorphisms	 have	 both	 been	 found	 in	 a	 higher	 than	 expected	 frequency	 in	patients	 with	 DGF	 (202,	 203).	 	 Other	 polymorphisms	 in	 IFN-g	 might	 also	 be	cytoprotective	 and	 we	 hope	 to	 be	 able	 to	 explore	 this	 by	 measuring	 these	cytokines	in	our	subject	group.		
Pharmacological	interventions	in	the	recipient	Possible	 pharmacological	 approaches	 for	 attenuating	 DGF	 in	 the	 recipient	include	 vasodilatory	 agents,	 anti-inflammatory	 agents	 and	 induction	immunosuppression.	 	Agents	 that	prevent	vasoconstriction,	 such	as	endothelin	receptor	 antagonists,	 calcium	 channel	 blockers	 and	 adenosine	 A1	 receptor	antagonists,	have	been	studied	with	inconclusive	results	(204,	205).		NO	itself	has	been	investigated	in	animal	models	of	heart,	lung,	liver	and	kidney	IRI.	 	Its	administration	has	been	either	by	inhalation,	(i.e.	a	systemic	treatment)	or	by	 topical	 application	of	L-arginine,	 the	primary	 substrate	 for	NOS.	 	 Several	studies	 have	 found	 that	 inhaled	 NO	 reduces	 infarct	 size	 and	 improves	 cardiac	function	 in	mouse	models	of	 IRI	(206,	207).	 	 In	 the	 lungs,	both	inhaled	NO	and	NO	augmentation	has	shown	promising	results	in	animal	models	of	IRI	(208).		In	
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liver	transplantation,	supplementation	with	NO	exerted	a	protective	effect	on	the	graft	 (209,	 210)	 and	 similar	 findings	 have	 been	 reported	 in	 the	 kidney	 (211,	212).				It	is	important	to	note	that	the	studies	referenced	above	which	are	reporting	on	NO	augmentation	are	describing	 indirect	 effects	of	NO,	 i.e.	 therapeutic	 agent	 is	administered	 which	 modulates	 the	 NO	 axis	 in	 some	 way	 to	 increase	 NO	concentration.		The	authors	are	therefore	hypothesizing	that	the	effects	seen	are	directly	 attributable	 to	 NO;	 from	what	 we	 know	 about	 the	 NO	 axis	 there	 are	likely	to	be	several	other	molecules	generated	that	may	also	be	influential.				Anti-inflammatory	agents	 that	prohibit	migration	of	cells	 involved	 in	either	the	innate	or	adaptive	immune	system	have	been	considered	with	varying	degrees	of	success	 in	 the	 treatment	 of	 IRI.	 	 These	 agents	 include	 recombinant	 P-selectin	glycoprotein	ligand	IgG	fusion	protein;	QPI-1002,	which	inhibits	p53	activation,	Erythropoietin	 and	 CXCR	 inhibitors.	 	 Although	 the	 theoretical	 benefits	 are	discernible,	none	have	shown	conclusive	evidence	in	clinical	application	(213).				Maintenance	 immunosuppression	 is	 usually	 commenced	 as	 triple	 therapy	involving	a	 steroid,	mycophenolic	 acid	and	a	 calcineurin	 inhibitor.	 	Calcineurin	inhibitors	 (such	 as	 Tacrolimus)	 mediate	 vasoconstriction.	 	 A	 recent	 meta-analysis	showed	calcineurin	inhibitor	avoidance	in	the	immediate	post	operative	period	was	 associated	with	 significantly	 less	DGF.	 	However,	 unsurprisingly,	 it	also	observed	significantly	higher	rates	of	acute	rejection	(214).		Although	all	of	the	therapies	above	have	been	trialed,	to	mitigate	DGF	in	various	organ	systems,	none	 of	 them	 have	 been	 incorporated	 into	 routine	 clinical	 practice.	 	 It	 would	therefore	be	reasonable	to	conclude	that	 therapeutic	agents	 to	prevent	or	 treat	DGF	remain	at	an	experimental	stage.		1.7.2.2.		Organ	preservation	techniques	Once	 the	 organ	 has	 been	 retrieved	 there	 is	 a	 window	 of	 time	 available	 to	transport	 and	 implant	 it	 without	 occurring	 permanent	 tissue	 damage;	 this	 is	known	 as	 the	 ‘cold	 ischemic	 time’	 (CIT)	 and	 as	 mentioned	 previously	 is	 and	
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important	 factor	 in	 the	 development	 of	 DGF.	 	 Cooling	 the	 organ	 (to	 4°C)	decreases	 the	 cellular	 metabolic	 rate	 and	 therefore	 attenuates	 injury	 (215).		Preservation	solutions	are	designed	to	maintain	osmotic	gradients	and	to	delay	acidosis	with	H+	buffer	systems;	 they	are	used	along	with	 cooling	 to	 transport	the	organ	in	a	standard	method	of	cold	static	storage.			Hypothermic	machine	perfusion	is	now	becoming	a	widely	used	practice	within	renal	transplantation;	studies	have	found	it	reduces	rates	of	DGF	particularly	in	ECD	 and	 DCD	 organs	 (216,	 217).	 	 Normothermic	 machine	 perfusion	 has	 also	been	 investigated	 although	 it	 is	 still	 at	 an	 experimental	 stage.	 	 This	 is	 a	warm	oxygenated	perfusion,	 the	aim	of	which	is	 to	maintain	cell	metabolism	but	may	also	allow	the	delivery	of	pharmacological	agents	or	gene	therapy	(218-220).		1.7.2.3.		Interventions	in	the	donor	Use	of	dopamine	in	stable	DBD	donors,	up	to	the	point	of	cross	clamping	during	the	donation,	has	been	 investigated;	 rates	of	DGF	were	 found	 to	be	 reduced	 in	the	treated	group	(24.7%	vs	35.4%;	p	=	0.01),	subgroup	analysis	found	that	this	effect	was	 greatest	 in	 organs	whose	 cold	 ischemic	 times	were	17.1-34.4	hours	(221).	 	 Calcium	 channel	 blockers	 have	 also	 been	 used	 in	 the	 donor,	 in	 the	recipient	and	 in	 the	perfusion	 fluid,	with	 reduced	 rates	of	DGF	 reported	 in	 the	treatment	 groups	 (222).	 	 Administration	 of	 Diannexin	 (which	 blocks	 a	 pro-inflammatory	 pathway)	 to	 marginal	 donors	 prior	 to	 organ	 retrieval	 has	 been	associated	with	 reduced	 incidence	and	duration	of	dialysis	 in	 recipients	 (223).		Once	again	none	of	these	interventions	are	used	routinely	in	clinical	practice	and	can	largely	be	considered	experimental	only.	
	
Ischemic	preconditioning	Ischemic	preconditioning	is	an	experimental	strategy	in	which	exposure	to	short,	sub-lethal	 episodes	 of	 ischemia	 results	 in	 attenuated	 tissue	 injury	 following	subsequent	 prolonged	 ischemia	 and	 reperfusion.	 	 The	 intervention	 can	 be	performed	in	both	the	donor	and	the	recipient	and	may	be	at	a	site	remote	to	the	graft.		This	phenomenon	is	profound	in	animal	studies	and	clinical	trials	are	now	being	published	showing	the	same	effects	(224-227)	
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1.7.3.		Management	of	DGF	
	Management	 of	DGF	 is	 largely	 supportive;	 other	 diagnoses	 should	 be	 excluded	and	 serial	 biopsies	 should	 be	 taken	 of	 the	 implanted	 organ	 to	 exclude	 acute	rejection	 and	 confirm	 ATN.	 	 Haemodialysis	 may	 be	 clinically	 necessary	 post	operatively	 to	 treat	 hyperkalemia,	 fluid	 overload	 or	 symptomatic	 uremia;	 its	influence	 on	 duration	 of	 DGF	 is	 not	 known.	 	 Haemodynamic	 instability	 and	nephrotoxins	should	be	avoided	in	any	patient	with	acute	kidney	injury	(228).		In	the	last	decade,	our	improved	understanding	of	the	mechanisms	of	oxidative	stress,	 vasospasm,	 cytokine	 signaling,	 endothelial	 cell	 injury	 and	 the	 immune	system	has	offered	potential	 therapeutic	 targets	 to	 treat	 IRI	 and	DGF,	but	 they	still	remain	significant	contributors	to	morbidity	and	mortality	in	the	transplant	recipient.		We	know	that	the	detrimental	effects	of	DGF	on	both	the	graft	life	and	patient	survival	are	significant	for	the	renal	transplant	recipient,	this	study	aims	to	look	at	nitric	oxide	and	its	metabolites	in	patients	at	highest	risk	of	DGF.	
		
Conclusion	
	Ischemia	and	reperfusion	are	inevitable	consequences	of	organ	transplantation.	Unlike	tissue	IRI	resulting	from	arterial	occlusion	(such	as	myocardial	infarction	in	 the	 heart),	 transplantation	 is	 unique	 in	 that	 there	 is	 complete	 cessation	 of	blood	flow,	removal	and	cooling	of	the	organ	followed	by	re-implantation	after	a	period	 of	 time.	 	 In	 this	 time,	 ischemia	 deprives	 cells	 of	 the	 energy	 needed	 to	maintain	 homeostasis	 leading	 to	 cellular	 injury,	 oedema	 and	 release	 of	 free	radicals.		On	reperfusion,	release	of	pro	inflammatory	cytokines	activate	immune	responses	in	order	to	allow	repair	and	regeneration	processes	to	begin.		The	fate	of	 the	 graft	 is	 therefore	 dependent	 on	 regeneration,	 as	 opposed	 to	 cell	 death,	prevailing.		In	transplantation	the	clinical	manifestation	of	IRI	is	delayed	graft	function	(DGF)	(229).	 	 We	 know	 that	 DGF	 results	 in	 poorer	 clinical	 outcomes	 for	 grafts	 and	
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recipients.	 	The	greater	 the	extent	of	 the	 IRI,	 the	greater	 the	 immune	response	and	 the	 potential	 for	worse	 allograft	 outcome.	 	 Long	 CIT	 times	 are	 associated	with	 higher	 levels	 of	 circulating	 anti-donor	 antibodies	 as	 well	 as	 with	complement	 binding	 with	 immunoglobulin	 complexes	 (230)	 in	 the	 immediate	post	 operative	 period.	 	 Longer	 term,	 biopsy	 proven	 chronic	 allograft	 changes	including	interstitial	fibrosis,	tubular	atrophy	and	endothelial	and	tubular	basal	membrane	thickening	are	also	linked	with	the	duration	of	cold	ischemia	(231).		In	 this	 study	 we	 investigate	 the	 relationship	 of	 NO	 production	 within	 this	pathway;	the	dichotomous	role	of	NO	in	IRI	provides	an	interesting	platform	for	this.	 	 We	 hypothesise	 that	 at	 low	 concentrations	 NO	 is	 protective,	 causing	vasodilation	thereby	potentially	reducing	the	no	reflow	phenomenon.		However	at	 higher	 concentrations,	 the	 inevitable	 production	 of	 toxic	 free	 radicals	 has	 a	deleterious	 effect.	 	 We	 will	 be	 looking	 at	 concentrations	 of	 NO	 metabolites	around	the	time	of	renal	transplantation	in	the	context	of	donation	after	cardiac	death	organs.	We	selected	those	we	expected	to	have	greater	 IRI	and	therefore	higher	 rates	 of	 DGF.	 	 We	 will	 also	 investigate	 the	 concentrations	 of	 pro-inflammatory	cytokines	responsible	for	stimulation	of	NO	production	and	look	to	see	 if	 the	 induction	 immunosuppression	modifies	 the	 pro-inflammatory	milieu	and	consequently,	the	NO	response.			
1.8.		Previously	Published	Work		Previously	 our	 unit	 has	 investigated	 topics	 relevant	 to	 this	 project	 that	 have	helped	 in	 the	 development	 of	 this	 study	 design.	 	 This	 includes	 work	 on	 the	polymorphic	expression	of	the	cytokine	IFN-γ	and	also	on	nitric	oxide	(52).		
Polymorphic	expression	of	IFN-γ	There	 have	 been	 many	 studies	 considering	 the	 possibility	 that	 a	 genetic	predisposition	 to	 produce	 a	 higher	 or	 lower	 amount	of	 various	 cytokines	may	contribute	to	outcomes	in	transplantation.		This	is	a	poignant	question	as,	if	this	paradigm	could	be	mapped,	it	may	allow	the	immunosuppression	regimen	to	be	
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customized	 to	 the	 patients’	 genetic	 predisposition	 to	 reject	 their	 transplanted	organ.		The	 level	 of	 IFN-γ	 production	 in	 the	 UK	 population	 has	 been	 shown	 to	 be	associated	with	polymorphic	expression	of	a	microsatellite	sequence	on	the	first	intron	of	 the	human	 IFN-γ	gene	 (232)	 (located	on	chromosome	12q24.1).	 	The	microsatellite	itself	is	a	non-functioning	part	of	the	gene,	however,	in	the	case	of	IFN-γ,	 microsatellite	 polymorphisms	 have	 been	 associated	 absolutely	 with	 a	single	 nucleotide	 polymorphism	 (SNP)	 of	 T	 to	 A	 at	 +874	 (233).	 	 To	 date,	 five	different	alleles	of	the	previously	discussed	microsatellite	have	been	described	in	the	UK	population.		Patients	may	be	homo	or	heterozygotes	for	any	combination	of	 the	 alleles;	however,	 it	 has	 been	 shown	 that	 patients	who	 express	 allele	#2	produce	more	IFN-γ	compared	to	those	that	do	not.		Furthermore,	patients	who	are	 homozygotes	 for	 allele	 #2	 produce	 more	 IFN-γ	 than	 any	 of	 the	 other	combinations	 (232).	 	 It	 has	 been	 shown	 conclusively	 that	 allele	 #2	 correlates	absolutely	with	the	functional	SNP	+874T.		Patients	may	therefore	be	genetically	sequenced	to	determine	which	one	of	three	possible	groups	they	fall	into:	- T/T	are	homozygotes	for	allele	#2	(highest	IFN-γ	producer)	- T/A	are	heterozygotes	for	allele	#2	(high	IFN-γ	producer)	- A/A,	allele	#2	is	absent	from	their	genome	(low	IFN-γ	producer)		The	 clinical	 significance	 of	 this	 polymorphism	 has	 been	 investigated;	 in	 renal	transplant	 recipients	 the	 T/T	 homozygote	 genotype	 is	 associated	 with	 higher	incidence	 of	 acute	 rejection	 episodes	 and	 chronic	 allograft	 nephropathy	 (234,	235).	 	 In	 lung	transplant	recipients	 the	presence	of	allele	#2	 is	associated	with	graft	fibrosis	(236),	further	more,	in	the	general	population	it	has	been	found	to	be	 protective	 against	 arthritis	 and	 systemic	 lupus	 erythematosus	 (237).	 	 	 As	previously	discussed,	 the	microsatellite	 is	 in	 itself	non-functional,	however	 the	+874T	 polymorphism,	 with	 which	 allele	 #2	 is	 associated,	 encodes	 the	 NF-κB	binding	site	(238).	 	It	is	hypothesized	that	this	accounts,	at	least	in	part,	for	the	functional	consequences	of	the	polymorphism.	
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NO	Our	group	has	previously	studied	NO	and	its	metabolites	in	the	context	of	renal	transplantation.		We	have	found	that	there	is	a	significant	increase	in	NO	during	episodes	of	acute	rejection;	this	was	studied	in	all	types	donor	kidney	(239).		We	have	 also	 found	 that	 NO	 levels	 differ	 between	 donor	 types;	 to	 account	 for	individual	 variability	 in	 baseline	 production	 this	 was	 calculated	 using	 a	reperfusion	ratio,	i.e.	the	difference	between	pre	operative	concentration	and	the	concentration	post	reperfusion	of	 the	 transplanted	organ,	 expressed	as	a	 ratio.		This	 reperfusion	 ratio	 was	 significantly	 higher	 in	 the	 recipients	 of	 DCD	 renal	transplants	when	compared	to	DBD	kidneys	and	also	that	 there	was	a	 trend	of	increase	in	the	ratio	when	moving	from	Living	donor	to	DBD	transplants.		To	summarize	previous	work	on	this	topic,	we	know	that	cytokines	are	produced	in	 variable	 amounts	 by	 members	 of	 the	 UK	 population	 depending	 upon	 their	genome,	 and	 in	 the	 case	of	 IFN-γ	 this	 is	determined	by	 the	SNP	+874T.	 	 IFN-γ	induces	up	regulation	of	iNOS	on	activated	macrophages	(via	its	activation	of	NF-κβ)	 and	 so	 is	 contemporaneous	 with	 the	 immune	 response	 to	 organ	transplantation.	 	NO	levels	differ	between	donor	groups	and	this	maybe	related	to	the	varying	levels	of	ischemic	insult.			
1.9.	Project	Objectives	
1.9.1.		Hypothesis	
	In	DCD	renal	 transplant	recipients	we	hypothesize	that	we	will	 find	changes	 in	the	levels	of	NO	metabolites	during	the	early	phase	of	organ	transplantation	and	that	these	changes	may	be	associated	with	known	risk	factors	for	delayed	graft	function	in	the	transplanted	organ.		We	expect	to	find	a	relationship	between	the	levels	of	NO	metabolites	and	the	 induction	 immunosuppression	agent	given	via	the	effects	of	immunosuppression	on	cytokine	production.		We	anticipate	finding	variability	 in	 the	 production	 of	 cytokines	 depending	 on	 the	 induction	immunosuppressive	agent	given.			
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1.9.2.		Aims	
	The	experimental	aims	of	this	study	are:	-		1.		To	investigate	the	levels	of	NO	metabolites	in	the	early	post-operative	period	in	patients	undergoing	renal	transplantation	using	two	different	methods.	2.	 To	 explore	 the	 role	 of	 NO	 in	 renal	 transplantation	 by	 investigating	 it’s	relationship	with	known	risk	factors	for	DGF.	3.		To	explore	the	role	cytokines	play	in	NO	production.		We	intend	to	study	levels	of	NO	metabolites	and	pro-inflammatory	cytokines	in	patients	 undergoing	 DCD	 kidney	 transplantation	 who	 are	 given	 different	induction	 immunosuppression.	 	 Results	 will	 be	 correlated	 with	 the	 rate	 of	delayed	graft	function	as	well	as	donor	and	recipient	characteristics.						
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CHAPTER	2:		METHODOLOGY																																	
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The	 following	chapter	will	describe	the	patient	selection,	sample	collection	and	experiments	performed	during	 this	project.	 	This	study	consisted	of	 two	parts;	the	first	part	incorporated	data	from	work	done	previously	at	Cardiff	Transplant	Unit,	 which	 looked	 at	 nitrate	 levels	 in	 living	 donor	 (LD),	 DBD,	 and	 DCD	 renal	transplants.	The	main	purpose	of	this	previous	study	was	association	of	nitrate	levels	with	acute	rejection	and	DGF.		However,	we	were	able	to	use	some	of	this	data,	 together	 with	 our	 own	 early	 samples,	 to	 conduct	 our	 pilot	 study.	 	 The	second	part	of	the	study	concentrates	on	DCD	renal	transplants	and	is	the	main	focus	of	this	work.		
2.1.		Part	1	Method	
2.1.1.		Experimental	subjects	
	Fifty-eight	 consecutive	 renal	 transplant	 recipients,	 who	 provided	 informed	consent,	were	 recruited	at	 the	University	Hospital	of	Wales	between	 July	2002	and	May	 2003.	 	 Three	 recipients	 had	 early	 transplant	 nephrectomy	 and	were	excluded	 from	 further	 analysis	 (1	 for	 bleeding	 secondary	 to	 previously	undiagnosed	 acute	 myeloid	 leukaemia	 and	 2	 for	 renal	 vein	 thrombosis).	 	 We	added	to	this	cohort	of	patients	with	samples	taken	from	our	first	eleven	patients	(methods	for	which	are	described	in	section	2.2).		The	total	population	of	part	1	of	 the	study	therefore	comprised	of	9	LD,	31	DBD	and	29	DCD	renal	 transplant	recipients.		The	departmental	protocol	for	immunosuppression	was	followed	for	all	of	the	patients	in	the	study,	however	this	changed	between	the	two	periods	of	recruitment;	 the	 first	58	patients	were	given	 500	milligrams	 (mg)	 intravenous	(IV)	 of	 methyl	 prednisolone	 intra-operatively.	 	 The	 remainder	 of	 the	 patients	were	treated	in	accordance	with	the	policy	at	the	time	of	their	recruitment	and	this	is	described	in	detail	in	section	2.2.		
2.1.2.		Sample	preparation	Peripheral	 blood	 samples	were	 collected	 pre-operatively	 and	 at	 2	 hours	 post-reperfusion	of	the	kidney	in	EDTA	tubes.		The	specimens	were	centrifuged	at	800	
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G	 for	 20	minutes	 and	 supernatant	 collected	 and	 stored	 at	 -80	 degrees	 Celsius	(°C)	for	analysis	at	a	later	date.	 	On	the	day	of	the	analysis,	the	specimens	were	thawed	and	vortexed.		
2.1.3.	Sample	analysis	All	of	 the	samples	were	analysed	 in	duplicate	using	the	Griess	reaction;	nitrate	and	nitrite	levels	were	determined	using	the	Parameter,	total	NO/Nitrite/Nitrate	kit	from	R&D	Systems.				2.1.3.1.		Scientific	principle	The	principle	of	the	assay	relies	on	colorimetric	detection	of	nitrite	as	an	azo-dye	product	of	the	Griess	reaction.	 	The	first	step	is	enzymatic	conversion	of	nitrate	to	 nitrite	 by	 nitrate	 reductase.	 	 The	 nitrite	 then	 reacts	 with	 sulfanilic	 acid	 to	produce	diazonium	ion,	which,	in-turn,	couples	with	N-ethylenediamine	to	form	an	azo-derivative.		The	azo-dye	absorbs	light	and	so	a	spectrophotometer	is	used	at	 540	 nanometer	 (nm)	 to	 determine	 levels	 of	 nitrite.	 	 This	 gives	 the	 total	concentration	 of	 nitrate	 and	 nitrite	 in	 a	 sample.	 	 To	 establish	 their	 individual	values	endogenous	nitrite	is	measured	first	by	omission	of	the	nitrate	reductase	enzyme	step.	 	This	value	is	subtracted	from	the	converted	nitrite	concentration	obtained	by	 carrying	out	enzymatic	 conversion	of	nitrate	 to	nitrite,	 to	give	 the	endogenous	nitrate	value.		We	 determined	 the	 nitrite	 and	 nitrate	 levels	 using	 the	 Griess	 reaction	 in	 all	samples;	 the	amount	of	nitrite	 in	 the	samples	was	negligible	and	so	the	nitrate	only	was	used	for	analysis.				2.1.3.2.		Griess	reaction	-	methods	The	 testing	 took	place	 in	 the	 laboratory	at	 the	 Institute	of	Nephrology,	Cardiff.		Good	 laboratory	 practice	 was	 followed	 at	 all	 times	 during	 these	 experiments.		The	procedure	is	detailed	in	appendix	2.			
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Calculation	of	results		We	 calculated	 average	 duplicate	 reading	 for	 each	 standard	 and	 sample	 and	subtracted	 the	 average	 blank	 standard	 optical	 density.	 	 A	 standard	 curve	was	created	by	plotting	mean	absorbance	for	each	standard	on	the	y-axis	against	the	total	nitrite	concentration	on	the	x-axis.	 	The	nitrite	concentrations	were	taken	from	the	corresponding	mean	absorbance	and	the	dilution	factor	was	corrected	to	 leave	 a	 value	 in	 μmol/l.	 	 Nitrate	 values	were	 calculated	 by	 subtracting	 the	endogenous	 nitrite	 concentration	 from	 the	 total	 nitrite	 concentration	 (after	nitrate	reductase)	using	the	plate	reader	(OPTIMA,	BMG	LABTECH).			
	
Figure	 2.1.	 	 An	 example	 of	 Griess	 reaction	 results.	 	 This	 shows	 the	 standard	
curve	and	the	calculation	of	results	that	is	produced	by	the	plate	reader.		Standard	
curve	r	=	0.99742	
	
2.1.4.		Statistical	analysis	Clinical	data	from	the	patients	was	collected	around	the	time	of	transplantation	and	during	the	follow	up	period	of	3	-	6	months	from	the	departmental	database	(VITALDATA).	 	 Statistical	 analysis	 was	 performed	 using	 IBM	 SPSS	 Statistics	
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version	20.	 	Data	was	expressed	as	a	ratio	between	the	pre	and	post-operative	nitrate	concentration	and	handled	using	non-parametric	tests.		The	nitrite	values	were	 not	 reported,	 as	 many	 of	 the	 tests	 returned	 un-recordable	 results;	 this	problem	is	addressed	in	more	detail	in	part	two	of	the	study	(see	section	2.4).		In	all	analysis	differences	with	p	<	0.05	were	considered	statistically	significant.		
	
2.2.		Part	2	Methods	
2.2.1.		Experimental	subjects	
	A	 total	 of	 35	 consecutive	 DCD	 kidney	 graft	 recipients	 transplanted	 at	 Cardiff	Transplant	Unit	between	January	2012	and	October	2014	were	studied.		Patients	were	excluded	only	if	they	were	not	deemed	competent	to	consent.		All	patients	who	were	 approached	 agreed	 to	 participate	 in	 the	 study,	 the	 consent	 form	 is	shown	in	appendix	3.		This	 was	 a	 non-interventional	 study	 and	 patient	 immunosuppression	 was	managed	 according	 to	 the	unit’s	 standard	 protocols	 and	 the	one	 of	 a	 separate,	concurrently	running	study	(197,	240).		The	departmental	protocol	for	recipients	of	DCD	renal	transplants	during	the	study	period	was	to	use	ATG	as	induction;	as	we	discussed	 in	chapter	1,	ATG	causes	release	of	cytokines;	particularly	TNF-α,	IL-1	and	IL-6.		These	in	turn	contribute	to	up	regulation	of	iNOS	and	therefore	we	would	expect	ATG	induction	to	have	an	effect	on	NO	production.	 	However,	we	should	bear	 in	mind	 that	ATG	 is	 administered	over	a	period	of	4	hours	 (which	commences	after	 the	 induction	of	anaesthesia)	with	a	high	dose	steroid	and	an	antihistamine	 (in	 order	 to	 reduce	 the	 clinical	 side	 effects	 of	 cytokine	 release	syndrome)	and	these	factors	may	interfere	with	this	anticipated	effect.		During	 the	 period	 of	 patient	 recruitment	 there	 was	 a	 concurrently	 running	national	 trial	 that	 the	 unit	 participated	 in	 (Campath,	 calcineurin	 inhibitor	reduction	 and	 chronic	 allograft	 nephropathy	 (3C)	 study	 (197,	 240)).	 	 Patients	who	were	also	enrolled	in	this	study	were	randomized	to	receive	either	Campath	or	Simulect	induction	as	opposed	to	the	usual	ATG	induction.			
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The	immunosuppression	regimens	were	as	follows:			1. ATG	 (1.25	 mg/kg	 day	 0-4)	 and	 Methyprednisolone	 (500	mg	 IV,	 day	 0)	with	oral	maintenance	of	Tacrolimus	 	 (0.025	mg/kg	BD),	MMF	 (1	g	BD)	and	Prednisolone	(20	mg	OD).	2. Simulect	 (20mg	 IV,	day	0	and	day	4)	and	Methyleprednisolone	 (500	mg	IV)	with	oral	maintenance	of	Tacrolimus		(0.05	mg/kg	BD),	MMF	(1g	BD)	and	Prednisolone	(20mg	OD).	3. Patient	 participating	 in	 a	 different	 study	 were	 randomized	 to	 receive	either,	Campath	(30mg	s/c	day	0	and	day	1)	or	Simulect	(20	mg	IV,	day	0	and	 day	 4)	 and	Methyplrednisolone.	 	 Followed	 by	 either	 Tacrolimus	 or	Sirolimus,	 MMF	 or	 Myfortic,	 and	 either	 20mg	 of	 Prednisolone	 or	 no	maintenance	steroid.		 Information	on	 the	 immunosuppression	 regimen	was	 recorded	as	part	of	 the	data	collection.		
	
2.2.2.		Sample	preparation	
	If	 a	 patient	 consented	 to	 participate	 in	 our	 study	 then	 10mls	 of	 peripheral	whole	blood	was	collected	in	EDTA	bottles	at	eight	time	points	(shown	below)	around	the	time	of	 transplantation.	 	Peripheral	blood	was	selected	to	analyse	(as	opposed	to	urine)	as	DGF	was	expected	in	at	least	50%	of	the	subjects	and	may	cause	anuria.		Taking	samples	from	the	renal	vein	would	have	allowed	us	to	more	accurately	reflect	changes	of	NO	metabolites	directly	attributed	to	the	kidney.	The	ethics	committee	felt	that	the	risks	of	renal	vein	sampling	were	an	unknown	 quantity	 in	 this	 context	 and	 therefore	 this	 was	 not	 an	 acceptable	intervention.	 	 We	 also	 anticipated	 that	 renal	 vein	 sampling	 may	 deter	 the	operating	surgeon	from	allowing	their	patients	to	participate	in	the	study.				
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Timing	of	sample	collections:	1. Sample	A:		Pre-operatively	2. Sample	B:		30	minutes	post-induction	of	anaesthesia	3. Sample	 C:	 	 Post	 skin	 incision	 but	 prior	 to	 the	 application	 of	 vascular	clamps	4. Sample	D:		30	minutes	post-reperfusion	of	the	graft	5. Sample	E:		2	hours	post-reperfusion	of	the	graft	6. Sample	F:		8	hours	post-reperfusion	of	the	graft	7. Sample	G:		24	hours	post-operatively	8. Sample	H:		72	hours	post-operatively		Plasma	samples	were	prepared	by	centrifuging	the	whole	blood	at	1000	G	for	15	minutes,	collecting	the	supernatant	and	splitting	into	500	μl	aliquots,	which	were	stored	at	-80	°C.		The	precipitate	was	discarded.		Data	 was	 collected	 on	 donor	 and	 recipient	 characteristics	 operative	 details,	immunosuppressive	 regimen,	 post-operative	 course	 and	 graft	 function	 for	 6	months	after	transplantation.		
	
2.2.3.		Identification	and	coding	
	Each	patient	was	assigned	a	sequential	number	(1-35);	all	samples	were	labelled	according	 to	 this	 number	 and	 the	 timing	 of	 the	 sample	 (A-H).	 	 The	 labelled	samples	were	stored	at	-80	°C	in	the	Institute	of	Nephrology,	University	Hospital	of	 Wales	 (UHW),	 Cardiff.	 	 The	 patient	 details	 were	 kept	 only	 by	 the	 lead	researcher	and	were	stored	in	a	locked	office	at	UHW.	
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2.3.		Plasma	Analysis	
	The	following	analysis	was	undertaken	on	the	samples:	1.	Nitrate	and	nitrite	analysis	using	the	Griess	reaction	2.	Nitrate	and	nitrite	analysis	using	ozone	chemiluminescence	3.	Cytokine	analysis	using	Luminex	4.		IFN-γ	analysis	using	an	enzyme	linked	immunosorbent	assay	(ELISA)	All	samples	were	run	in	duplicate	for	each	method.			
2.3.1.		Griess	reaction	
	Nitrate	 and	 nitrite	 levels	 were	 determined	 using	 the	 Parameter,	 Total	
NO/Nitrite/Nitrate	kit	from	R&D	Systems	as	described	in	2.1.3.2.		We	determined	the	nitrite	and	nitrate	levels	using	the	Griess	reaction	in	all	samples	taken	from	the	first	11	recruited	patients	(88	samples	in	total).				It	became	apparent	when	analysing	the	initial	results	and	comparing	them	with	those	 obtained	 from	 using	 the	 ozone	 chemiluminescence	 method	 (described	below)	that	the	level	of	nitrite	in	our	samples	was	so	small	that	it	was	below	the	levels	of	sensitivity	for	this	assay;	the	minimum	detectable	amount	quoted	by	the	manufactures	 of	 the	 kit	 is	 0.78	 μmol/l.	 	 Due	 to	 the	 limited	 sensitively	 of	 the	Griess	reaction	we	only	used	ozone	chemiluminescence	to	determine	nitrite	and	nitrate	 concentration	 in	 the	 remaining	 samples.	 	 All	 testing	was	 performed	 in	duplicate	and	the	mean	of	the	two	values	used	for	analysis.		
	
2.3.2.		Ozone	chemiluminescence	
	We	 measured	 NO	 metabolites,	 nitrite	 and	 nitrate	 using	 ozone-based	chemiluminescence	 	 (NO	 analyser,	 NOA280i,	 Sievers)	 in	 all	 of	 our	 collected	samples.				
	 58	
2.3.2.1.		Scientific	principle	The	 principle	 of	 the	 technique	 is	 as	 follows:	 	 a	 cleavage	 agent	 specific	 to	 the	metabolite	of	 interest	 is	used	 to	 cleave	NO.	 	This	NO	 is	 then	carried	 through	a	sodium	hydroxide	(NaOH)	trap	by	nitrogen	gas.		The	purpose	of	this	“trap”	is	to	prevent	contamination	of	the	sample	with	any	extra	NO,	which	may	be	generated	from	other	constituents	of	the	plasma	and	to	protect	the	NO	analyser	(NOA)	from	acidic	vapours.	 	After	bubbling	through	the	NaOH	the	NO	is	carried	to	the	NOA,	here	 it	 is	 forced	 to	 react	 with	 ozone	 (O3),	 forming	 unstable	 nitrogen	 dioxide	(NO2).		In	order	to	stabilize	itself	NO2	very	quickly	gives	up	a	photon	(hv),	and	the	electric	 discharge	 from	 this	 is	 measured	 in	 milliVolts	 (mV)	 by	 the	 NOA	photomultiplier	tube.				
NO	+	O3	èNO2		+	O2	èNO2-	+	O2	+	hv		
Sievers	NOA	AnalysisTM	Liquid	Version	3.2.1	acquires	the	data	as	a	series	of	peaks	and	 is	 capable	 of	 calculating	 the	 area	 under	 the	 curve	 to	 give	 a	 value	 in	 mV	(millivolts),	 this	 is	 then	 read	 from	 a	 standard	 curve	 constructed	 of	 known	concentrations	and	 is	measured	 in	nanomols	per	 litre	(nmol/L).	 	This	standard	curve	must	be	constructed	on	each	day	of	experiments	as	there	may	be	variation	in	the	rate	of	NO	detection	by	the	NOA.			2.3.2.2.		Chemiluminescence	methods	The	 testing	 took	 place	 in	 the	 laboratory	 at	 the	 Institute	 of	 Cardiology,	 Cardiff	under	the	guidance	of	Dr.	Phillip	James.		Good	laboratory	practice	was	followed	during	these	experiments.		
Sample	preparation	The	 reagents	 that	 were	 used	 were	 dependent	 upon	 whether	 we	 were	 doing	nitrite	 or	 nitrate	 analysis	 and	 will	 be	 described	 in	 more	 detail	 subsequently,	however	sample	preparation	was	uniform	to	both	reactions.		The	frozen	plasma	samples	were	stored	at	-80	oC	until	needed	then	thawed	in	a	water	bath	at	37	oC	for	three	minutes	and	used	(undiluted)	immediately.	
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Method	–	Plasma	nitrite	Tri-iodide	 is	 the	 cleaving	 agent	 used	 to	 measure	 nitrite;	 it	 consists	 of	 glacial	acetic	acid,	potassium	iodide	and	iodine.		The	acid	converts	nitrite	into	nitric	acid	then	the	following	reaction	occurs	to	release	NO		
																																			HNO2	+	2I-	+	2H+	è	2NO	+	I2	+	2H20	
	
Reagent	preparation	Tri-iodide	was	made	up	daily	by	combining	1g	of	potassium	iodide	dissolved	in	20	millilitres	(ml)	of	purified	water	with	650	mg	of	 iodine	crystals	dissolved	 in	70ml	of	glacial	acetic	acid.		The	mixture	was	stirred	for	30	minutes	prior	to	use.	Standards	were	prepared	using	serial	dilutions	of	a	known	concentration	and	1	molar	(M)	NaOH	was	taken	from	stock,	see	figures	2.2,	2.3	and	2.4.		
	
Figure	2.2:		Standard	curve	of	nitrite.		An	example	of	the	peaks	used	to	construct	
a	daily	standard	curve,	concentrations	used	are:		Water,	62.5		nanomolar	(nM),	125	
nM,	250	nM,	500	nM	and	1000	nM	sodium	nitrite.	
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Figure	 2.3:	 	 Area	under	 the	 curve	nitrite.	 	The	area	under	 the	 curve	 (AUC)	of	
each	peak	was	used	to	calculate	the	coefficient,	 the	 figures	were	corrected	by	the	
AUC	of	water	to	ensure	the	curve	went	through	0.		
		
	Figure	2.4:		Nitrite	analysis.	
A	-	100	µl	sample	is	injected	through	the	rubber	septum	
B	-	Custom	made	vessel	containing	5mls	of	tri-iodide	
C	-	Temperature	is	maintained	at	50	°C	by	a	water	bath	and	hot	plate	
D	-	NO	is	carried	by	N2	gas	stream	controlled	by	a	flowmeter	
E	-	Released	NO	is	carried	into	a	round-bottom	flask		
F	–	Containing	1	M	NaOH	
G	–	NO	vapor	is	directed	to	the	NO	analyser	
										A	
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Laboratory	procedure	1. 5mls	 of	 tri-iodide	 were	 pipetted	 into	 a	 custom	made	 vessel	 (a	 drop	 of	AntifoamTM	was	added	into	the	vessel).	2. The	temperature	was	maintained	at	50	oC	by	a	beaker	of	water	kept	on	a	hot	plate.	3. 15	mls	of	NaOH	was	added	to	the	round-bottomed	flask.	4. The	tubing	was	connected	to	the	nitrogen	gas	and	the	NO	analyser.	5. 100μl	of	prepared	sample	was	injected	in	to	the	rubber	bung	and	the	data	collected.	6. After	5	injections	of	plasma	the	tri-iodide	was	discarded	and	replaced.		Values	 were	 recorded	 as	 AUC	 in	 mV	 for	 each	 sample	 (run	 in	 duplicate)	 as	calculated	by	Sievers	NOA	AnalysisTM	Liquid	Version	3.2.1.		Results	were	calculated	on	a	daily	basis	using	the	standard	curve	constructed	that	morning	and	a	mean	value	in	nmol/L	taken.				
Method	–	Plasma	nitrate	Plasma	nitrate	levels	were	measured	by	using	vanadium	chloride.		The	following	reaction	occurs	to	reduce	nitrate	in	to	NO.	
	
2VCL3	+	4HCL	+	NO3-	è2VCL5	+	2H2O	+	2NO		Cleaving	of	NO	will	only	occur	at	high	temperatures	so	the	reaction	chamber	 is	submerged	in	a	water	bath	at	85	oC.		
Reagent	preparation	Vanadium	 chloride	 solution	 is	 prepared	 by	 adding	 80	mls	 1M	HCL	 to	 20ml	 of	purified	water	then	dissolving	785	mg	of	vanadium	chloride	in	the	diluted	acid.		The	mixture	is	stirred	for	15	minutes	before	being	filtered	using	a	22	μm	filter.		Once	filtered	the	solution	is	a	bright	clear	turquoise	colour	(as	shown	in	the	flask	in	figure	2.7).				
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Standards	were	prepared	using	serial	dilutions	of	known	concentrations	of	sodium	nitrate,	see	figures	2.5	and	2.6.	
	
	
Figure	 2.5:	 	 Standard	 curve	 of	 nitrate.	 	 An	 example	 of	 the	 peaks	 used	 to	
construct	a	daily	 standard	 curve,	 concentrations	used	are:	 	Water,	 6.25	µM,	12.5	
µM,	25	µM,	50	µM	and	100	µM	sodium	nitrate	
	
			 			 			 			 	 	 		
Figure	 2.6:	 	 Area	under	 the	 curve	nitrate.	 	The	AUC	of	each	peak	was	used	 to	
calculate	the	coefficient,	the	figures	were	corrected	by	the	AUC	of	water	to	ensure	
the	curve	went	through	0.	
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Figure	2.7:		Nitrate	analysis.	
A	-	20	µl	sample	is	injected	through	the	rubber	septum		
B	-	2-neck	round	bottom	flask	containing	30	ml	vanadium	chloride	reagent.	
C	–	Temperature	is	maintained	at	85	°C	by	a	water	bath	
D	–	Water	bath	linked	to	IKATRON®	ETS-D4	fuzzy	
E	–	NO	is	carried	in	N2	gas	stream	controlled	by	a	flowmeter	through	a	condenser	
F	–	Released	NO	is	carried	to	a	round-bottom	flask	containing	1	M	NaOH	
G	–	NO	vapor	is	directed	to	the	NO	Analyser				
Laboritory	procedure	1. 30	mls	of	vanadium	chloride	is	added	to	the	purge	vessel	as	shown.	2. The	temperature	of	the	water	bath	is	maintained	at	85	oC.	3. Evaporated	vanadium	runs	back	into	the	reaction	chamber	when	it	makes	contact	with	the	custom	designed	water-cooled	funnel.	4. The	tubing	is	connected	to	nitrogen	gas	and	the	NO	analyser.	
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5. 15	μl	of	prepared	sample	 is	 injected	 in	 to	 the	rubber	bung	and	 the	data	collected.	6. After	 20	 injections	 of	 plasma	 the	 vanadium	 chloride	 is	 discarded	 and	replaced.		
Analysis	Standard	curves	were	generated	daily	for	both	nitrite	and	nitrate	analysis.		This	is	essential	to	the	chemiluminescence	technique	as	daily	variation	in	detection	is	known	to	occur.	 	This	 is	 thought	 to	be	due	to	sensitivity	of	 the	photomultiplier	tube	to	changes	in	room	temperature	or	oxygen	pressure.		Standard	curves	were	generated	by	plotting	area	under	the	curve	on	the	y	axis	against	serial	dilutions	of	known	nitrite	or	nitrate	on	the	x	axis.	 	All	samples	were	run	in	duplicate	and	average	values	in	μmol/l	calculated.		
	
2.4.		A	Comparison	of	Methods	for	NO	Analysis	
2.4.1.		Introduction	
	Attenuating	 the	 effects	 of	 IRI	 is	 undoubtedly	 an	 essential	 part	 of	 the	 future	 of	renal	 transplantation.	 	 In	 chapter	 I	 we	 reviewed	 the	 complexities	 of	 IRI	 and	explored	 the	 rationale	 behind	 the	 objectives	 of	 this	 study;	 namely	 to	 look	 at	metabolites	of	nitric	oxide	and	 the	 inflammatory	 cytokines	 that	stimulate	 their	production	 in	 patients	 receiving	 deceased	 renal	 transplants,	 with	 a	 view	 to	correlating	 this	with	 the	 clinical	 outcome	 of	DGF.	 	We	 have	 seen	 how	 current	evidence	 suggests	 conflicting	 roles	 for	NO	metabolites;	 how	NO2-,	 a	metabolite	itself,	may	act	as	a	source	of	NO	during	times	of	hypoxia	(241),	how	endothelial	dysfunction	 (a	 fundamental	 step	 in	 IRI)	 results	 in	 uncoupling	 of	 eNOS	 and	therefore	reduced	NO	production	(60)	and	how	this	has	lead	to	research	into	the	possibility	of	 a	 therapeutic	 role	 for	supplementation	of	NO	metabolites	around	the	 time	 of	 transplantation	 (77).	 	 With	 regards	 to	 renal	 transplantation	 it	 is	important	 to	remember	that	NO	may	be	produced	by	both	eNOS	and	 iNOS	and	that	the	ROS	produced	as	a	consequence	of	NO	metabolization	have	physiological	effects	that	also	appear	to	be	dose	dependent	(146).	
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From	our	 review	of	 the	 literature	 surrounding	 the	 topics	 of	 IRI,	NO	 and	 renal	transplantation,	 it	 became	 clear	 that	 concentration	 of	 NO	 is	 likely	 to	 be	 a	significant	 factor	 influencing	 the	 effects	 of	 NO	 and	 its	 metabolites.	 	 It	 was	therefore	of	paramount	importance	to	be	able	to	measure	these	metabolites	i.e.	NO2-	 and	 NO3-	 accurately	 with	 precision	 and	 low	 intravariability.	 	 From	 our	preliminary	research	into	the	topic	it	seemed	that	we	were	expecting	to	find	only	nanomolar	 concentrations	 of	 NO2-	 in	 plasma	 samples.	 	 Studies	 conducted	previously	in	this	unit	and	by	others	on	similar	topics	had	been	performed	using	the	Griess	reaction	for	the	measurement	of	NO	metabolites.	 	This	is	an	effective	method	for	 looking	at	NO3-	however	we	were	skeptical	about	 the	ability	of	 this	method	 to	accurately	quantify	NO2-	 in	our	plasma	samples.	 	To	 investigate	 this	further	 we	 used	 two	 different	 methods	 to	 analyze	 the	 same	 88	 samples	 and	compared	 the	 results.	 	 The	 aim	 of	 this	 was	 to	 determine	 which,	 of	 two	 well-established	methods	of	NO	analysis,	was	most	appropriate	for	our	study	group.	
	In	order	 to	handle	 the	data	 correctly,	we	 first	 looked	at	 the	distribution	of	 the	values	 obtained.	 	 Neither	 NO2-	 nor	 NO3-	 were	 found	 to	 reliably	 have	 a	 normal	distribution,	therefore,	non-parametric	tests	were	used	for	analysis.			
	
2.4.2.		Results	of	Griess/chemiluminescence	correlation	
	We	used	all	samples	 from	the	 first	11	patients	recruited	to	determine	which	of	the	 two	methods	 that	 were	 available	 to	 us	 was	 the	 most	 appropriate	 for	 our	study.	 	Eighty-eight	plasma	samples	 from	11	patients	 collected	at	 specific	 time	points	 around	 the	 time	 of	 renal	 transplantation	 were	 analysed	 using	 the	 two	different	methods.		Both	the	reaction	and	ozone	chemiluminescence	may	be	used	to	quantify	NO2-	and	NO3-	in	plasma;	this	analysis	was	performed	in	duplicate	on	all	 88	 samples.	 	 The	 correlations	 between	 the	 values	 obtained	 with	 the	 two	different	 methods	 were	 calculated	 using	 the	 Spearman’s	 rank	 correlation	coefficient.					
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2.4.2.1.		Nitrite	When	we	examined	the	initial	results	for	NO2-	the	values	obtained	were	outside	the	range	of	the	Griess	assay	(3.12-200	µmol/L)	although	the	R&D	kit	which	we	used	does	quote	a	minimum	detectable	value	of	0.25	µmol/L.		Moreover,	there	was	no	correlation	between	the	values	obtained	for	each	sample	using	the	two	tests	see	table	2.1	below.			The	physiological	range	of	NO2-	in	fasted	human	plasma	is	56-210	nmol/L	(242),	which	is	considerably	below	the	range	detectable	by	the	reaction.		Even	taking	into	account	that	we	were	expecting	a	rise	in	concentration	this	was	not	an	acceptable	method	for	analysis	in	physiological	samples.				Ozone	 chemiluminescence	 (Seivers,	 NOA	 280i)	 is	 capable	 of	 detecting	 nM	concentrations	 in	 liquid	 samples	 with	 a	 sensitivity	 of	 ≈	 1	 picomole.	 	 It	 is	therefore	over	1000	 times	more	 sensitive	 than	 the	Griess	 reaction	and	as	such	we	 decided	 not	 to	 perform	 NO2-	 analysis	 using	 the	 Griess	 method	 on	 the	remaining	 24	 samples.	 	 Any	 reference	 to	NO2-	values	 henceforth	will	 therefore	refer	 to	 those	 obtained	 using	 ozone	 chemiluminescence.	 	 Table	 2.1	 below	demonstrates	 the	 lack	 of	 correlation	 found	 between	 the	 values	 obtained	 using	each	 method	 using	 the	 Spearman’s	 rank	 correlation	 coefficient	 at	 each	 time	point.	
	
Sample Correlation coefficient NO2- Significance p= 
A 0.46 NS 
B 0.14 NS 
C 0.13 NS 
D 0.08 NS 
E -0.3 NS 
F -0.2 NS 
G 1.53 NS 
H 0.41 NS 	
Table	2.1:		The	correlation	coefficient	of	nitrite	measurement.		The	correlation	
coefficient	of	NO2-	between	samples	measured	using	ozone	chemiluminescence	and	
the	Griess	reaction.		
	 67	
2.4.2.2.		Nitrate	When	we	looked	at	the	results	for	NO3-	tight	correlation	was	found	between	the	values	 obtained	 using	 the	 Griess	 reaction	 and	 Ozone	 Chemiluminescence			rs(267)	=	0.87,	p	=	<0.0001.		Table	2.2	below	illustrates	the	correlation	coefficient	found	 between	 the	 values	 taken	 at	 each	 sampling	 time	 point	 using	 the	Spearman’s	rank	correlation	coefficient.		
Sample Correlation coefficient NO3- Significance p= 
A 0.88 <0.0001 
B 0.9 <0.0001 
C 0.82 <0.0001 
D 0.87 <0.0001 
E 0.86 <0.0001 
F 0.8 <0.0001 
G 0.84 <0.0001 
H 0.93 <0.0001 
	
Table	 2.2:	 	 The	 correlation	 coefficient	 of	 nitrate	 measurement.	 	 	 The	
correlation	 coefficient	 of	 NO3-	 between	 samples	 measured	 using	 ozone	
chemiluminescence	and	the	Griess	reaction		This	concordance	is	attributable	to	the	higher	levels	of	NO3-	found,	bringing	the	analyte	(NO3-)	into	the	detectable	range	of	the	Griess	assay.		
	
	
2.4.3.		Discussion	
	We	chose	to	collect	plasma	from	our	subjects	as	opposed	to	urine;	urine	has	been	used	in	other	studies	looking	at	NO	metabolites	and	the	kidney	however	we	did	not	think	that	this	would	provide	us	with	accurate	results	for	two	reasons.		The	first	being	any	renal	transplant	recipient	(unless	they	have	undergone	a	bilateral	native	 nephrectomy)	 may	 still	 excrete	 some	 urine	 produced	 by	 the	 residual	function	 of	 their	 native	 kidneys.	 	 The	 second	 consideration	 is	 that	 we	 were	expecting	around	50%	of	our	study	group	to	have	DGF	in	the	first	few	days	post	transplant;	some	of	these	patients	may	not	produce	any	or	very	little	urine	at	all	
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during	this	time.		Urine	was	therefore	not	a	reliable	medium	in	which	to	measure	NO	production	or	cytokines	for	our	study.	
	One	of	the	challenges	when	undertaking	this	study	was	the	measurement	of	the	NO	metabolites	 themselves.	 	 Previous	work	 done	 by	 this	 unit	 (and	 indeed	 the	majority	of	the	published	literature	within	the	field	of	transplantation)	uses	the	griess	 reaction	 for	measurement	of	 nitrite	 and	 nitrate,	 although	 this	 is	 not	 the	case	in	other	areas	of	research	(for	example	in	the	field	of	cardiology	(243-249)).			The	benefits	of	the	Griess	reaction	are	that	it	is	an	inexpensive	and	quick	method,	allowing	 multiple	 samples	 to	 be	 quantified	 in	 duplicate	 simultaneously.	 	 In	contrast,	 ozone	 chemiluminescence	 is	 an	 extremely	 labor	 and	 time	 intensive	method	but	is	much	more	sensitive	and	accurate.	 	We	were	therefore	hoping	to	find	good	correlation	between	our	measurements	using	the	two	different	assays,	thus	 validating	 the	 use	 of	 the	 Griess	 reaction	 in	 future	 work.	 	 This	 was	unfortunately	not	 the	 case	 (as	 is	reported	above);	when	measuring	NO2-	 in	 the	plasma	 samples	 of	 the	 renal	 transplant	 recipients	 the	 levels	 were	 too	 low	 to	allow	accurate	quantification	using	the	Griess	reaction	and	so	we	performed	our	quantification	 of	 NO2-	 using	 ozone	 chemiluminescence.	 	 However,	 in	 the	 NO3-	measurements	 we	 found	 good	 correlation	 between	 the	 values	 obtained	 using	both	 methods	 and	 therefore	 we	 believe	 the	 Griess	 reaction	 could	 be	 used	 in	future	work	for	detection	of	NO3-	only.		For	consistency	in	this	study	we	used	the	values	obtained	from	ozone	chemiluminescence	for	our	analysis	of	both	NO2-	and	NO3-.		We	would	conclude	that	when	measuring	NO	metabolites	in	the	plasma	of	renal	transplant	 recipients	 the	 griess	 reaction	 is	 an	 acceptable	 method	 if	 solely	measuring	NO3-.	 	If,	however,	NO2-	measurement	is	required	the	Griess	reaction	is	not	sensitive	enough	for	accurate	quantification	of	the	levels	found	in	human	plasma	and	a	more	sensitive	technique	such	as	ozone	chemiluminescence	should	be	employed.	
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2.5.		Cytokine	Measurement	
	Cytokines	were	measured	using	2	techniques;	Luminex	and	an	ELISA	
	
2.5.1.		Luminex	for	cytokine	measurement	
	2.5.1.1.		Scientific	principle	Luminex	is	a	multiplex	immunosorbant	assay,	it’s	roots	lie	in	the	ELISA	however	luminex	assays	have	the	advantage	of	being	able	 to	detect	multiple	analytes	on	one	plate	(unlike	ELISAs	which	can	only	detect	a	single	analyte	at	a	time).		Their	common	feature	is	that	they	are	both	antibody	sandwich	assays.		The	principle	of	the	luminex	assay	is	as	follows:		1.	Colour	coded	beads	(or	microparticles)	with	an	analyte	specific	antibody	are	mixed	with	samples	or	standards.	2.	 Another	 analyte	 specific	 detection	 antibody	 is	 added	 which	 binds	 to	 its	particular	target.	3.	Streptavidin-PE	is	then	added	which	binds	to	the	detection	antibody.	4.	A	dual	 laser	 flow	cytometer	 is	used	to	quantify	 the	analytes	of	 interest.	 	One	laser	 is	 able	 to	 distinguish	 between	 different	 coloured	 beads	 and	 therefore	identifies	 the	analyte,	whilst	 the	other	one	detects	 the	signal	intensity	given	off	by	the	bound	streptavidin-PE	there	by	quantifying	the	analyte.		Luminex	 technology	 has	many	 applications	 in	 medicine,	 including	 HLA	 typing	and	antibody	monitoring	in	organ	transplantation,	see	figure	2.8.											
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Figure	2.8:		Steps	of	the	Luminex	assay						
	 71	
Kits	 are	 available	 to	 detect	 a	 variety	 of	 biomarkers;	 we	 used	 the	 Luminex	
Performance	 Assay,	 Human	 Cytokine	 Premixed	 Kit	 A	 from	 R&D	 Systems	 to	investigate	levels	of	IL-2,	IL-6,	IL-10,	IL-17,	TNF-α	and	IFN-γ	in	our	study	group.		These	 cytokines	 were	 quantified	 in	 samples	 taken	 around	 the	 time	 of	transplantation	 at	 the	 following	 points;	 pre-operatively	 (A),	 post	 skin	 incision	but	 prior	 to	 the	 application	 of	 vascular	 clamps	 (C),	 at	 30	 minutes	 post	reperfusion	of	the	graft	(D),	at	2	hours	post	reperfusion	of	the	graft	(E)	and	at	24	hours	post	operatively	(G).		2.5.1.2.	Luminex	method	The	testing	took	place	in	the	Welsh	transplantation	and	immunology	laboratory	at	 the	Welsh	blood	service	under	 the	guidance	of	Dr.	Francis	Edwards	and	Dr.	Emma	 Burrows.	 	 Good	 laboratory	 practice	 was	 followed	 during	 these	experiments	the	procedure	is	described	in	appendix	4.		
Analysis	of	Luminex	cytokine	results	Results	 were	 collected	 on	 the	 Bio-Rad®	 analyser.	 	 A	 standard	 curve	 was	generated	 using	 a	 five	 parameter	 logistic	 (5	 PL)	 curve	 fit.	 	 Using	 a	 logistic	regression	 model	 ensures	 greater	 accuracy	 across	 a	 broader	 range	 of	concentrations	 and	 is	 the	 recommended	 method	 for	 analyzing	 multiplex	sandwich	 immunoassays.	 	 The	 samples	were	 run	 in	 duplicate	 and	 the	 average	calculated	before	being	multiplied	by	the	X4	dilution	factor.			
2.5.2.		ELISA	-	IFN-γ	
	When	we	 looked	 at	 our	 luminex	 results,	 although	 the	 standard	 curves	 had	 all	given	 acceptable	 r2	values	 and	 the	 assay	 appeared	 to	 be	working,	we	 detected	less	IFN-γ,	IL-2	and	IL-10	in	the	samples	than	was	expected.		We	contacted	R&D	Systems,	who	produced	 the	kit,	 and	 sent	 them	all	of	our	 results	 to	 check;	 they	were	not	able	 to	ascertain	why	 the	 levels	 in	 the	 sample	were	 so	 low	and	were	confident	 that	 the	 assay	 had	 worked	 correctly	 however,	 as	 we	 still	 remained	suspicious,	they	sent	us	a	specific	human	IFN-γ	ELISA	kits	to	check	the	results.		
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	A	representative	from	the	company	came	out	to	assist	us	with	the	initial	runs	of	the	assay	and	 to	 look	 through	 the	data	 from	 the	 luminex	experiments	 to	see	 if	there	 was	 any	 identifiable	 cause	 for	 the	 unexpected	 discrepancy.	 	 They	 were	unable	to	identify	any	technical	problems	with	the	data	or	the	equipment	in	the	laboratory.	 	The	ELISA	revealed	much	higher	 levels	of	 IFN-γ	as	we	would	have	expected	in	9/35	patients,	however	in	26/35	patients	no	IFN-γ	was	detected	at	all	in	any	of	the	samples	using	either	method.				One	 possible	 explanation	may	 be	 that	 the	 amount	 of	 cytokines	 in	 the	 plasma	samples	 is	 below	 the	 level	 of	 detectability	 of	 the	 assays.	 	 An	 alternative	possibility,	 based	 on	 the	 experience	 of	 immunologists	 who	 use	 these	 assays	routinely,	 	 is	 that	although	the	 luminex	assay	was	accurately	detecting	them	in	the	 standards	 provided	 in	 the	 kit	 by	 R&D	 Systems	 it	 was	 not	 binding	 to	 the	human	forms	in	patient	plasma	samples.		A	future	extension	to	this	work	may	be	to	 look	 into	 other	 techniques	 for	 quantifying	 these	 cytokines.	 	We	 did	 not	 feel	data	 from	9	patients	 could	provide	any	meaningful	 result	 therefore	 there	 is	no	report	of	IFN-γ	in	the	results	chapter.		The	results	for	the	other	cytokines	IL-6,	10	and	TNF-α	all	returned	quantities	in	line	with	what	we	would	expect.	 	The	standard	curves	were	acceptable	and	the	duplicate	readings	were	concordant;	in	conclusion	we	have	no	reason	to	suspect	that	these	results	are	not	accurate	and	reliable.		2.5.2.1.		Scientific	principles	ELISA	 stands	 for	 enzyme	 linked	 immunosorbant	 assay;	 it	 uses	 a	 polyclonal	antibody	 specific	 for	 the	analyte,	 in	 this	 case	 IFN-γ,	which	 is	pre-coated	onto	a	plate.		The	sample	is	added	into	the	wells	and	any	IFN-γ	present	is	bound	to	the	immobilized	 antibody.	 	 After	 washing,	 a	 further	 antibody	 specific	 for	 IFN-γ	 is	added	 to	 the	wells.	 	 This	 binds	 to	 the	 analyte,	 sandwiching	 it	 between	 the	 two	antibodies.		After	a	final	wash	to	remove	any	unbound	substances	an	enzymatic	substrate	is	added.		As	the	plate	develops	the	enzyme	produces	a	colour	change,	which	is	read	using	a	microplate	reader,	see	figure	2.9.	
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Figure	2.9:		Steps	of	the	ELISA	assay.						
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2.5.2.2.		ELISA	method	The	testing	took	place	in	the	Welsh	transplantation	and	immunology	laboratory	at	 the	Welsh	blood	service	under	 the	guidance	of	Dr.	Francis	Edwards	and	Dr.	Emma	 Burrows.	 	 Good	 laboratory	 practice	 was	 followed	 during	 these	experiments,	the	procedure	followed	is	detailed	in	appendix	5.		
Anaylsis	of	ELISA	Results	 were	 collected	 on	 the	 Bio-Rad®	 analyser.	 	 A	 standard	 curve	 was	generated	 using	 a	 four	 parameter	 logistic	 (4	 PL)	 curve	 fit.	 	 Using	 a	 logistic	regression	 model	 ensures	 greater	 accuracy	 across	 a	 broader	 range	 of	concentrations	see	figure	2.10.		The	samples	were	run	in	duplicate	and	the	mean	calculated.		
	
Figure	2.10.		An	example	of	the	4	PL	curves	used	for	interpretation	of	the	
ELISA.	
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2.6.		Statistical	Analysis	and	Data	Reporting		Clinical	data	from	the	patients	was	collected	around	the	time	of	transplantation	and	 during	 the	 follow	up	 period	 of	 6	months	 from	 the	 departmental	 database	(VITALDATA).	 	 Statistical	 analysis	 was	 performed	 using	 IBM	 SPSS	 Statistics	version	20.		Data	was	expressed	using	median,	range	and	interquartile	range	as	it	was	 not	 found	 to	 be	 normally	 distributed.	 	 Mann-Whitney	 U,	 Friedman	 and	Kruskal-Wallis	H	tests	(with	post-hoc	Bonferroni	correction)	were	used	to	 look	at	 differences	 between	 groups.	 	 Multiple	 regression	 analysis	 and	 Spearman’s	rank	 correlation	 coefficient	were	 used	 to	 look	 for	 associations.	 In	 all	 analyses	differences	with	p	<	0.050	were	considered	statistically	significant.				NO	metabolites	were	measured	 in	nmol/L	using	ozone	chemiluminescence,	 the	results	 were	 converted	 to	 µmol/L	 and	 given	 to	 one	 decimal	 place	 for	 ease	 of	reporting	 in	 the	results	section.	 	Test	were	performed	 looking	at	 the	change	 in	concentration	of	NO	metabolites	 this	was	calculated	to	address	the	variation	 in	baseline	production	within	the	population.	 	 In	order	to	look	at	 the	relationship	between	NO3-	and	NO2-	we	created	a	ratio	and	used	this	to	look	for	associations	with	our	variables.	 	When	describing	the	graphs,	median	values	were	quoted	 if	reporting	a	significant	test;	illustrations	that	did	not	show	significant	differences	do	not	have	individual	values	quoted.	The	analysis	performed	was	aimed	at	addressing	three	areas:		1.	 	 Ozone	 chemiluminescence	 and	 the	 Griess	 reaction	 were	 compared	 for	measuring	metabolites	of	nitric	oxide.	2.	 	 	Risk	for	IRI	in	renal	transplantation	were	correlated	with	nitric	oxide	levels	using	regression	models.	3.		Nitric	oxide	levels	were	correlated	with	production	of	inflammatory	cytokines								
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CHAPTER	 3.	 	 RESULTS	 –	 Demographics	 of	 the	 Study	
Group	and	NO	Methods	Analysis	
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3.1.		Introduction		The	 following	chapter	will	describe	the	demographics	of	 the	study	group.	 	This	study	consisted	of	two	parts	the	results	for	each	study	follow	later	in	the	chapter.		
	
3.2.	Demographics	of	Part	1	Study	Group	
	As	part	of	previous	work	at	the	Cardiff	Transplant	Unit	that	had	investigated	the	levels	 of	 NO	 metabolites	 in	 acute	 rejection	 (239),	 plasma	 samples	 had	 been	collected	pre	and	post	reperfusion	from	patients	undergoing	both	living	and	DBD	renal	transplantation	and	DCD	transplants	to	investigate	our	theory	that	factors	influential	 in	 renal	 IRI	 may	 lead	 to	 changes	 in	 NO	 levels.	 	 This	 cohort’s	demographics	are	presented	in	Table	3.1.			Total	 69	Donor	type	 LD	 9	DBD	 31	DCD	 29	Median	cold	ischemic	time	in	hours	in	DCDs	(range)	 11	(4	-	21)	Donor	median	age	in	years	(range)	 50	(5	-	74)	Donor	gender	 Male	 40	Female	 29	Recipient	median	age	in	years	(range)	 49	(23	-	73)	Recipient	gender	 Male	 54	Female	 15	Median	baseline	NO	metabolites	μmol/L	(range)	 39	(7.1	-	481)	Median	post	perfusion	NO	metabolites	μmol/L	(range)	 34	(2.9	-	431)	
	
Table	3.1:		Patient	characteristics	of	part	1	study	group.		The	population	 included	9	LD,	31	DBD	and	29	DCD	renal	 transplant	recipients.		The	 samples	we	 used	 for	 analysis	were	 collected	 pre-operatively	 and	 2	 hours	
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post	 reperfusion	 of	 the	 organ.	 	 To	 accommodate	 the	 variability	 in	 baseline	measurements	 that	 occurs	 naturally	 within	 the	 population,	 we	 calculated	 a	reperfusion	ratio	(RRT)	i.e.	the	ratio	between	the	pre	and	post	operative	nitrate	concentration	 and	 looked	 initially	 at	 the	 differences	 between	 donor	 types,	 see	3.4	Part	1	results.			
3.3.		Demographics	of	Part	2	Study	Group		Due	 to	 the	 study	 design	 the	 patient	 cohort	were	 not	 selected	 in	 anyway	 other	than	that	they	underwent	DCD	renal	transplant	at	Cardiff	transplant	unit	within	the	study	period	and	consented	to	take	part	in	the	study.		The	rate	of	consent	for	those	who	were	approached	to	participate	was	100%,	this	reflects	 the	minimal	intervention	that	was	required	for	the	patients	to	take	part	and	that	they	were	all	approached	by	two	experienced	registrars.				Thirty-five	patients	were	recruited	between	March	2012	and	April	2014.	During	this	time,	a	total	of	64	DCD	renal	transplants	were	done	that	were	not	recruited	to	the	study	due	to	unavailability	of	the	researcher	(in	clinical	practice	in	London	October	2012	–	October	2013).		A	total	of	280	plasma	samples	from	35	patients	were	collected.	The	samples	were	stored	at	-80	degrees	Celsius	and	investigated	for	metabolites	 of	 nitric	 oxide	 and	 pro-inflammatory	 cytokines	 as	described	 in	the	previous	methods	 section.	The	demographics	are	 summarized	 in	 the	Table	3.2.										
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Total	 35	Donor	median	age	in	years	(range)	 63	(26-76)	Donor	Gender	 Male	 16	Female	 19	Median	cold	ischemic	time	in	hours	(range)	 14	(7-36)	Median	primary	warm	ischemic	time	in	minutes	(range)	 14	(8-34)	Median	secondary	warm	ischemic	time	in	minutes	(range)	 45	(25-58)	Storage	method	 Cold	static	 18	Machine	perfusion	 17	Recipient	median	age	in	years	(range)	 58	(29-75)	Recipient	gender	 Male	 27	Female	 8	Mode	of	dialysis	 Pre-dialysis	 2	PD	 16	HD	 17	Induction	immunosuppression	 ATG	 13	Campath	 10	Simulect	 12	Median	baseline	NO2-	μmol/L	(range)	 0.3	(0.1-0.9)	Median	baseline	NO3-	μmol/L	(range)	 42.2	(8.3-103.6)		
Table	3.2:		Patient	characteristics	of	part	2	study	group.	
	
	
3.3.1.		Sex		Of	the	35	participants	in	the	study	8	(22.9%)	were	female	and	27	(77.1%)	were	male.		Of	the	35	donor	kidneys	used	19	(54.3)	were	from	female	donors	and	16	(45.7%)	were	from	male	donors.		
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3.3.2.		Age		The	recipient	ages	ranged	from	29	to	75	years	with	a	mean	age	of	55.8	years	and	a	median	 age	of	58	years.	 	The	donor	ages	 ranged	 from	26	 to	76	years	with	a	mean	age	of	56.1	and	a	median	age	of	63	years.		Data	from	a	recent	paper	using	statistics	 from	 the	 UK	 transplant	 registry	 reported	 national	 figures;	 median	recipient	age	was	53	years	(interquartile	range	(IQR)	43–62)	and	median	donor	age	 was	 49	 years	 (IQR	 37–59)	 (32).	 	 In	 this	 study	 cohort	 both	 donor	 and	recipient	 ages	 are	 found	 to	 be	 higher	 than	 the	 national	 averages	 this	 may	represent	 the	 use,	 by	 our	 unit,	 of	 ECD	 DCD	 kidneys	 which	 some	 centres	nationally	are	less	likely	to	accept	for	transplantation.		
	
3.3.3.		Immunosuppression	regimens		3.3.3.1.		Induction	immunosuppression	The	induction	immunosuppression	received	by	the	participants	in	our	study	was	of	 particular	 importance	 since	 this	was	 one	 of	 the	 research	 questions;	 namely	whether	 the	 induction	 immunosuppression	played	 a	 role	 in	 the	 levels	of	nitric	oxide	 following	 reperfusion.	 	 As	 described	 in	 the	 methods	 chapter,	 subjects	received	one	of	three	induction	immunosuppression	medications;	13/35	(37%)	received	 ATG;	 10/35	 (29%)	 received	 Campath	 and	 12/35	 (34%)	 received	Simulect.		3.3.3.2.		Maintenance	immunosuppression	
Calcineurin	inhibitors	All	patients	were	commenced	on	Tacrolimus	on	the	first	postoperative	day.		
Inhibitors	of	nucleotide	synthesis	MMF	 was	 commenced	 on	 the	 first	 post-operative	 day	 in	 17/35	 (49%)	 of	 the	patients;	Myfortic	 in	14/35	 (40%)	and	4/35	 (11%)	were	not	prescribed	either	medication.		
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Corticosteroids	Twenty-three	 out	 of	 35	 (65.7%)	 patients	 were	 commenced	 on	 20	 mg	 of	prednisolone	on	the	first	postoperative	day.	 	Twelve	out	of	35	(34.3%)	patients	did	not	receive	an	oral	corticosteroid.			
	
3.3.4.		Mode	of	dialysis	
	Two	(6%)	of	the	35	patients	 included	 in	the	study	were	pre-dialysis,	17	(48%)	used	haemodialysis	and	16	(46%)	were	peritoneal	dialysis	patients.			3.3.5.		Previous	transplantation		For	 32/35	 (91%)	 of	 the	 patients	 this	was	 their	 first	 renal	 transplant,	 in	 2/35	(6%)	cases	it	was	their	second	and	one	(3%)	patient	received	their	third	kidney.	
	
	
3.3.6.		Ischemic	times	
	Cold	ischemic	times	were	recorded	in	hours;	the	median	time	was	14	hours	and	the	mean	13	hours	30	minutes	with	a	range	of	7	hours	36	minutes	to	25	hours	12	minutes.	 Nationally,	 the	 median	 cold	 ischemic	 time	 as	 reported	 by	 NHSBT	 in	their	Annual	Report	On	Kidney	Transplantation	was	13	hours	for	the	recruitment	period.		The	median	and	mean	1st	warm	ischemic	time	(defined	as	time	of	asystole	until	the	time	cold	perfusion	was	instigated)	were	both	14	minutes	with	a	range	of	8-34	minutes.		The	median	second	warm	ischemic	time	(out	of	ice	until	reperfusion	of	 the	 organ)	was	 45	minutes	 and	mean	 47	minutes	with	 a	 range	 of	 25	 to	 58	minutes,	shown	in	Figure	3.1.		
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Figure	3.1:		The	distribution	of	important	risk	factors	of	part	2	of	the	study.	
Box	and	whisker	plots	showing	the	median,	interquartile	and	central	ranges	of	the	
donor	 and	 recipient	 age,	 the	 CIT	 in	 hours	 and	 the	 1st	 and	 2nd	 WIT	 in	 minutes.	
Median	(range):	donor	age	in	years	=	63	(26-76),	recipient	age	in	years	=	58	(29	–	
55),	 CIT	 in	 hours	 14	 (7	 –	 36),	 1st	WIT	 in	minutes	 =	 14	 (8	 –	 34)	 and	 2nd	WIT	 in	
minutes	=	45	(25	–	58).	
	
	
3.3.7.		DGF	
	As	previously	discussed,	DGF	 is	commonly	defined	 in	the	scientific	 literature	 in	multiple	ways,	two	of	the	most	common	being;	1)	 Where	 creatinine	 does	 not	 reduce	 by	 10%	 in	 the	 first	 48	 hours	 post-operatively.	2)	Requirement	for	dialysis	in	the	first	7	days	post	operatively.	
	
0
5
10
15
20
25
Cold Ischemic Time
 
D
ur
at
io
n 
in
 H
ou
rs
Re
cip
ien
t
Do
no
r
0
20
40
60
80
Recipient and Donor Age
 
A
ge
 in
 y
ea
rs
0
5
10
15
20
First Warm Ischemic Time
 
D
ur
at
io
n 
in
 M
in
ut
es
0
20
40
60
80
100
Second Warm Ischemic Time
 
D
ur
at
io
n 
in
 M
in
ut
es
	 83	
The	first	of	these	definitions	is	a	more	objective	measure	(as	the	use	of	dialysis	may	be	subject	to	differing	local	criteria)	and	is	therefore	the	one	we	shall	apply	to	our	results.		Using	 this	 definition,	 DGF	 in	 this	 cohort	occurred	 in	 25/35	 (71%)	 of	 patients.	There	 was	 immediate	 function	 in	 9/35	 (26%)	 grafts	 and	 there	was	 one	 early	graft	loss	at	16	hours	due	to	venous	thrombosis.	Of	those	25	patients	with	DGF,	only	23	required	dialysis.	1/23	(4%)	was	only	dialysed	once	in	the	first	24	hours,	14/23	(16%)	were	dialysed	 for	up	to	7	days	and	8/23	(35%)	required	dialysis	for	more	than	7	days.		The	 incidence	 of	 71%	 DGF	 is	 on	 the	 higher	 side	 of	 the	 range	 reported	 in	 the	literature,	probably	due	to	the	higher	than	average	use	of	older	donor	organs.	
	
	
3.3.8.		Rejection	episodes	
	Seven	of	the	34	patients	with	functioning	grafts	developed	acute	rejection	within	the	first	six	months	after	transplantation.		The	median	time	from	transplantation	to	acute	rejection	was	90	days	and	none	occurred	within	the	sample	collection	period.	 	 Acute	 rejection	 is	 outside	 the	 scope	 of	 this	 project	 and	 will	 not	 be	discussed	further.		
	
3.3.9.		Storage	method		After	organ	retrieval	all	kidneys	are	transported	to	the	recipient	centre	 in	cold	static	 storage.	 	 Once	 the	 organs	 arrived	 at	 Cardiff	 Transplant	 Unit	 they	 were	prepared	for	implantation	and	then	a	further	storage	period	followed	whilst	the	patient	was	 prepared	 for	 implantation,	 during	 this	 time	 17/35	 (48.6%)	 donor	kidneys	underwent	hypothermic	machine	perfusion,	18/35	(51.4%)	underwent	just	 cold	 static	 storage.	 	 Selection	 of	 storage	 method	 was	 based	 on	 the	anticipated	 duration	 of	 CIT;	 at	 the	 time	 the	 vast	majority	 of	DCD	organs	were	
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received	 as	 a	 pair	 therefore	 the	 second	 organ	 to	 be	 transplanted	 underwent	hypothermic	machine	perfusion	whilst	the	first	was	being	transplanted.		The	first	organ	underwent	cold	static	storage.		
	
3.3.10.		Baseline	nitrite	and	nitrate	concentration		Within	the	population	there	 is	variation	 in	the	circulating	concentration	of	NO;	the	 baseline	 values	 of	 NO2-	 and	 NO3-	 was	 measured	 (time	 point	 A)	 for	 all	participants	in	the	study.		The	baseline	median	(range)	concentration	of	NO2-	in	μmol/L	was	0.3	(0.1-0.9)	and	the	baseline	NO3-	in	μmol/L	was	42.2	(8.3-103.6).		
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3.4.		Part	1	Results		The	 data	 included	 Nitrate	 levels	 measured	 (as	 previously	 described)	 in	 the	plasma	samples	of	9	LD,	31	DBD	and	29	DCD	renal	 transplant	 recipients	using	the	 Griess	 method.	 	 The	 samples	 we	 used	 for	 analysis	 were	 collected	 pre	operatively	 and	 2	 hours	 post	 reperfusion	 of	 the	 organ.	 	 We	 calculated	 a	reperfusion	ratio	(RRT)	i.e.	the	ratio	between	the	pre	and	post-operative	nitrate	concentration	and	looked	initially	at	the	differences	between	types	of	transplant,	shown	in	Figure	3.2.		
	
Figure	 3.2:	 Reperfusion	 ratio	 of	 nitrate	 in	 LD,	 DBD	 and	 DCD	 kidneys.		
Reperfusion	ratio	(post-operative:pre-operative)	of	the	levels	of	the	NO	metabolite	
nitrate	 in	 a	 series	 of	 patients	undergoing	 renal	 transplantation	 from	 live	 donors	
(LD),	brain	death	donors	(DBD)	and	circulatory	death	donors	(DCD).	 	The	values	
are	 median,	 interquartile	 and	 central	 range.	 	 The	 reperfusion	 ratio	 was	
significantly	 higher	 in	 patients	 receiving	 a	 kidney	 transplant	 from	 a	 DCD	 donor	
compared	 to	 both	 LD	 and	 DBD	 kidneys	 using	 a	 Mann	 Whitney	 U	 test	 (n	 =	 69,	
p=0.050).		We	 found	 that	 as	we	move	 from	 LD	 to	 DBD	 and	 then	 to	 DCD	 transplants	 the	mean	RRT	of	nitrate	increases,	that	is	to	say	that	the	difference	between	the	pre-
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operative	and	the	post-reperfusion	nitrate	level	is	greater.		Significant	difference	was	found	between	DCD	transplants	and	the	two	other	types	of	transplantation	(p	=	0.050).	 	We	hypothesized	 that	 this	may	reflect	 the	 increasing	 IRI	between	these	modes	of	donation.	This	finding	prompted	us	to	look	in	more	detail	at	the	DCD	group	with	a	particular	interest	into	the	risk	factors	for	IRI.			Our	 research	 question	 was;	 is	 there	 an	 association	 between	 risk	 factors	 for	increased	IRI	in	renal	transplantation	(warm	and	cold	ischemic	times,	donor	and	recipient	 age,	 donor	 sex)	 and	 changes	 in	 NO	 metabolites	 in	 DCD	 kidney	transplants?					In	DCD	transplants,	we	found	statistically	significant	increases	in	RRT	when	cold	ischemic	time	was	greater	than	12	hours	(p=0.03)	and	where	the	donor	age	was	greater	than	55	years	(p=0.04).		Although,	when	considering	donor	age,	one	can	see	 that	 there	 is	 a	 significant	 overlapping	 of	 the	 values	 involved,	 as	 shown	 in	Figure	3.3	and	3.4.						
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Figure	 3.3:	 	Difference	 in	RRT	between	DCD	kidney	 transplants	with	 CIT	 of	
less	than	or	equal	to	12	hours	and	greater	than	12	hours.	RRT	of	the	levels	of	
the	NO	metabolite	nitrate	in	a	series	of	patients	undergoing	renal	transplantation	
from	DCD	 donors.	 	The	values	are	median,	 interquartile	and	 central	 range.	 	RRT	
was	 significantly	 higher	 in	 patients	 who’s	 CIT	 is	 greater	 than	 12	 hours	 using	 a	
Mann	Whitney	U	test	(n=	29,	p=0.03).	
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Figure	3.4:		Difference	in	RRT	between	kidney	transplants	whose	donor	age	is	
less	than	or	equal	to	55	years	and	greater	than	55	years.		RRT	of	the	levels	of	
the	NO	metabolite	nitrate	in	a	series	of	patients	undergoing	renal	transplantation	
from	DCD	 donors.	 	The	values	are	median,	 interquartile	and	 central	 range.	 	RRT	
was	 significantly	 higher	 in	 patients	 who’s	 donor	 age	was	 greater	 than	 55	 years	
using	a	Mann	Whitney	U	test	(n=	29,	p=0.04).	
		Both	 CIT	 and	 donor	 age	 are	 risk	 factors	 for	 IRI,	 as	 discussed	 previously.	 	 No	changes	 in	RRT	were	 seen	when	 looking	at	other	 risk	 factors	 for	DGF,	 such	as	WIT	or	recipient	age.	 	These	results	correlate	with	data	from	a	recent	UK	study	looking	at	outcomes	in	deceased	renal	transplants;	the	paper	reported	decreased	graft	 survival	 in	 DCD	 transplants	 whose	 CIT	 was	 greater	 than	 12	 hours	(interestingly	 this	 effect	was	not	 seen	 in	DBD	transplants)	 and	decreased	graft	survival	in	kidneys	from	older	donors	(regardless	of	mode	of	donation)	(14).	
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3.4.1.		Summary	of	findings	
	This	 pilot	 investigation	 has	 shown	 that	 changes	 in	 nitrate	 vary	 significantly	depending	 on	donor	 type	 and	 that	 the	 greatest	 change	 is	 associated	with	DCD	donors.		Within	the	DCD	subgroup	the	data	suggests	that	CIT	is	the	predominant	factor,	although,	without	adjustment	for	confounding	variables	is	inconclusive.		
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CHAPTER	 4:	 	 RESULTS	 –	 Part	 2:	 Metabolites	 of	 NO	 in	
Recipients	of	DCD	Kidneys	 in	 the	Peri-operative	Period	
and	Associations	with	Risk	Factors	for	DGF.	
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4.1.		Introduction	
	In	the	previous	chapter	we	have	seen	how	changes	in	NO	metabolites	are	more	pronounced	in	DCD	renal	transplants.	In	the	methodology	section	2.4	(page	68)	we	concluded	that	in	order	to	accurately	quantify	both	nitrite	and	nitrate,	in	the	context	of	this	study,	ozone	chemiluminescence	should	be	used.	 	In	this	chapter	we	will	investigate	the	levels	of	NO	we	found	around	the	time	of	transplantation	using	the	chemiluminescence	method	and	see	what	factors	may	be	affecting	the	production	 of	 NO.	 	 When	 considering	 the	 data	 presented	 it	 is	 important	 to	remember	that	NO	(and	therefore	NO2-	and	NO3-)	were	being	produced	in	tissues	throughout	the	body	and	also	that	those	extra-renal	tissues	were	subject	to	the	systemic	insult	of	 IRI.	 	To	accommodate	this	and	baseline	variability	within	the	population,	our	analysis	will	be	focused	on	changes	in	NO2-	and	NO3-	as	opposed	to	the	absolute	values	measured.				For	each	of	the	NO	metabolites	analysed,	we	will	consider	variables	known	to	be	risk	factors	for	the	extent	of	IRI	namely	WIT,	CIT,	age	of	the	donor	and	recipient.	We	will	also	look	to	see	if	NO	is	affected	by	the	method	of	storage	of	the	organ	before	transplantation.	i.e.	machine	perfusion	as	opposed	to	cold	static	storage.		In	 a	 separate	 section	 we	 will	 explore	 the	 temporal	 pattern	 of	 change	 of	 pro-inflammatory	cytokines	post	reperfusion	and	their	relation	with	NO	metabolites.	We	 will	 conclude	 by	 investigating	 whether	 changes	 in	 NO	 metabolites	 are	affected	by	differing	induction	regimes,	as	they	are	known	to	affect	the	release	of	pro-inflammatory	cytokines.		
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4.2.	Nitrite	
4.2.1.		Nitrite	concentration	
	All	280	samples	collected	from	the	35	patients	were	analysed	in	duplicate	using	tri-iodide	to	cleave	NO	from	NO2-,	which	was	subsequently	quantified	by	the	NOA	photomultiplier	 (ozone	 chemiluminescence).	 	 The	 graph	 below,	 Figure	 4.1	depicts	what	happens	to	the	NO2-	levels	in	the	8	hours	after	reperfusion,	shown	with	the	pre	and	post	op	values	for	comparison.			
	
Figure	4.1:		Box	and	whisker	plots	illustrating	the	nitrite	distribution	at	each	
sample	time	point.	 	Box	and	whisker	plots	showing	the	median,	interquartile	and	
central	range	of	nitrite	at	each	sample	point.	 	There	are	no	significant	differences	
between	the	samples	in	the	peri-operative	period	(n=	35,	χ2(6)	=	4.779,	p	=	0.572:	
Friedman	test).	
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There	were	no	significant	changes	in	NO2-	over	time	using	a	Friedman	test	(χ2(6)	=	4.779,	p	=	0.572).		We	were	interested	to	see	if	there	was	an	inherent	differing	ability	 to	produce	NO	amongst	 the	recipients,	which	would	explain	why	overall	changes	 were	 not	 significant;	 therefore	 we	 looked	 to	 see	 if	 there	 was	 any	relationship	between	the	age	of	the	recipient	and	the	change	in	NO2-.		There	was	no	 correlation	between	 the	baseline	NO2-	and	 the	age	of	 the	 recipient	however	there	was	a	strong	negative	correlation	between	the	age	of	the	recipient	and	the	change	in	NO2-at	8	hours	post	reperfusion	rs	(33)	=	-0.435,	p	=	0.01	see	Figure	4.2	below.		
	
	
	
Figure	4.2:	 	Changes	 in	nitrite	8	hours	post-reperfusion.	 	Scatterplot	showing	
the	relationship	between	changes	of	NO2-	at	8	hours	post-reperfusion	and	recipient	
age,	shown	with	line	of	best	fit	(n=35,	rs	(33)	=	 -0.435,	p	=	0.01:	Spearman’s	rank	
order	correlation).	
	4.2.1.1.		Conclusion	We	have	 found	that	 increasing	age	 is	associated	with	an	 impaired	ability	of	 the	body	 to	mount	 a	 NO2-	 response	 to	 IRI	 in	 the	 context	 of	 renal	 transplantation.		This	finding	is	in	keeping	with	the	known	changes	that	occur	as	the	vasculature	ages.	In	both	humans	and	animals,	studies	have	found	that	increased	production	of	reactive	oxygen	species	lead	to	endothelial	dysfunction	and	that	this	process	
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becomes	more	 prevalent	with	 age	 (250-252).	 	High	 levels	 of	 superoxide	 cause	functional	 inactivation	of	NO	(253)	and	production	of	peroxynitrite	(251),	 thus	compromising	endothelial	function.		This	is	aggravated	by	an	age	related	decline	in	 eNOS	 expression	 (254,	 255)	 as	 well	 as	 eNOS	 uncoupling	 (causing	 further	peroxynitrite	 release)	 as	 a	 result	 of	 mitochondrial	 ROS	 formation	 and	mitochondrial	 DNA	 lesions	 (256,	 257).	 	 This	 study	 confirms	 that	 this	 is	 a	biochemically	detectable	phenomenon	in	the	renal	transplant	recipient.		As	 a	 result	 of	 the	 differing	 inherent	 ability	 of	 individuals	 to	 mount	 a	 nitrite	response	depending	on	their	age,	it	became	apparent	that	subsequent	analysis	to	look	for	other	factors	associated	with	IRI	that	may	contribute	to	changes	in	NO2-	should	 use	 regression	 in	 order	 to	 account	 for	 the	 mal-distribution	 of	 the	 age	factor.			
4.2.2.		IRI	and	changes	in	nitrite		IRI	is	a	multifactorial	and	complex	phenomenon.		We	do	know	that	the	age	of	the	recipient,	the	donor	and	the	duration	of	the	warm	and	cold	ischemic	times	are	all	contributing	factors	to	DGF	in	a	transplanted	organ	(198,	258)	and	that	DGF	may	reflect	a	more	severe	IRI.	 	We	were	therefore	interested	to	see	if	there	was	any	relationship	 between	 these	 variables	 and	 changes	 of	 NO2-	 found	 in	 plasma	around	the	time	of	transplantation.			In	 order	 to	 correct	 for	 the	 natural	 variation	 in	 the	 baseline	 concentration	we	calculated	the	change	of	NO2-	and	used	this	as	the	dependent	variable	as	opposed	to	absolute	values	measured.		We	looked	at	how	the	concentration	changed	from	the	baseline	value	to	ensure	that	other	factors,	such	as	induction	of	anaesthesia	and	 surgical	 stimulus,	 were	 not	 influencing	 our	 results.	 	 When	 looking	 at	 the	period	 post-reperfusion	 of	 the	 transplanted	 kidney,	 we	 calculated	 the	 change	between	the	pre	and	post-reperfusion	value	as	 this	was	 felt	 to	most	accurately	isolate	 any	 effects	 attributable	 to	 reperfusion.	 	We	 used	 regression	 analysis	 to	see	if	there	were	any	associations	between	the	age	of	the	donor	or	recipient,	the	
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CIT	and	the	1st	and	2nd	WITs	and	changes	in	NO2-	that	occur	after	reperfusion	of	the	 transplanted	 kidney.	 There	was	 no	 relationship	 between	 the	 factors	 listed	above	and	 the	 change	of	NO2-	 in	our	earliest	post	 reperfusion	 sample	 (30	min.	post	 perfusion	 of	 the	 transplanted	 kidney).	 	 However	 at	 2	 and	 8	 hours	 post	perfusion	 we	 found	 some	 of	 these	 factors	 to	 be	 significantly	 influencing	 NO2-	changes.		At	2	hours	post-reperfusion,	regression	analysis	revealed	that	the	change	of	NO2-	was	negatively	related	to	the	age	of	the	recipient	(p=0.050)	and	the	model	that	included	 these	 factors	 was	 predictive	 with	 an	 R2=	 0.159.	 	 The	 regression	coefficient	and	standard	errors	can	be	seen	in	the	table	below	Table	4.2.		At	8	hours	post-reperfusion	regression	analysis	revealed	that	the	change	of	NO2-	positively	related	to	the	primary	WIT	(p	<	0.0005)	and	negatively	related	to	the	age	of	the	recipient	(p=0.001).		The	model	for	NO2-	at	8	hours	that	included	these	factors	was	 predictive	with	 an	R2=	 0.546	 (p	 <	 0.0005).	 	 Regression	 coefficient	and	standard	errors	can	be	seen	in	the	table	below	Table	4.2.	
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2	Hours	Post	
reperfusion	
	 SE	 Beta	 p	
Age	of	
Recipient	
	 0.003	 -0.443	 0.050	
Age	of	Donor	 	 0.002	 0.326	 0.149	
CIT	 	 0.006	 -0.032	 0.858	
1st	WIT	 	 0.006	 0.173	 0.362	
2nd	WIT	 	 0.002	 -0.218	 0.247	
	
8	Hours	Post	
reperfusion	
	 SE	 Beta	 p	
Age	of	
Recipient	
	 0.003	 -0.666	 0.001	
Age	of	Donor	 	 0.003	 -0.272	 0.129	
CIT	 	 0.007	 -0.139	 0.302	
1st	WIT	 	 0.008	 0.567	 <0.0005	
2nd	WIT	 	 0.003	 -0.112	 0.421	
	 	 	 	 	
	
Table	4.1:		Change	of	nitrite	at	2	and	8	hours	post-reperfusion		
Summary	 of	 multiple	 regression	 analysis,	 change	 of	 NO2-	 in	 μmol/L	 at	 2	 and	 8	
hours	post	reperfusion.	SE	=	Standard	error	of	the	coefficient;	Beta	=	standardized	
coefficient.		Twenty	 four	 and	 72	 hours	 post	 operatively	 there	were	 no	 relationships	 found	between	our	factors	and	changes	in	NO2-.			4.2.2.1.		Conclusion	In	 this	 section	we	 have	 found	 that	 changes	 in	 NO2-	 are	 related	 to	 certain	 risk	factors	for	IRI	and	that	this	change	appears	to	become	biochemically	detectable	between	2	and	8	hours	post	 reperfusion.	 	Both	primary	WIT	and	 recipient	age	are	recognised	risk	 factors	 for	DGF	and	from	our	analysis	we	can	see	that	 they	both	 are	 influential	 in	 NO2-	change	 at	 8	 hours	 post-reperfusion.	 Changes	 at	 2	hours	are	affected	only	by	the	age	of	the	recipient.		This	reinforces	our	findings	in	4.2.1	 that	 aging	 decreases	 the	 body’s	 ability	 to	 produce	 NO	 in	 the	 context	 of	transplantation.	 	 Decreased	 production	 of	NO	may	 therefore	 be	 a	 contributing	mechanism	 to	 the	 greater	 incidence	 of	DGF	 (and	 therefore	 IRI)	 found	 in	 older	recipients.	 (14).	 	 Prolonged	 WIT	 is	 a	 risk	 factor	 for	 IRI;	 we	 did	 not	 find	 any	
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previous	studies	linking	it	specifically	to	changes	in	NO	however,	in	this	analysis,	it	was	found	to	be	influential.		We	hypothesised	that	this	may	be	due	to	changes	occurring	in	the	endothelium	of	the	transplanted	organ	as	a	result	of	reperfusion	injury.	
	
	
Other	factors	that	may	play	a	role	in	nitrite	changes:	
	
4.2.3.	 	 The	 effect	 of	 machine	 perfusion	 on	 nitrite	 concentration	 post	
reperfusion	
	To	 examine	 if	 the	 use	 of	 machine	 perfusion	 had	 an	 effect	 on	 change	 in	 NO2-	concentration	 a,	 Mann	 Whitney	 U	 test	 was	 performed	 to	 compare	 the	 two	groups.	 	 There	 were	 no	 statistically	 different	 changes	 in	 NO2-	 concentration	between	 the	 group	 that	 underwent	 machine	 perfusion	 and	 the	 group	 that	underwent	 cold	 static	 storage	 at	 any	 point	 post-reperfusion	 see	 Figure	 4.3	below.		
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Figure	4.3:		Nitrite	concentration	according	to	storage	method.		Data	showing	
the	 median	 nitrite	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion,	
according	 to	 storage	 method.	 	 No	 significant	 differences	 were	 found	 between	
groups	(n=35,	pre-operative	p=0.483,	30	minutes	post-reperfusion	p=0.878,	2	hours	
post-reperfusion	 p=0.832,	 8	 hours	 post-reperfusion	 p=0.484,	 24	 hours	 post-
operative	p=0.102:	Mann	Whitney	U	test).	
	
	
4.2.4.	 	 Effect	 of	 recipient	 and	 donor	 sex	 on	 changes	 in	 nitrite	 post	
reperfusion	
	To	 see	 if	 sex	 of	 the	 recipient	 or	 donor	 had	 an	 effect	 on	 change	 in	 NO2-	concentration,	 a	 Mann	 Whitney	 U	 test	 was	 performed	 to	 compare	 the	 two	groups.	 There	 were	 no	 statistically	 different	 changes	 in	 NO2-	 concentration	between	 male	 and	 female	 recipients	 at	 any	 point.	 	 Similarly	 there	 was	 no	difference	 in	 NO2-	 concentrations	 found	 in	 recipients	 receiving	 kidneys	 from	male	or	female	donors.		See	Figures	4.4	and	4.5	below.		The	numerical	difference	seen	in	the	post	-reperfusion	samples	was	pre-existing	in	the	base	line	ones.		
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Figure	4.4:		Nitrite	concentration	according	to	recipient	sex.		Data	showing	the	
median	 nitrite	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion	
according	 to	 sex	 of	 the	 recipient.	 	 No	 significant	 differences	were	 found	 between	
groups	(n=35,	pre-operative	p=0.451,	30	minutes	post-reperfusion	p=0.390,	2	hours	
post-reperfusion	 p=0.954,	 8	 hours	 post-reperfusion	 p=0.952,	 24	 hours	 post-
operative	p=0.424:	Mann	Whitney	U	test).					
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Figure	 4.5:	 	 Nitrite	 concentration	according	 to	 donor	 sex.	 	Data	showing	the	
median	 nitrite	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion	
according	 to	 sex	 of	 the	 donor.	 	 No	 significant	 differences	 were	 found	 between	
groups	(n=35,	pre-operative	p=0.523,	30	minutes	post-reperfusion	p=0.506,	2	hours	
post-reperfusion	 p=0.707,	 8	 hours	 post-reperfusion	 p=0.471,	 24	 hours	 post-
operative	p=0.581:	Mann	Whitney	U	test).		
	
4.2.5.		Summary	of	findings	
	In	 this	 section	we	have	 seen	 that	aging	appears	 to	 impair	 the	body’s	 ability	 to	produce	NO2-	and	that	the	1st	WIT,	that	is	associated	with	IRI,	is	also	influential	in	the	change	of	NO2-	levels	during	the	process	of	renal	transplantation.			We	have	also	seen	that	these	nitrite	changes	are	not	influenced	by	the	sex	of	the	donor	or	 the	recipient,	and	not	statistically	by	the	organ	storage	method.	 	Next	we	will	look	to	analyse	NO3-	to	see	if	it	is	influenced	by	the	same	factors.		
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4.3.		Nitrate	
4.3.1.		Nitrate	concentration	
	We	looked	to	see	if	changes	in	NO3-	followed	the	same	pattern	as	nitrite	and	if	its	changes	were	influenced	by	the	same	risk	factors	for	IRI.		Figure	4.6	shows	how	the	nitrate	concentration	changed	over	the	sampling	period.					
	
Figure	4.6:		Box	and	whisker	plots	illustrating	the	nitrate	distribution	at	each	
sample	time	point.	 	Box	and	whisker	plots	showing	the	median,	interquartile	and	
central	 range	 of	 nitrite	 at	 each	 sample	 point.	 	 Changes	 in	 NO3-	 over	 time	 were	
statistically	significant,	(n=35,	χ2(3)	=	12.097,	p	=	0.003:	Friedman	test).	 	Pairwise	
comparisons	with	 a	 Bonferroni	 correction	 for	multiple	 comparisons	 showed	NO3-	
concentration	 increased	 significantly	 between	 samples	 30	 minutes	 and	 8	 hours	
post-reperfusion	(p	=	0.005).		
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Unlike	NO2-	we	found	that	NO3-	 levels	changed	significantly	over	that	sampling	period.	 If	 we	 look	 at	 the	 period	 around	 organ	 reperfusion	 we	 see	 that	 the	concentration	rises	steadily.		A	Friedman	test	was	run	to	determine	if	there	were	statistical	differences	 in	 the	 change	of	NO3-	levels	during	 the	 sample	 collection.		Changes	in	NO3-	over	time	were	statistically	significant,	χ2(3)	=	12.097,	p	=	0.003.		Pairwise	comparisons	were	performed	with	a	Bonferroni	correction	for	multiple	comparisons;	NO3-	concentration	increased	significantly	between	samples	taken	at	30	minutes	and	8	hours	post-reperfusion	(p	=	0.005).			To	see	if	changes	in	NO3-	were	influenced	by	the	age	of	the	recipient	(as	we	had	found	 with	 NO2-)	 we	 performed	 correlation	 analysis	 using	 Speaman’s	 rank	correlation.		Once	again	there	was	a	strong	negative	correlation	between	the	age	of	 the	 recipient	and	 the	 change	of	NO3-	 at	8	hours	post	 reperfusion	 rs	 (32)	=	 -0.508,	p	=	0.002,	 see	Figure	4.7.	 	There	was	also	negative	 correlation	between	recipient	age	and	the	change	 in	NO3-	at	30	minutes	post-reperfusion	rs	 (32)	=	 -0.358,	p	=	0.038,	Figure	4.8.		
	
		
	
Figure	 4.7:	 	 Changes	 in	 nitrate	 at	 8	 hours	 post-reperfusion.	 	 	 Scatterplot	
showing	the	relationship	between	changes	of	NO3-	at	8	hours	post-reperfusion	and	
recipient	 age,	 shown	 with	 line	 of	 best	 fit.	 	 (n=35,	 rs	 (32)	 =	 -0.508,	 p	 =	 0.002:	
Spearman’s	rank	order	correlation).	
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Figure	4.8:	 	Changes	 in	nitrate	at	30	minutes	post-reperfusion.	 	 	Scatterplot	
showing	the	relationship	between	changes	of	NO3-	at	30	minutes	post	reperfusion	
and	 recipient	age,	 shown	with	 line	of	best	 fit.	 	 (n=35,	 rs	 (32)	=	 -0.358,	p	=	 0.038:	
Spearman’s	rank	order	correlation).	
		
4.3.2.		IRI	and	change	in	nitrate	
	Regression	 analysis	 was	 performed	 using	 the	 same	 variables	 as	 we	 had	 used	during	 the	 nitrite	 analysis	 to	 see	 if	 these	 factors	 were	 also	 effecting	 nitrate	changes.		The	variables	we	included	were	WIT,	CIT	and	donor	and	recipient	age.		At	no	point	was	any	relationship	found	between	risk	factors	for	IRI	and	changes	in	NO3-	as	shown	in	Table	4.4.	 	It	is	surprising	that	recipient	age	is	not	significant	as	 there	 was	 good	 correlation	 found	 in	 the	 previous	 analysis	 it	 is	 possibly	 a	reflection	that	the	study	is	underpowered.		
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2	Hours	Post-	
reperfusion	
	 SE	 Beta	 p	
Age	of	
Recipient	
	 0.180	 -0.194	 0.406	
Age	of	Donor	 	 0.158	 0.209	 0.373	
CIT	 	 0.398	 -0.010	 0.959	
1st	WIT	 	 0.430	 0.046	 0.817	
2nd	WIT	 	 0.149	 -0.229	 0.248	
	
8	Hours	Post-	
reperfusion	
	 SE	 Beta	 p	
Age	of	
Recipient	
	 0.226	 -0.309	 0.182	
Age	of	Donor	 	 0.208	 -0.028	 0.904	
CIT	 	 0.475	 -0.192	 0.277	
1st	WIT	 	 0.524	 0.098	 0.605	
2nd	WIT	 	 0.177	 -0.210	 0.254	
	 	 	 	 	
	
Table	4.2:	 	Change	of	nitrate	at	2	and	8	hours	post-reperfusion.	 	Summary	of	
multiple	 regression	 analysis,	 change	 of	 NO3-	 in	 μmol/L	 at	 2	 and	 8	 hours	 post-
reperfusion.	SE	=	Standard	error	of	the	coefficient;	Beta	=	standardized	coefficient.	
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Other	factors	that	may	play	a	role	in	nitrate	changes:	
	
4.3.3.		The	effect	of	machine	perfusion	on	nitrate	concentration	
	To	see	if	use	of	machine	perfusion	had	an	effect	on	change	in	NO3-	concentration	the	Mann	Whitney	U	test	was	performed	to	compare	the	two	groups.		There	were	no	 statistically	different	 changes	 in	NO3-	 concentration	between	 the	group	 that	underwent	machine	perfusion	and	the	group	that	underwent	cold	static	storage	at	any	point	post	reperfusion,	see	Figure	4.9	below.			
		
	
Figure	4.9:		Nitrate	concentration	according	to	storage	method.		Data	showing	
the	 median	 nitrate	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion,	
according	 to	 storage	 method.	 	 No	 significant	 differences	 were	 found	 between	
groups	(n=35,	pre-operative	p=0.258,	30	minutes	post-reperfusion	p=0.422,	2	hours	
post-reperfusion	 p=0.483,	 8	 hours	 post-reperfusion	 p=0.932,	 24	 hours	 post-
operative	p=0.577:	Mann	Whitney	U	test).	
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4.3.4.		The	effect	of	recipient	and	donor	sex	on	changes	in	nitrate		
	To	see	if	sex	of	the	recipient	or	donor	had	an	effect	on	change	in	NO3-	the	Mann	Whitney	 U	 test	 was	 performed	 to	 compare	 the	 two	 groups.	 	 There	 were	 no	statistically	 different	 changes	 in	 NO3-	 concentration	 between	male	 and	 female	recipients	 at	 any	 point	 during	 the	 sampling	 period.	 	 Similarly	 there	 was	 no	difference	 in	 NO3-	 concentrations	 found	 in	 recipients	 receiving	 kidneys	 from	male	or	female	donors.		See	Figures	4.10	and	4.11	below.	
	
	
	
Figure	4.10:	 	Nitrate	concentration	according	to	recipient	sex.	 	Data	showing	
the	 median	 nitrate	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion,	
according	 to	 sex	of	 the	 recipient.	 	No	 significant	differences	were	 found	between	
groups	(n=35,	pre-operative	p=0.832,	30	minutes	post-reperfusion	p=0.347,	2	hours	
post-reperfusion	 p=0.252,	 8	 hours	 post-reperfusion	 p=0.563,	 24	 hours	 post-
operative	p=0.803:	Mann	Whitney	U	test).		
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Figure	4.11:		Nitrate	concentration	according	to	donor	sex.		Data	showing	the	
median	 nitrate	 concentration	 in	 μmol/L	 during	 the	 period	 post-reperfusion,	
according	 to	 sex	 of	 the	 donor.	 	 No	 significant	 differences	 were	 found	 between	
groups	(n=35,	pre-operative	p=0.301,	30	minutes	post-reperfusion	p=0.67,	2	hours	
post-reperfusion	 p=0.317,	 8	 hours	 post-reperfusion	 p=0.066,	 24	 hours	 post-
operative	p=0.179:	Mann	Whitney	U	test).		
	
4.3.5.		Summary	of	findings	Nitrate	levels	rose	significantly	in	the	8	hours	after	reperfusion	of	the	kidney	and	this	change	was	found	to	be	negatively	associated	with	the	age	of	the	recipient.		Unlike	NO2-	we	did	not	 find	any	association	between	changes	 in	NO3-	and	WIT,	(this	could	represent	differing	roles	for	NO2-	and	NO3-	in	the	context	of	IRI),	nor	did	we	find	that	recipient	or	donor	sex,	or	storage	method	was	influential.			
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4.4.		Nitrate/Nitrite	ratio	
4.4.1.		Introduction	
	In	the	previous	sections	we	have	found	that	changes	in	NO2-	are	linked	to	factors	affecting	IRI	such	as	the	WIT	and	the	age	of	the	recipient.		We	have	also	seen	that	NO3-	seems	not	to	be	affected	by	the	warm	ischemia	time.				From	our	knowledge	of	the	Nitrate	–	Nitrite	–	Nitric	oxide	axis	we	know	that:	- NO	may	be	oxidized	to	NO2-	in	the	presence	of	ceruloplasmin	- NO	may	be	oxidized	to	NO3-	in	the	presence	of	oxyhaemoglobin		- NO2-	can	be	reduced	to	NO	in	hypoxic	conditions	- NO3-	can	be	reduced	to	NO2-	by	bacteria	in	the	gut	- NO2-	and	NO3-	may	be	taken	in	the	diet	or	formed	by	oxidation	of	NO	(77)	During	the	process	of	retrieval,	implantation	and	reperfusion	of	the	kidney	the	of	the	 Nitrate	 –	 Nitrite	 –	 Nitric	 oxide	 axis	 will	 fluctuate	 depending	 upon	 the	physiological	conditions	at	the	time.		In	order	to	analyse	the	axis	in	the	context	of	this	study	we	looked	at	the	ratio	between	NO3-	and	NO2-	see	Figure	4.14	below.		
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4.4.2.		NO3-	/	NO2-	changes	over	the	sampling	period	
	Figure	4.12	below	shows	how	the	ratio	of	NO3-	/	NO2-	behaved	over	the	sampling	period.	 	
	
	
Figure	 4.12:	 	 Box	 and	whisker	 plots	 illustrating	 the	 nitrate/nitrite	 ratio	 at	
each	sample	time	point.		Box	and	whisker	plots	showing	the	median,	interquartile	
and	 central	 range	 of	 nitrate/nitrite	 ratio	 at	 each	 sample	 point.	 	 There	 are	 no	
significant	 differences	 between	 the	 samples	 in	 the	 peri-operative	 period	 (n=35,	
χ2(4)	=	4.682,	p	=	0.322:	Friedman	test).	
	Changes	 in	 NO3-/NO2-	 over	 time	 were	 not	 found	 to	 be	 statistically	 significant,	χ2(4)	=	4.682,	p	=	0.322	using	a	Friedman	test.		
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4.4.3.		IRI	and	changes	in	the	ratio		
	Having	identified	recipient	age	and	1st	WIT	as	important	factors	for	NO2-	we	used	these	 (along	with	 CIT)	 as	 variables	 for	 regression	 analysis	 of	 the	 NO3-	 /	 NO2-,	along	with	the	pre-operative	value	(to	ensure	the	model	 looked	at	change),	see	Table	4.6.		
2	Hours	 SE	 Beta	 p	
Age	of	Recipient	 1.738	 0.318	 0.141	
Age	of	Donor	 1.52	 -0.202	 0.348	
1st	WIT	 4.162	 0.139	 0.446	
2nd	WIT	 1.467	 0.139	 0.477	
CIT	 4.059	 -0.067	 0.698	
	
8	Hours	 SE	 Beta	 p	
Age	of	Recipient	 1.923	 0.417	 0.063	
Age	of	Donor	 1.766	 -0.215	 0.331	
1st	WIT	 4.468	 -0.243	 0.183	
2nd	WIT	 1.536	 0.038	 0.828	
CIT	 4.059	 0.148	 0.378	
	
Table	4.3:	 	Nitrate/nitrite	ratio	at	2	and	8	hours	post-reperfusion.	 	Summary	
of	 Multiple	 Regression	 Analysis	 Change	 of	 NO3-	 /	 NO2-	 at	 2	 and	 8	 hours	 post	
reperfusion	B	=	unstandardized	regression	coefficient;	SE	=	Standard	error	of	 the	
coefficient;	Beta	=	standardized	coefficient.	
	
4.4.4.		Summary	of	findings	The	 ratio	 between	 nitrate	 and	 nitrite	 in	 our	 samples	 was	 not	 influenced	 by	factors	 that	 effect	 IRI.	 	 We	 could	 therefore	 conclude	 that	 the	 ratio	 between	nitrate	and	nitrite,	in	spite	of	their	known	biochemical	relationship,	is	less	useful	than	the	changes	in	concentration	of	the	individual	metabolites.		
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4.5.		Discussion	
	This	chapter	has	demonstrated	that:	1.		At	2	and	8	hours	post	reperfusion	of	the	transplanted	kidney,	changes	in	NO2-	are	influenced	by	WIT	and	the	recipient	age.	2.		Increasing	age	is	associated	with	a	reduced	ability	to	produce	NO2-	and	NO3-.	3.		NO3-	concentration	increased	significantly	up	to	8	hours	post	reperfusion.		The	WIT	and	the	age	of	the	recipient	significantly	influenced	changes	in	NO2-	at	2	and	 8	 hours	 after	 reperfusion	 regardless	 of	 the	 effect	 of	 induction	immunosuppression.	 	 Both	 WIT	 and	 recipient	 age	 are	 known	 contributing	factors	 to	 IRI	 (198,	 258).	 This	 study	 found	 as	 WIT	 increased	 the	 so	 did	 the	change	seen	in	NO2-,	 indicating	that	the	greater	the	extent	of	IRI	the	greater	the	concentration	 of	NO2-	 at	 8	 hours	post-reperfusion	of	 the	 kidney.	 	Whether	 the	NO2-	 is	 produced	 by	 the	 endothelium	of	 transplanted	 organ	 or	 systemically	 by	the	recipient	is	beyond	the	scope	of	this	study	to	prove	conclusively,	however	the	relationship	 seen	 with	 recipient	 age	 implies	 that	 this	 is	 a	 systemic	 response.		This	 reaction	 is	 thought	 to	 occur	 as	 a	 consequence	 of	 cytokine	 up-regulation	(and	 therefore	 activation	 of	 NOS)	 produced	 by	 the	 inflammatory	 mediators	released	in	response	to	IRI	(259).		The	next	chapter	will	investigate	the	patterns	of	 cytokine	 release	 in	 our	 patient	 cohort	 and	 look	 to	 see	 if	 there	 are	 any	associations	with	NO	release.	
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CHAPTER	5:	 	RESULTS	–	Concentrations	of	Cytokines	 in	
Recipients	of	DCD	Kidneys	 in	 the	Peri-operative	Period	
and	the	Effect	of	Induction	Immunosuppression	
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5.1.		Introduction	
	In	 the	 previous	 chapter	 we	 looked	 at	 NO	 changes	 in	 the	 plasma	 of	 patients	undergoing	DCD	renal	transplant.	 	We	found	that	NO	metabolite	concentrations	were	influenced	by	factors	contributing	to	IRI.		Changes	in	NO	may	be	due	to	pro-inflammatory	cytokines,	which	stimulate	iNOS	up-regulation.		To	investigate	this	further	 we	 measured	 IL-6,	 IL-10,	 and	 TNF-α	 in	 the	 available	 plasma	 samples	using	 a	 Luminex	 Performance	 Assay.	 	 The	 samples	 selected	 for	 analysis	 were	times	 A	 (pre-operative),	 C	 (post-skin	 incision,	 prior	 to	 clamping	 of	 the	 blood	vessels),	 D	 (30	minutes	 post-reperfusion),	 E	 (2	 hours	 post-reperfusion)	 and	G	(24	hours	post-operative)	and	they	were	analysed	in	duplicate	for	each	patient.		We	selected	timings	around	reperfusion	that	we	thought	maybe	relevant	as	well	as	the	baseline	and	24	hours	post	operatively	for	comparison.			
5.2.		Cytokine	Response	to	Reperfusion	
	When	 the	 distributions	 of	 the	 cytokines	 in	 the	 baseline	 samples	 was	 initially	analysed,	 the	 concentrations	were	 not	 normally	 distributed	 and	 therefore	 the	data	was	further	analysed	using	non-parametric	tests.		
5.2.1.		IL-6	
	IL-6	levels	rose	after	reperfusion	of	the	kidney,	with	the	peak	found	2	hours	after	reperfusion.	 	We	used	a	Friedman	test	 to	see	 if	 these	changes	were	statistically	significant;	pairwise	comparisons	were	performed	with	a	Bonferroni	correction	for	multiple	comparisons.	 	Changes	 in	 IL-6	were	 found	to	 increase	significantly	χ2(4)	 =	 92.99,	 p	 <	 0.0005.	 	 Post	 hoc	 analysis	 revealed	 statistically	 significant	differences	between	the	concentrations	measured	post	skin	incision	(C)	(as	well	as	 the	 pre-operative	 sample	 (A))	 and	 those	 found	 at	 30	 minutes	 and	 2	 hours	post-reperfusion	(D	and	E).	 	Figure	5.1	below	illustrates	the	changes	found	and	the	 box	 plot	 shows	how	 the	 response	 to	 reperfusion	 varied	within	 the	 sample	population.	 	We	can	 see	 that	post	reperfusion	(D	+	E),	 there	 is	 a	much	greater	
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range	 in	 the	 concentration	of	 IL-6	 (see	Figure	5.1),	 this	may	be	attributable	 to	differing	propensity	to	produce	cytokines	in	the	individual	subjects	or	may	be	as	a	 result	 of	 the	 induction	 immunosuppression.	 Later	 on	 in	 this	 chapter	we	will	look	to	determine	further	what	factors	may	be	influencing	this	variation.			
	
Figure	 5.1:	 	 IL-6	 distribution.	 	 Box	 and	 whisker	 plot	 showing	 the	 median,	
interquartile	and	central	range	of	IL-6	in	pg/ml	around	the	time	of	reperfusion	and	
at	 24	 hours	 post-operatively.	 	 Changes	 in	 IL-6	 vary	 significantly	 (n=35,	 χ2(4)	 =	
92.99,	p	<	0.0005:	Friedman	test).		Median	(range)	in	pg/ml:	Pre	operatively	=	5	(0	
–	58),	post	skin	incision	=	6	(0	–	535),	30	minutes	post-reperfusion	=	20	(1	–	16200),	
2	hours	post-reperfusion	=	79	(13	–	13135)	and	24	hours	post	operatively	=	16	(3	–	
128).	
	
	
	
	
Pr
e-o
pe
rat
ive
Po
st-
sk
in 
inc
isi
on
30
 m
inu
tes
 po
st-
rep
erf
us
ion
2 h
ou
rs 
po
st-
rep
erf
us
ion
24
 ho
ur
s p
os
t-r
ep
erf
us
ion
0
200
400
600
800
IL-6 Concentration
Sample Time
pg
/m
l
	 115	
	
5.2.2.		IL-10	
	The	levels	of	IL-10	also	rose	after	reperfusion	with	a	peak	at	2	hours	(sample	E).		A	Friedman	test	found	statistically	significant	changes	χ2(4)	=	91.604,	p	<	0.0005	in	 IL-10	 concentration.	 	 Post	 hoc	 analysis	 revealed	 statistically	 significant	differences	between	the	concentrations	measured	post	skin	incision	(C),	(as	well	as	 the	 pre-operative	 sample	 (A))	 and	 those	 found	 at	 30	 minutes	 and	 2	 hours	post-reperfusion	 (D	 and	 E).	 	 Once	 again	 the	 range	 in	 samples	 D	 and	 E	 varied	greatly	as	is	illustrated	in	the	box	and	whisker	plot	below,	Figure	5.2.	
	
Figure	 5.2:	 	 IL-10	 distribution.	 	 Box	 and	 whisker	 plot	 showing	 the	 median,	
interquartile	and	 central	 range	of	 IL-10	 in	pg/ml	around	 the	 time	of	 reperfusion	
and	at	24	hours	post-operatively.		Changes	in	IL-10	vary	significantly	(n=35,	χ2(4)	=	
91.604,	p	<	0.0005:	Friedman	test).	 	Median	(range)	in	pg/ml:	Pre	operatively	=	1	
(0	–	8),	post	skin	incision	=	2	(0	–	1306),	30	minutes	post	perfusion	=	53	(1	–	7474),	
2	 hours	 post	 perfusion	 =	 125	 (5	 –	 3925)	 and	 24	 hours	 post	 operatively	 =	 5	 (1	 –	
151).	
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5.2.3.		TNF-α	
	Changes	in	TNF-α	were	not	found	to	be	significantly	different	χ2(4)	=	2.192,	p	=	0.701	using	a	Friedman	test.	 	Again	the	largest	ranges	were	seen	in	the	samples	taken	after	reperfusion	of	the	kidney,	see	Figure	5.3.		
	
	
Figure	 5.3:	 	 TNF-α	 distribution.	 Box	 and	 whisker	 plot	 showing	 the	 median,	
interquartile	and	central	range	of	TNF-α	in	pg/ml	around	the	time	of	reperfusion	
and	 at	 24	 hours	 post-operatively.	 	 Changes	 in	 TNF-α	 do	 not	 vary	 significantly	
(n=35,	 χ2(4)	 =	 2.192,	 p	 =	 0.701:	 Friedman	 test).	 	 Median	 (range)	 in	 pg/ml:	 Pre	
operatively	 =	 17	 (3	 –	 52),	 post	 skin	 incision	 =	 17	 (4	 –	 1306),	 30	 minutes	 post	
perfusion	=	25	(7	–	2232),	2	hours	post	perfusion	=	32	(8	–	4400)	and	24	hours	post	
operatively	=	21	(0	–	159).		
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5.2.4.		Summary	All	of	these	cytokines	increased	after	reperfusion	of	the	kidney;	this	study	found	significant	rises	30	minutes	and	2	hours	post-reperfusion	in	IL-6	and	IL-10.		The	aetiology	 of	 this	 is	 likely	 to	 be	multifactorial	 and	 include	 the	 process	 of	 organ	reperfusion	 as	 well	 as	 the	 recipients’	 response	 to	 the	 surgical	 stimulus.		However,	 induction	 immunosuppression	 might	 have	 exerted	 a	 significant	influence	and	the	next	section	of	analysis	will	look	at	how	this	differed	between	groups.	
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5.3.		Cytokine	Response	to	Induction	Immunosuppression		This	 section	 will	 look	 at	 cytokine	 changes	 between	 groups	 who	 received	different	induction	immunosuppression.		It	is	important	to	be	mindful	of	the	way	these	medications	are	administered;	 Simulect	was	administered	approximately	one	 hour	 pre	 operatively;	 Campath	 during	 the	 period	 of	 this	 study	 was	administered	subcutaneously	during	the	anaesthetic	 induction;	and	finally	ATG	was	administered	as	an	infusion	over	4-6	hours	during	the	operative	procedure.		Both	Campath	and	Simulect	infusions	are	complete	by	the	time	the	third	sample	(post	 induction	of	 anaethesia	and	prior	 to	 skin	 incision)	 is	 taken,	however,	 the	ATG	 infusion	 is	 on	 going	whilst	 samples	 the	 third	 sample	 is	 taken,	 as	well	 as	whilst	the	samples	are	taken	at	30	minutes	and	2	hours	post	perfusion.		
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5.3.1.		IL-6	
	As	shown	in	the	previous	section	(5.2.1.)	we	found	a	significant	rise	in	IL-6	levels	after	 reperfusion.	 	 When	 we	 broke	 the	 group	 down	 to	 look	 at	 the	 effects	 of	induction	 immunosuppression	we	 can	 see	 that	 this	 rise	was	most	 profound	 in	the	ATG	group	followed	by	the	Campath	group	and	then	Simulect,	see	Figure	5.4.		
	
	
Figure	 5.4:	 	 IL-6	 concentration	 according	 to	 induction	 immunosuppression	
group.	 	 Median	 IL-6	 concentrations	 in	 pg/ml	 shown	 over	 time	 according	 to	
induction	immunosuppression	group.	 	Using	the	Kruskal-Wallis	H	tests	significant	
differences	 are	 found	 at	 30	 minutes	 post-reperfusion	 (n=35,	 χ2(2)	 =	 11.92	 p	 =	
0.003)	 and	 2	 hours	 post-reperfusion	 (n=35,	 χ2(2)	 =	 12.639	 p	 =	 0.002)	 between	
groups.		Each	 immunosuppression	group	was	analyzed	looking	at	 the	pre-operative	and	post-reperfusion	samples	in	order	to	explore	further	the	effects	of	each	induction	therapy.		Within	all	of	the	groups	we	found	statistically	significant	rises	of	IL-6	in	
Pr
e-o
pe
rat
ive
Po
st-
sk
in 
inc
isi
on
30
 m
inu
tes
 po
st-
rep
erf
us
ion
2 h
ou
rs 
po
st-
rep
erf
us
ion
24
 ho
ur
s p
os
t-r
ep
erf
us
ion
0
50
100
150
200
250
300
Sample Time
M
ed
ia
n 
pg
/m
l
IL-6 Concentration
ATG
Campath
Simulect
	 120	
the	 post-reperfusion	 samples.	 	 In	 the	 ATG	 group,	 a	Wilcoxon	 signed-rank	 test	determined	 that	 there	 was	 a	 statistically	 significant	 increase	 in	 median	 IL-6	concentration	 (101	 pg/ml)	 between	 the	 pre-operative	 (5	 pg/ml)	 and	 the	 30	minute	 post-reperfusion	 sample	 (106	 pg/ml),	 z	 =	 3.059,	 p	 =	 0.002	 and	 also	between	the	pre-operative	and	the	2	hour	post-reperfusion	sample	(256	pg/ml),	
z	=	3.18,	p	=	0.001,	median	increase	(252	pg/ml).		In	 the	Campath	group	 there	was	also	a	 significant	difference	between	 the	pre-operative	and	post-reperfusion	samples;	median	 increase	 in	 IL-6	concentration	at	30	minutes	was	19	pg/ml,	pre-operative	median	5	pg/ml	and	the	30	minute	post-reperfusion	sample	23	pg/ml,	z	=	2.083,	p	=	0.005,	at	2	hours	the	median	increase	was	80	pg/ml,	 the	2	hour	post-reperfusion	median	was	86	pg/ml,	z	 =	2.803,	p	=	0.005.		In	the	Simulect	group	there	was	a	statistically	significant	median	increase	in	IL-6	concentration	(3	pg/ml)	between	the	pre-operative	(7	pg/ml)	and	the	30	minute	post-reperfusion	 sample	 (10	 pg/ml),	 z	 =	 2.66,	p	 =	 0.008	 and	 also	 between	 the	pre-operative	and	the	2	hour	post-reperfusion	sample	(53	pg/ml),	z	=	3.059,	p	=	0.002,	median	increase	(46	pg/ml).	
	The	 statistical	 analysis	 found	 significant	 increases	 in	 all	 of	 the	immunosuppression	 groups,	 the	 graphical	 representation	 in	 Figure	 5.4	 above	shows	 that	 this	 is	most	profound	 in	 the	ATG	group.	 	As	mentioned	previously,	when	 considering	 the	 immunosuppression	 groups	 individually	 we	 must	remember	that	the	groups	are	small	and	therefore	we	may	be	seeing	the	results	of	 a	 type	 1	 error.	 	 To	 check	 to	 see	 if	 one	 immunosuppression	had	more	 of	 an	effect	we	 used	 a	Kruskal-Wallis	H	 tests	 to	 compare	 the	 groups;	 at	 30	minutes	post-reperfusion	and	2	hours	post-reperfusion	there	were	significant	differences	between	 induction	 groups,	 χ2(2)	 =	 11.92	 p=	 0.003	 and,	 χ2(2)	 =	 12.639	 0.002	respectively.	 	 Pairwise	 comparisons	 were	 performed	 using	 Dunn's	 (1964)	procedure	with	a	Bonferroni	correction	for	multiple	comparisons.		This	post	hoc	analysis	 revealed	 that	 the	 statistically	significant	differences	were	between	 the	Simulect	and	ATG	groups	see	Figure	5.5	below.	
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Figure	5.5:	 	Distribution	of	 IL-6	at	30	minutes	and	2	hours	post-reperfusion	
according	 to	 induction	 immunosuppression.	 	 Box	 and	whisker	 plots	 showing	
median,	interquartile	and	central	range	of	IL-6	in	pg/ml	between	induction	groups	
at	 each	 statistically	 significant	 sample.	At	30	minutes	post	 reperfusion	 there	 is	a	
significant	 difference	 in	 (median)	 IL-6	 concentration	 in	 pg/ml	 between	 Simulect	
(10)	 and	 ATG	 (106),	 n=35,	 p	 =	 0.003,	 at	 2	 hours	 post	 reperfusion	 there	 is	 a	
significant	difference	in	IL-6	concentration	between	Simulect	(53)	and	ATG	(256),	
n=35,		p	=	0.001.		This	 section	 has	 shown	 that	 induction	 immunosuppression	 has	 a	 significant	effect	on	cytokine	release	in	the	context	of	renal	transplantation.	 	In	the	case	of	IL-6,	we	found	post-reperfusion	concentration	increases	in	all	of	the	groups.		It	is	possible	 that	 this	 was	 caused	 by	 organ	 reperfusion	 however	 further	 analysis	found	a	difference	between	patients	who	 received	ATG	and	Simulect.	 	 IL-6	has	been	studied	after	reperfusion	in	live	donor	kidneys	(166),	de	Vries	et	al.	found	that	IL-6	concentration	rises	after	reperfusion	in	samples	taken	directly	from	the	renal	 artery	 and	 vein	 at	 30	 minutes	 post-reperfusion	 and	 the	 current	 study	supports	that	finding.		The	paper	also	proposes	that	it	is	the	allograft	itself	rather	than	 systemic	 production	 by	 the	 recipient	 that	 causes	 this	 rise	 (it	 was	 not	specific	 about	 the	 immunosuppression	 regimen	 administered	 to	 the	 subjects).		Furthermore	the	same	study	looked	at	IL-6	in	a	mouse	model	and	found	it	to	be	protective	against	renal	IRI.		
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	Simulect	 is	 a	 monoclonal	 antibody	 specific	 for	 the	 IL-2	 receptor	 (CD25);	 IL-2	regulates	 activation	 and	 proliferation	 of	 cytotoxic	 T-cells	 as	well	 as	 B-cell,	 NK-cell	 and	 regulatory	 T-cell	 function	 (260,	 261)	 thus	 Simulect	 suppresses	 the	immune	 response.	 	 Specifically,	 Simulect	 binds	 to	 the	 ectodomain	 of	 IL-2Rα	blocking	 IL-2	 signalling.	 	 Other	 IL-2	 receptors,	 for	 example	 IL-2Rβ	 and	 γc,	 are	shared	 with	 other	 cytokines	 (IL-4,	 IL-7,	 IL-9	 and	 IL-15)	 however	 IL-2Rα	 is	thought	 to	 be	 unique	 to	 IL-2	 (262),	 the	 specificity	 of	 the	monoclonal	 antibody	target	 lead	 us	 to	 the	 conclusion	 that	 although	 IL-6	 concentration	 rose	 in	 the	Simulect	group	this	may	be	the	effects	of	reperfusion,	where	as	the	rise	found	in	ATG	may	be	due	to	the	drug	itself	and	this	could	be	why	we	found	a	difference	between	the	changes	in	these	two	groups.	
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5.3.2.		IL-10	
	In	section	5.2.2.	we	found	that	IL-10	levels	rose	significantly	after	reperfusion	of	the	 kidney	 Figure	 5.6	 below	 shows	 how	 IL-10	 varied	 according	 to	 induction	immunosuppression.		
	
	
Figure	5.6:	 	 IL-10	concentration	according	to	 induction	immunosuppression	
group.	 	 Median	 IL-10	 concentrations	 in	 pg/ml	 shown	 over	 time	 according	 to	
induction	immunosuppression	group.	 	Using	the	Kruskal-Wallis	H	tests	significant	
differences	 are	 found	 at	 30	minutes	 post-reperfusion	 	 (n=35,	 χ2(2)	 =	 21.124	 p	 <	
0.0005)	and	2	hours	post-reperfusion	n=35,	 (χ2(2)	=	19.112,	p	<	0.0005)	between	
groups.		As	 with	 IL-6,	 we	 looked	 to	 see	 if	 there	 was	 a	 change	 within	 the	immunosuppression	groups	post-reperfusion,	once	again,	there	were	significant	
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rises	in	all	groups	at	30	minutes	and	2	hours	post	perfusion.		The	results	for	each	group	are	described	and	the	significant	results	are	illustrated	in	Figure	5.7.		In	 the	 ATG	 group	 a	 Wilcoxon	 signed-rank	 test	 determined	 that	 there	 was	 a	statistically	 significant	 increase	 in	 median	 IL-10	 concentration	 (477	 pg/ml)	between	 the	 median	 pre-operative	 (1	 pg/ml)	 and	 the	 30	 minute	 post-reperfusion	sample	(477	pg/ml),	z	=	3.18,	p	=	0.001	and	also	between	the	pre-operative	 and	 the	 2	 hour	 post-reperfusion	 sample	 (604	 pg/ml),	 z	 =	 3.18,	 p	 =	0.001,	median	increase	=	603	pg/ml.		In	the	Campath	group	again	there	was	a	significant	difference	between	the	pre-operative	 and	 post-reperfusion	 samples;	 the	 median	 increase	 in	 IL-10	concentration	at	30	minutes	was	56	pg/ml,	pre-operative	median	=	1	pg/ml	and	the	 30	minute	 post-reperfusion	median	 =	 57	pg/ml,	 z	 =	 2.803,	p	 =	 0.005,	 at	 2	hours	 the	median	 increase	was	96	 pg/ml,	 the	 2	 hour	post-reperfusion	median	was	97	pg/ml,	z	=	2.803,	p	=	0.005.		In	the	Simulect	group	there	was	a	statistically	significant	median	increase	in	IL-10	 concentration	 (5	 pg/ml)	 between	 the	 pre-operative	 (1	 pg/ml)	 and	 the	 30	minute	post-reperfusion	sample	(6	pg/ml),	z	=	2.197,	p	=	0.028	and	also	between	the	pre-operative	and	the	2	hour	post-reperfusion	sample	(23	pg/ml),	z	=	3.059,	
p	=	0.002,	median	increase	=	21	pg/ml.		Although	there	were	increases	post-reperfusion	in	all	of	the	immunosuppression	groups,	it	is	clear	from	the	graph	and	the	absolute	median	values	that	ATG	seems	to	have	had	a	more	profound	effect;	Kruskal-Wallis	H	tests	were	used	 to	 see	 if	there	were	differences	between	the	groups.		At	30	minutes	post-reperfusion	and	2	 hours	 post-reperfusion	 there	 were	 significant	 differences	 in	 IL-10	concentrations	 between	 induction	 immunosuppressants:	 χ2(2)	 =	 21.124,	 p	 <	0.0005	 and,	 χ2(2)	 =	 19.112,	 p	 <	 0.0005	 respectively,	 see	 Figure	 5.6	 above.		Pairwise	 comparisons	were	 performed	 using	 Dunn's	 (1964)	 procedure	with	 a	Bonferroni	correction	for	multiple	comparisons.		This	post	hoc	analysis	revealed	that	the	statistically	significant	differences	at	30	minutes	post-reperfusion	were	between	 the	Simulect	 and	both	Campath	and	ATG	groups	and	at	2	hours	post-
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reperfusion	 were	 found	 between	 ATG	 and	 both	 Simulect	 and	 Campath;	 the	significance	levels	of	the	post-hoc	analysis	are	shown	below	Figure	5.7.		
	
Figure	5.7:		Distribution	of	IL-10	at	30	minutes	and	2	hours	post-reperfusion	
according	 to	 induction	 immunosuppression.	 	 Box	 and	whisker	 plots	 showing	
median,	 interquartile	 and	 central	 range	 of	 IL-10	 in	 pg/ml	 between	 induction	
groups	 at	 each	 statistically	 significant	 sample.	 	 At	 30	 minutes	 post	 reperfusion	
there	is	a	significant	difference	in	(median)	IL-10	concentration	in	pg/ml	between	
Simulect	(6)	and	both	ATG	(477),	n=35,		p	<	0.0005	and	Campath	(57)	p	=	0.021,	at	
2	 hours	 post	 reperfusion	 there	 is	 a	 significant	 difference	 in	 IL-10	 concentration	
between	ATG	(603)	and	both	Campath	(97),	n=35,		p	=	0.048	and	Simulect	(23)	p	<	
0.0005.			At	 30	minutes	 post-reperfusion	 lower	 levels	 of	 IL-10	 are	 seen	 in	 the	 Simulect	group,	with	 significantly	different	 IL-10	 levels	 found	between	 the	Simulect	 and	both	ATG	and	Campath.	 	At	2	hours	post	 reperfusion	our	experiments	 found	a	significant	difference	 between	 both	 the	 Campath	 and	Simulect	 group	 and	ATG.		After	 reperfusion	 of	 the	 transplanted	 kidney,	 IL-10	 production	 is	 increased,	along	with	 IL-2	 and	 IL-6	 (263)	 our	 findings	 are	 in	 line	 with	 this	 as	 shown	 in	section	5.2.2.		ATG	and	Campath	appear	to	be	adding	to	this	post-reperfusion	of	the	kidney,	with	ATG	having	more	of	 an	effect	 than	Campath.	 	 It	 is	beyond	 the	scope	of	this	project	to	determine	the	mechanism	of	the	changes	found	however	it	is	clear	that	the	induction	immunosuppression	administered	has	a	significant	effect	on	the	pattern	of	cytokine	release.	
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5.3.3.		TNF-α	
	In	section	5.2.3.	we	looked	for	changes	in	TNF-α	concentration	over	our	sampling	period	and	although	we	saw	a	general	 trend	of	 increase	post-reperfusion	these	changes	were	not	significant.		Figure	5.8	below	illustrates	the	effect	that	different	immunosuppression	had	on	the	cytokine	release.		It	is	noticeable	from	Figure	5.8	that	ATG	has	a	dramatic	effect	on	the	post-reperfusion	samples	however	 in	 the	other	 immunosuppression	 groups	 the	 post	 reperfusion	 peak	 seen	 in	 the	interleukins	is	not	found.	
	
	
	
Figure	5.8:		TNF-α	concentration	according	to	induction	immunosuppression	
group.	 	 Median	 TNF-α	 concentrations	 in	 pg/ml	 shown	 over	 time	 according	 to	
induction	immunosuppression	group.	 	Using	the	Kruskal-Wallis	H	tests	significant	
differences	 are	 found	 at	 30	 minutes	 post-reperfusion	 (n=35,	 χ2(2)	 =	 14.235,	 p	 =	
0.001)	 and	 2	 hours	 post-reperfusion	 (n=35,	 χ2(2)	 =	 17.363,	 p	 <	 .0005)	 between	
groups.	
Pr
e-o
pe
rat
ive
Po
st-
sk
in 
inc
isi
on
30
 m
inu
tes
 po
st-
rep
erf
us
ion
2 h
ou
rs 
po
st-
rep
erf
us
ion
24
 ho
ur
s p
os
t-r
ep
erf
us
ion
0
50
100
150
200
250
300
Sample Time
M
ed
ia
n 
pg
/m
l
TNF-α Concentration
ATG
Campath
Simulect
	 127	
As	with	the	other	cytokines,	we	 looked	to	see	 if	 there	was	a	change	within	the	immunosuppression	 groups	 post	 perfusion;	we	 found	 a	 significant	 increase	 in	TNF-α	 in	 the	 ATG	 group	 and	 a	 significant	 decrease	 post-reperfusion	 in	 the	Simulect	 group.	 	 The	 Campath	 group	 was	 found	 to	 rise	 at	 2	 hours	 post-reperfusion.		In	 the	 ATG	 group	 a	 Wilcoxon	 signed-rank	 test	 determined	 that	 there	 was	 a	statistically	 significant	 increase	 in	 median	 TNF-α	 concentration	 (304	 pg/ml)	between	 the	 pre-operative	 (10	 pg/ml)	 and	 the	 30	 minute	 post-reperfusion	sample	(314	pg/ml),	z	=	2.521	p	=	0.012	and	also	between	the	pre-operative	and	the	2	hour	post-reperfusion	 sample	 (519	pg/ml),	z	 =	2.521,	p	 =	0.012,	median	increase	=	509	pg/ml.		In	the	Campath	group	there	were	no	differences	at	30	minutes	post-reperfusion,	at	2	hours	post-reperfusion	the	median	increase	was	12	pg/ml,	the	pre-operative	median	was	 18	 pg/ml,	 the	 2	 hour	 post-reperfusion	median	was	 30	 pg/ml,	 z	 =	2.073,	p	=	0.038.		In	 the	 Simulect	 group	 there	 was	 a	 significant	 median	 decrease	 in	 TNF-α	concentration	 (4	 pg/ml)	 between	 the	 pre-operative	 (19	 pg/ml)	 and	 the	 30	minute	 post-reperfusion	 sample	 (15	 pg/ml),	 z	 =	 -2.667,	 p	 =	 0.008	 and	 also	between	the	pre-operative	and	the	2	hour	post-reperfusion	sample	(15	pg/ml),	z	=	-2.803,	p	=	0.005,	median	decrease	(4	pg/ml).		Kruskal-Wallis	H	tests	were	run	to	see	if	TNF-α	concentrations	differed	between	induction	groups.	 	At	both	30	minutes	 (χ2(2)	=	14.235,	p	 =	0.001)	and	2	hours	(χ2(2)	=	17.363,	p	 <	 .0005)	post-reperfusion	 significant	differences	were	 found	between	 immunosuppression	 groups.	 	 Pairwise	 comparisons	 were	 performed	using	 Dunn's	 (1964)	 procedure	 with	 a	 Bonferroni	 correction	 for	 multiple	comparisons.	 	 This	 post	 hoc	 analysis	 revealed	 that	 the	 statistically	 significant	differences	were	between	the	Simulect	and	ATG	groups	at	both	time	points,	the	significance	levels	of	the	post	hoc	analysis	are	shown	below	Figure	5.9.	
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Figure	5.9:		Distribution	of	TNF-α	at	30	minutes	and	2	hours	post-reperfusion	
according	 to	 induction	 immunosuppression.	 	 Box	 and	whisker	 plots	 showing	
median,	 interquartile	 and	 central	 range	 of	 TNF-α	 in	 pg/ml	 between	 induction	
groups.	At	30	minutes	post-reperfusion	there	is	a	significant	difference	in	(median)	
TNF-α	 concentration	 in	 pg/ml	 between	 Simulect	 (15)	 and	 ATG	 (314),	 n=35,	 p	<	
0.0005,	 at	 2	 hours	 post-reperfusion	 there	 is	 a	 significant	 difference	 in	 TNF-α	
concentration	between	Simulect	(15)	and	ATG	(519),	n=35,		p	<	0.0005.			Post-reperfusion	 concentration	 of	 TNF-α	 differed	 between	 ATG	 and	 Simulect;	TNF-α	 plays	 a	 significant	 role	 in	 IRI	 as	 a	 pro-inflammatory	mediator	 and	 anti	TNF-α	agents	have	been	found	to	attenuate	ischemic	injury	(264,	265)	although	not	 in	 clinical	human	 trials.	 	 In	 our	 experiments	 although	we	 did	 not	 find	 any	overall	effect	of	reperfusion	on	TNF-α	concentration,	we	did	see	that	ATG	seems	to	 cause	 an	 increase	 in	 the	 levels	 found	 and	 that	 Simulect	 may	 supress	 its	production.		
	
5.3.4.		Summary	of	findings	
	This	 section	 has	 shown	 that	 induction	 immunosuppression	 had	 a	 significant	effect	 on	 cytokine	 release	 post	 reperfusion,	 despite	 the	 different	 timings	 of	administration.	 	 All	 of	 the	 cytokines	 we	 measured	 were	 increased	 by	 ATG.		Simulect	seemed	to	cause	an	increase	in	IL-6	and	possibly	in	IL-10	although	the	change	was	small	and	may	be	due	to	type	1	error;	Campath	was	associated	with	
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an	increase	in	IL-6	and	IL-10	and	also	TNF	-α	(at	2	hours	post-reperfusion	only).		We	were	 limited	 in	the	number	of	 the	samples	we	were	able	 to	analyse	and	so	further	work	may	 be	 to	 look	 at	 sample	 F	 (taken	 8	 hours	 post-reperfusion)	 to	complete	the	picture;	alternative	methods	should	also	be	used	for	quantifying	IL-2,	IL-17	and	IFN-γ	as	the	Luminex	results	returned	too	many	undetectable	values	for	useful	analysis.		The	next	question	this	work	will	address	is	the	relationship,	if	any,	between	cytokine	concentration	and	changes	in	NO	metabolites.	
	
	
5.4.		Cytokine	Correlation	with	NO	and	IRI.	
	Using	 Spearman’s	 rank	 correlation,	 we	 looked	 to	 see	 if	 the	 rises	 in	 cytokines	were	associated	with	changes	in	NO	metabolites;	in	chapter	5.2	we	saw	that	the	peak	measurement	of	 all	 cytokines	was	at	2	hours	post-reperfusion	and	 in	4.2	and	4.3	we	found	that	changes	of	NO2-	and	NO3-	were	associated	with	risk	factors	for	 IRI	at	2	and	8	hours	post-reperfusion,	 therefore	these	were	the	samples	we	used.	 	 We	 did	 not	 find	 any	 significant	 relationships	 in	 our	 analysis.	 	 We	 also	looked	 to	 see	 if	 the	 factors	affecting	NO2-	 and	NO3-,	which	we	had	 identified	 in	chapter	4,	had	any	influence	over	the	concentration	of	cytokines	in	our	samples	using	 regression	 analysis.	 	We	 did	 not	 identify	 any	 significant	 factors	however	we	 can	 see	 that	 the	 cytokines	 were	 significantly	 affected	 by	 induction	immunosuppression.	 	The	final	results	chapter	will	try	to	investigate	the	role	of	induction	immunosuppression	in	more	detail.		
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CHAPTER	 6:	 	 RESULTS	 –	 The	 Effect	 of	 Induction	
Immunosuppression	 on	 Metabolites	 of	 NO	 in	 the	 Peri-
operative	period	of	a	DCD	Renal	Transplant		
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6.1.		Introduction	
	All	 of	 the	 patients	 received	 one	 of	 three	 induction	 immunosuppressants;	Simulect	 is	 administered	 one	 hour	 pre-operatively	 and	 so	may	 be	 expected	 to	exert	any	effect	early	on	in	the	sampling	period,	Campath	is	administered	during	anaesthetic	induction	subcutaneously	and	so,	like	Simulect,	effects	may	be	seen	in	the	early	samples.		ATG	is	administered	as	an	infusion	over	4	to	6	hours	during	the	 operative	 procedure.	 	 For	 this	 reason	 effects	 of	 ATG	 may	 not	 be	 fully	apparent	until	 at	 least	 sample	F,	 taken	8	hours	post	 reperfusion	of	 the	kidney.		The	 following	 section	 will	 explore	 changes	 in	 NO2-	 and	 NO3-	 according	 to	 the	induction	agent	administered.	
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6.2.		Nitrite	
	The	median	concentrations	of	NO2-	according	to	 induction	 immunosuppression	are	shown	in	the	line	graph	below	Figure	6.1.	
	
	
	
Figure	 6.1:	 	 Median	 concentration	 of	 nitrite	 according	 to	 induction	
immunosuppression.	 	 Graph	 demonstrating	 the	 median	 NO2-	 concentration	 in	
μmol/L	over	time,	according	to	induction	immunosuppression.		At	30	minutes	post-
reperfusion	 the	 changes	between	 immunosuppression	group	differed	 significantly	
(n=35,	χ2(2)	=	6.38,	p	=	0.041:	Kruskal-Wallis)			It	 is	 noticeable	 in	 Figure	6.1	 above	 that	 the	 baseline	NO2-	 concentration	 in	 the	Campath	group	appears	to	be	higher	than	the	other	immunosuppression	groups;	this	is	likely	to	reflect	the	relatively	small	sample	size	of	the	study.		Although	this	was	not	found	to	be	a	statistically	significant	difference,	it	may	have	an	influence	on	 the	other	 results	 and	we	will	 refer	back	 to	 this	observation	 throughout	 the	
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following	analysis.		Sub-analysis	of	induction	regimes	is	at	best	exploratory	given	the	 small	 involved	 in	 each	 induction	 group.	 The	 following	 results	 should	therefore	be	interpreted	with	caution.		The	 median	 distributions	 across	 the	 sampling	 period	 are	 shown	 for	 each	induction	therapy	below,	Figures	6.2,	6.3	and	6.4.		
	
	
Figure	 6.2:	 	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrite	
concentration	 in	 the	 Simulect	 group.	 	 Box	 and	 whisker	 plots	 showing	 the	
median,	 interquartile	and	 central	 range	of	NO2-	 concentration	 in	μmol/L	at	 each	
sample	point	 in	 the	Simulect	group.	 	There	are	no	significant	differences	between	
the	samples	in	the	peri-operative	period	(n=12,	χ2(6)	=	3.932,	p	=	0.686:	Friedman	
test).	
	No	 statistical	 differences	were	 found	 between	 sampling	 points	 in	 the	 Simulect	group.	
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Figure	 6.3:	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrite	
concentration	 in	 the	 ATG	 group.	 	 Box	 and	whisker	 plots	 showing	 the	median,	
interquartile	 and	 central	 range	 of	NO2-	 concentration	 in	 μmol/L	 at	 each	 sample	
point	in	the	ATG	group.		There	are	no	significant	differences	between	the	samples	in	
the	peri-operative	period	(n=13,	χ2(6)	=	6.573,	p	=	0.362:	Friedman	test).			The	effect	of	ATG	on	cytokine	 release	 is	 extensively	 reported;	 so	much	so	 that	
cytokine	release	syndrome	 is	one	of	 its	documented	 side	effects.	 	However	how	this	translates	into	an	effect	on	NO	has	not	been	investigated	(no	relevant	studies	were	returned	in	a	PubMed	search	containing	both	terms).		We	may	hypothesise	that	cytokine	release,	induced	by	ATG,	would	lead	to	up-regulation	of	iNOS	and	therefore	NO	synthesis	however	 there	 is	nothing	 in	 the	published	 literature	 to	confirm	 this	 theory.	 	One	 study	by	Puschel	 et.	Al	 looked	at	ATG	and	NO	 in	 the	context	 of	microvascular	 thrombus	 formation;	 this	 group	 found	 an	 increase	 in	eNOS	and	iNOS	after	ATG	administration	however	no	detectable	effect	from	NO	as	 a	 result	 (they	 did	 not	 measure	 NO	 metabolites	 themselves).	 They	
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hypothesized	 that	 this	 may	 be	 as	 a	 result	 of	 post-translational	 changes	influencing	the	enzymes	ability	to	produce	NO	(266).		There	were	no	significant	differences	 found	 between	 the	 samples	 post-reperfusion	 in	 this	 group	 in	 our	data.				
	
Figure	 6.4:	 	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrite	
concentration	 in	 the	 Campath	 group.	 	 Box	 and	 whisker	 plots	 showing	 the	
median,	 interquartile	and	 central	 range	of	NO2-	 concentration	 in	μmol/L	at	 each	
sample	point	 in	 the	ATG	group.	 	There	are	no	 significant	differences	between	the	
samples	in	the	peri-operative	period	(n=10,	χ2(6)	=	9.048,	p	=	0.171:	Friedman	test).			It	 is	 noticeable	 from	 Figure	 6.3	 and	 6.4,	 that	 Campath	 appeared	 to	 have	 a	different	 effect	 to	ATG,	with	 a	 peak	 of	NO2-	 found	 around	 the	 time	of	 the	 skin	incision	followed	by	a	plateau	in	concentration	after	reperfusion.		This	apparent	difference	in	response	may	be	as	a	result	of	both	the	selective	nature	of	Campath	(as	a	monoclonal	antibody)	 in	 its	mechanism	of	action	against	CD52	antibodies	
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and	may	 also	 represent	 the	 pleiotropic	 nature	 of	 cytokines,	 that	 is	 to	 say	 that	their	action	is	dependent	upon	the	physiological	conditions	of	the	tissues	at	the	time.	 	 There	 were	 no	 differences	 found	 between	 individual	 samples	 in	 the	Campath	group	but	we	were	interested	to	see	if	there	were	differences	between	the	immunosuppression	groups.			Kruskal-Wallis	H	tests	were	used	to	see	if	there	were	differences	in	the	change	of	NO2-	concentrations	between	induction	groups	post	reperfusion.	 	At	30	minutes	post-reperfusion	 the	 changes	 between	 immunosuppression	 groups	 were	significantly	 different	 χ2(2)	 =	 6.38,	 p	 =	 0.041.	 	 Pairwise	 comparisons	 were	performed	 using	 Dunn's	 (1964)	 procedure	 with	 a	 Bonferroni	 correction	 for	multiple	 comparisons.	 	 This	 post	 hoc	 analysis	 revealed	 that	 the	 statistically	significant	 differences	 were	 between	 Campath	 and	 both	 the	 Simulect	 and	 the	ATG	 groups,	 the	 p	 values	 are	 shown	 on	 the	 box	 plot	 below,	 Figure	 6.5.	 	 No	differences	were	identified	at	the	other	times.		
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Figure	6.5.		Distribution	of	nitrite	at	30	minutes	post-reperfusion,	according	
to	 induction	 immunosuppression.	 	 Box	 and	 whisker	 plots	 showing	 median,	
interquartile	 and	 central	 range	 of	 change	 in	 NO2-	 in	 μmol/L	 between	 induction	
groups	at	30	minutes	post	perfusion,	n=35.	 	There	was	a	 significant	difference	 in	
the	median	change	between	Campath	(0.098	μmol/L)	and	ATG	(-0.022	μmol/L)	p	=	
0.018	and	Campath	and	Simulect	(-0.049	μmol/L	)	p	=	0.041.			
6.2.1.		Conclusion	
	We	 have	 found	 that	 the	 change	 of	 NO2-	 at	 30	minutes	 post	 perfusion	 differed	according	to	induction	group.		All	of	the	agents	used	are	known	to	have	an	effect	on	 cytokine	 release	 although	 the	 pattern	 of	 cytokine	 release	 varies	 with	 the	medication	 used.	 	 As	 discussed	 in	 the	 induction	 immunosuppression	 chapter	 of	the	 introduction,	 ATG	 may	 cause	 a	 cytokine	 storm	 involving	 many	 pro-inflammatory	cytokines;	in	particular	IL-16	and	TNF-α	and	this	was	reflected	in	the	findings	of	this	study.		Both	TNF-α	and	IL	-1	act	synergistically	with	IFN-γ	to	up-regulate	NF-κβ	which	in	turn	causes	up-regulation	of	NOS	and	NO	production.		We	may	have	expected	ATG	to	cause	an	increase	in	both	NO	metabolites	via	the	classical	pathway	of	iNOS	up	regulation	and	subsequent	oxidation	of	NO	to	NO2-	(catalysed	 in	 plasma	 by	 ceruloplasmin)(74)	 and	 by	 the	 reaction	 of	 NO	 with	
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oxyhaemoglobin	to	produce	NO3-	however	this	was	not	seen	in	terms	of	NO2-	in	our	 results.	 	 This	 could	 be	 a	 consequence	 of	 the	 duration	 of	 the	 ATG	 infusion	causing	us	to	miss	the	peak	of	its	action	on	NO2-	which	is	less	stable	than	NO3-	in	whole	blood	(75).			Campath	 is	 thought	 to	 suppress	pro-inflammatory	 cytokines	 such	as	 IFN-γ	and	IL-17	 and	 increase	 anti-inflammatory	 cytokines	 such	 as	 IL-4	 and	 IL-10	 (242).	Once	again	our	results	from	IL-10	measurement	support	this.	 	Theoretically	we	may	 have	 expected	 to	 find	 that	 this	 translated	 in	 to	 suppression	 of	 NO	production.		On	review	of	the	median	change	of	NO2-	within	the	Campath	group		(Figure	6.4)	this	theory	was	not	confirmed,	there	was	predominantly	a	positive	change	 in	NO2-	 in	 the	 first	24	hours	after	administration	of	 the	medication	and	we	found	that	recipients	in	the	Campath	produced	significantly	more	NO2-	than	those	who	 received	ATG	 in	 our	 early	 samples.	 	 This	 finding,	which	 contradicts	our	 theoretical	 knowledge	 of	 Campath	 and	 cytokines,	 may	 represent	 their	
contextual	 and	 synergistic	 nature;	 that	 is	 to	 say	 that	 the	 effects	 of	 cytokine	release	on	a	 cell	depend	upon	 the	 conditions	 the	 cell	 is	 exposed	 to	at	 the	 time	and	 that	 varying	 combinations	 of	 cytokine	 release	 may	 cause	 varying	biochemical	effects.		Our	findings	suggest	that	Campath	may	be	influential,	along	with	other	factors,	in	changes	in	NO2-	concentration.			Simulect,	 similarly	 to	 Campath,	 increases	 production	 of	 some	 cytokines	whilst	surpressing	others;	production	of	IL-10	is	stimulated	whist	IFN-γ,	TNF-α	and	IL-6	are	suppressed	(267,	268).			We	did	not	find	that	Simulect	administration	had	any	 biochemical	 effect	 on	 NO2-	 concentration,	 we	 did	 find	 that	 IL-10	concentration	rose	after	Simulect	administration	and	we	also	found	a	reduction	in	TNF-α	in	this	group.			
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6.3.		Nitrate	
	Figure	 6.6	 shows	 the	 median	 concentration	 of	 NO3-	 measured	 according	 to	induction	immunosuppression	group.	
	
	
Figure	 6.6:	 	 Median	 concentration	 of	 nitrate	 according	 to	 induction	
immunosuppression.	 	 Graph	 demonstrating	 the	 median	 NO3-	 concentration	 in	
μmol/L	 over	 time,	 according	 to	 induction	 immunosuppression.	 Using	 a	 Kruskal-
Wallis	analysis	 there	were	no	significant	differences	between	 induction	groups	at	
any	time	point,	n=35.	
	It	 appears	 that	NO3-	 concentration	 is	 highest	 in	 the	ATG	group,	with	 a	 general	trend	 of	 an	 initial	 fall	 in	 concentration,	 rising	again	 back	 towards	 the	 baseline	post	 reperfusion.	 	 As	 we	 observed	 in	 4.5.2.,	 baseline	 values	 appear	 different	between	immunosuppression	groups;	to	correct	for	this	our	subsequent	analysis	looks	 at	 change	 in	 nitrate	 levels	 as	opposed	 to	 absolute	 values.	 	 The	 following	three	Figures,	6.7,	6.8	and	6.9,	depict	the	ranges	found	for	each	induction	group.	
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Figure	 6.7:	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrate	
concentration	 in	 the	 Simulect	 group.	 	 Box	 and	 whisker	 plots	 showing	 the	
median,	 interquartile	and	 central	 range	of	NO3-	 concentration	 in	μmol/L	at	 each	
sample	point	 in	 the	Simulect	group.	 	There	are	no	significant	differences	between	
the	 samples	 in	 the	 peri-operative	 period	 (n=12,	 χ2(6)	 =	 1.3,	 p	 =	 0.972:	 Friedman	
test).	
	There	were	no	statistical	differences	between	 the	sample	times	in	 the	Simulect	group.	
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Figure	 6.8:	 	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrate	
concentration	 in	 the	 ATG	 group.	 	 Box	 and	whisker	 plots	 showing	 the	median,	
interquartile	 and	 central	 range	 of	NO3-	 concentration	 in	 μmol/L	 at	 each	 sample	
point	in	the	ATG	group.		There	are	no	significant	differences	between	the	samples	in	
the	peri-operative	period	(n=13,	χ2(6)	=	6.641,	p	=	0.465:	Friedman	test).	
	There	were	no	statistical	differences	between	the	sample	times	in	the	ATG	group.	
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Figure	 6.9:	 	 Box	 and	 whisker	 plots	 illustrating	 the	 median	 nitrate	
concentration	 in	 the	 Campath	 group.	 	 Box	 and	 whisker	 plots	 showing	 the	
median,	 interquartile	and	 central	 range	of	NO3-	 concentration	 in	μmol/L	at	 each	
sample	in	the	Campath	group.		The	change	in	NO3-	concentration	in	μmol/L	varried	
significantly	across	the	sampling	period	(n=10,	χ2(6)	=	14.714,	p	<	0.023:	Friedman	
test).	Median	(range):	Sample	A	=	42.8	(30.4	–	79.2),	Sample	B	=	38.1	(24.4	–	89.1),	
Sample	C	=	36.1	(26.9	–	88.3),	Sample	D	=	33.5	(27	–	92.6),	Sample	E	=	35.6	(29.1	–	
103.6),	Sample	F	=	42	(33.6	–	127.9),	Sample	G	=	44.2	(24.3	–	126.6)	and	Sample	H	
=	51.8	(35	–	73.7).	
	The	change	of	NO3-	 concentration	was	 statistically	 significantly	different	at	 the	different	time	points	in	the	Campath	group,	χ2(6)	=	14.714,	p	<	0.023.		Post	hoc	analysis	 revealed	 statistically	significant	differences	 in	 change	 in	NO3-	between	samples	 B	 (taken	 30	 min	 post-induction	 of	 anaesthesia	 (and	 Campath	administration),	C	(taken	post	skin	incision	but	prior	to	clamping	of	the	vessels),	and	D	(taken	30min	post	reperfusion	of	the	transplanted	kidney)	and	sample	H	(taken	 72	 hours	 post	 operatively)	 (p	 =	 0.05),	 (p	 =	 0.006)	 and	 (p	 =	 0.003)	
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respectively.		There	was	also	a	significant	change	between	samples	C	and	D	and	sample	F	(taken	8	hours	post	reperfusion	of	the	transplanted	kidney)	(p	=	0.022)	(p	=	0.012)	respectively.		
	Nitrate	 concentration	 appears	 to	 be	 affected	 by	 Campath	 induction.	 	 Kruskal-Wallis	H	tests	were	used	 to	 see	 if	 there	were	differences	 in	 the	 change	of	NO3-	concentrations	 between	 induction	 groups	 post-reperfusion.	 	 This	 analysis	 did	not	show	any	significant	differences	between	these	groups.			
6.3.1.		Conclusion	
	In	this	section	we	have	found	that	changes	in	NO3-	concentration	were	evident	in	the	Campath	group	only,	we	also	found	that	changes	in	NO2-	at	30	minutes	post	reperfusion	 were	 significantly	 higher	 in	 the	 Campath	 group	 in	 comparison	 to	both	ATG	 and	 Simulect.	 	We	 have	 found	differences	 in	 both	 nitrite	 and	nitrate	concentrations	 related	 to	 the	 induction	 therapies;	 in	 order	 to	 check	 that	 our	previous	 findings	were	 not	 purely	 attributable	 to	 the	 induction	 the	 regression	analysis	was	repeated	including	induction	immunosuppression	as	a	variable,	the	recipient	age	and	1st	WIT	were	still	 found	to	be	significant	so	we	are	confident	that	the	results	are	not	just	down	to	the	immunosuppression,	although	from	the	subsequent	analysis	it	is	likely	that	it	also	plays	a	role.			
Concluding	remarks:	Induction	immunosuppression	is	clearly	influential	on	the	results	of	this	study;	the	concentration	of	cytokines	in	our	samples	seems	to	be	particularly	 affected.	 	We	 have	 not	 been	 able	 to	 demonstrate	 any	 relationship	between	NO	and	the	cytokines	that	we	were	able	to	measure.	The	lack	of	a	direct	relationship	 between	NO	 and	 the	 cytokines	 found	 in	 this	 study	may	 represent	the	differing	effect	of	induction	immunosuppression	on	cytokine	production,	but	there	may	 also	 be	 a	 contributing	 effect	 of	 the	 two	pathways	 of	NO	production	that	were	 reviewed	 in	Chapter	1;	we	would	expect	both	 the	classical	 pathway,	which	results	from	up-regulation	of	iNOS	in	response	to	inflammatory	cytokines,	and	the	alternative	Nitrate	–	Nitrite	-	NO	pathway,	which	is	activated	at	times	of	
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hypoxia	and	releases	NO	from	NO2-	and	NO3-,	to	play	a	role	in	NO	release	in	the	context	of	renal	transplantation.		It	is	beyond	the	scope	of	this	project	to	identify	the	mechanism	of	production	in	our	recipients	however	the	inability	to	link	the	cytokine	 production	 with	 the	 concentrations	 of	 NO2-	 and	 NO3-	 implies	 a	significant	role	for	the	alternative	mechanism.		A	future	extension	of	this	project	may	be	 to	 look	at	 iNOS	up	 regulation	and	also	 investigate	 the	patient’s	 genetic	predisposition	 to	 produce	 cytokines.	 	 In	 the	 context	 of	 this	 study	 endothelial	dysfunction	 as	 a	 result	 of	 IRI	 may	 also	 limit	 the	 production	 of	 NO	 by	 NOS	pathways.	 	 IRI	 is	 a	 complex	 phenomenon	 but	 one	 of	 clinical	 importance	 to	transplant	physicians	and	their	patients;	this	project	has	studied	one	element	of	a	 multifactorial	 process	 and	 identified	 some	 significant	 associations,	 in	 the	following	chapter	we	will	summarise	and	collate	our	findings.	
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CHAPTER	7:		DISCUSSION	AND	CONCLUSIONS	
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Discussion	and	Conclusions	
	Renal	 ischemia	reperfusion	 injury	plays	a	significant	 role	 in	 the	 short	 and	 long	term	 outcomes	 post	 kidney	 transplantation.	 	 A	 shortfall	 between	 supply	 and	demand	 of	 organs	 for	 transplantation	 has	 resulted	 in	 an	 expansion	 of	 the	boundaries	 of	 acceptability	 in	 terms	of	 ECD	 and	DCD	kidney	 donors	 accepting	that	these	organs	are	more	susceptible	to	IRI.		Research	into	the	mechanisms	and	therapeutic	options	to	attenuate	this	injury	is	important	to	facilitate	expansion	of	transplant	 programs	within	 the	 health	 service.	 	 NO	production	 is	 undoubtedly	modulated	 by	 IRI	 owing	 to	 the	 dysfunction	 caused	 by	 the	 injury	 on	 the	endothelium.	This	study	set	out	to	investigate	NO	levels	around	the	time	of	renal	transplantation	 by	 quantifying	 NO	 metabolites	 found	 in	 the	 blood	 of	 renal	transplant	recipients	peri-operatively	and	correlating	them	with	 factors	known	to	influence	IRI.		From	our	review	of	the	literature	and	previous	research	done	in	the	department	we	found	that	NO,	NO2-	and	NO3-	exist	in	a	dynamic	axis	and	NO2-	and	NO3-	may	have	differing	roles	with	NO2-	serving	as	reservoir	of	NO	to	be	utilised	in	hypoxic	conditions.	 	 The	method	 of	 quantifying	 NO	metabolites	 used	 by	 our	 unit	 (and	also	 found	 frequently	 in	 the	 literature	 in	 the	 field	 of	 transplantation)	was	 the	Griess	reaction	however	a	broader	literature	review	revealed	that	other	medical	sub-specialties	 (mainly	 cardiology)	were	utilising	and	 recommending	different,	more	 sensitive	 methods.	 	 Given	 our	 hypothesis	 that	 NO2-	 and	 NO3-	 may	 play	differing	 roles	 and	 also	 have	 differential	 effects	 depending	 on	 concentration	 it	was	 important	 to	 this	 study	 that	 an	 accurate	 method	was	 used	 and	 so	 in	 my	initial	experiments	I	quantified	NO2-	and	NO3-	using	both	the	Griess	reaction	and	ozone	 chemiluminescence.	 	 As	 reported	 in	 section	 2.4,	 I	 found	 that	 when	measuring	NO3-	in	the	plasma	of	renal	transplant	recipients	the	Griess	reaction	is	an	acceptable	method	and	has	the	advantage	of	being	cheaper,	quicker	and	less	labour	intensive	than	ozone	chemiluminescence.		If,	however,	NO2-	measurement	is	required	the	Griess	reaction	is	not	sensitive	enough	for	accurate	quantification	of	 the	 levels	 found	 in	 human	 plasma	 and	 a	 more	 sensitive	 technique	 such	 as	
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ozone	chemiluminescence	should	be	employed.	 	Given	the	aims	of	this	project	I	chose	to	use	ozone	chemiluminescence	for	the	rest	of	my	NO	analysis.		As	well	as	measuring	NO	metabolites	I	was	also	interested	in	levels	and	changes	of	 cytokines	 in	my	samples,	 specifically,	 to	see	 if	 they	 could	be	 correlated	with	the	changes	seen;	a	Luminex	based	assay,	was	chosen	in	conjunction	with	staff	at	the	WTAIL	who	are	experienced	with	the	technique	and	equipment,	as	discussed	in	section	2.5.2.	I	encountered	difficulties	with	three	of	the	cytokines	I	chose	to	investigate	and	a	future	extension	of	this	project	may	be	the	addition	of	this	data	by	 a	 different	 method.	 	 The	 results	 obtained	 were	 verified	 by	 another,	 more	experienced,	scientist,	checked	by	the	manufacturers	of	the	kit	and	in	the	case	of	IFN-γ,	 confirmed	 with	 a	 different	 test	 and	 whilst	 disappointed	 not	 to	 have	 a	complete	set	of	data	the	whole	group	were	satisfied	that	the	reported	results	for	the	remaining	cytokines	were	accurate.		At	the	time	of	starting	my	thesis	our	group	had	previously	found	that	total	NO2-	and	NO3-	levels	are	elevated	during	times	of	acute	rejection	and	that	levels	of	NO	metabolites	differ	according	to	type	of	transplant.		As	my	pilot	study	I	was	able	to	add	 samples	 from	 my	 first	 11	 subjects	 to	 this	 data	 and	 demonstrate	 a	significantly	 greater	 change	 in	 NO3-	 in	 the	 recipients	 of	 DCD	 kidneys	 when	compared	to	kidneys	from	DBD	or	live	donors;	within	the	DCD	group	I	found	that	the	 cold	 ischemic	 time	 and	 the	 donor	 age	 were	 also	 influential.	 	 Having	confirmed	that	risk	factors	for	IRI	i.e.	DCD	donation,	donor	age	and	cold	ischemic	time	 seemed	 to	 be	 important	 and	 that	 for	 the	 purposes	 of	 this	 study	 accurate	quantification	 of	 both	 NO2-	 and	 NO3-	 was	 most	 appropriate	 with	 ozone	chemiluminescence	 the	 next	 objective	was	 to	 look	 at	 each	 NO	metabolite	 and	identify	any	factors	affecting	its	production.		When	 reviewing	 the	 NO2-	 data,	 as	 expected,	 we	 saw	 a	 rise	 in	 concentration	following	 reperfusion	 of	 the	 kidney,	 on	 further	 analysis	 of	 the	 data	 I	demonstrated	that	increasing	age	impairs	the	ability	of	the	body	to	mount	a	NO2-	response.	 This	 if,	 as	 is	 believed	 NO2-	 exerts	 a	 protective	 effect	 early	 after	reperfusion	(145,	146)	it	may	explain,	in	part,	why	a	greater	incidence	of	DGF	is	
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found	 in	 older	 recipients.	 	 One	 limitation	 of	 this	 study	 is	 that	 we	 have	 not	investigated	NOS	expression	as	this	may	assist	us	in	explaining	this	finding.		An	Elisa	 method	 of	 quantifying	 NOS,	 tested	 previously	 by	 our	 group,	 proved	unreliable	 for	 frozen	 samples	 and	 its	 use	 in	 fresh,	 centrifuged	 samples	 is	prohibitively	 impractical.	 	 My	 next	 step	 was	 to	 see	 if	 any	 of	 the	 known	 risk	factors	 for	 IRI,	 namely	 WIT,	 CIT	 and	 donor	 and	 recipient	 age	 influenced	 and	changes	in	NO2-;	I	found	that	in	the	8	hours	after	graft	reperfusion	both	recipient	age	and	1st	WIT	affected	changes	in	NO2-	concentration.		Possible	explanations	as	to	how	WIT	may	be	influential	include:			1.		It	reflects	damage	to	the	graft	as	a	result	of	IRI	therefore	stimulating	iNOS	up-regulation	and	NO	production.		2.		It	reflects	the	production	of	NO	via	the	Nitrate-Nitrite-NO	axis.				A	further	extension	to	this	work	may	be	to	look	at	eNOS	and	iNOS	up-regulation	in	the	same	samples.		As	part	of	my	analysis	I	looked	at	other	variables	including	storage	method	and	donor/recipient	 sex,	none	of	 these	 investigations	 revealed	any	associations	with	NO2-	changes.			The	next	stage	was	to	see	if	NO3-	behaved	in	the	same	way	as	NO2-;	I	found	that	NO3-	levels	rose	significantly	in	the	8	hours	after	reperfusion	and	I	would	deduce	that	this	represents	NO	production.		I	found	the	same	association	with	recipient	age	i.e.	changes	in	NO3-	post	reperfusion	are	negatively	correlated	with	recipient	age	and	this	supports	the	theory	that	increasing	age	blunts	the	NO	response	via	its	 detrimental	 effect	 on	 the	 endothelium.	 	 No	 other	 significant	 relationships	were	identified.		It	seems	that	only	NO2-	was	influenced	by	WIT,	which	may	be	a	protective	response	to	the	 injury	of	 ischemia	and	reperfusion	and	supports	 the	theory	 that	NO2-	 is	mobilised	 via	 the	Nitrate-Nitrite-NO	 axis	 during	 hypoxia	 as	opposed	to	the	classical	pathway.		To	explore	that	idea	further	I	looked	to	see	if	the	ratio	of	NO2-	to	NO3-	was	important	however	my	analysis	did	not	reveal	any	significant	associations	further	to	those	seen	already.		A	interesting	expansion	of	this	 project	 would	 be	 measurement	 of	 peroxynitrite	 in	 the	 samples	 as	 its	production,	which	occurs	as	a	result	of	the	reaction	of	NO	and	superoxide,	causes	damage	 to	 renal	 tubular	 structure	 and	 may	 therefore	 be	 contributing	 to	 the	
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deleterious	 effects	 that	 have	 been	 associated	 with	 NO.	 	 This	 reaction	 is	 more	likely	to	take	place	during	pro-inflammatory	states,	such	as	IRI,	when	superoxide	is	in	abundance	and	may	go	someway	to	explain	the	“conflicting	roles”	of	NO	that	were	 discussed	 in	 the	 introduction.	 	 It	 may	 be	 that	 NO3-	 was	 not	 increased	enough	 to	have	 a	 detrimental	 effect	 and	 a	 threshold	might	 need	 to	 be	 crossed	before	the	reaction	is	driven	towards	peroxynitrite	and	deleterious	effects.		One	of	the	aims	of	this	project	was	to	establish	whether	NO	is	protective	or	detrimental	
in	IRI,	because	of	 the	 limitations	previously	discussed	this	 thesis	was	unable	to	answer	 that	 question	 and	 I	 believe	 that	 extra	 data	 regarding	 eNOS/iNOS	expression	and	peroxynitrite	concentration	may	be	required	in	order	to	do	so.		Clarification	of	the	role	of	NO	and	its	metabolites	in	renal	IRI	may	in	the	future	allow	 its	 protective	 effects	 to	 be	 isolated	 and	utilised	 therapeutically	 by	 either	augmentation	of	NO	or	inhibition	of	any	harmful	metabolites.	 	Neither	NO2-	nor	NO3-	demonstrated	any	direct	relationship	with	DGF,	 this	reflects	 the	 limitation	of	study	size	and	was	partly	expected;	DGF	represents	the	clinical	manifestation	of	 one	 end	 of	 the	 continuum	 of	 IRI,	 whilst	 it	 is	 important	 in	 terms	 of	 patient	outcomes	 and	 a	 useful	 way	 of	 defining	 injury,	 IRI	 is	 not	 exclusive	 to	 the	 DGF	group	 and	 it	 is	 unlikely	 that	 molecules	 which	 are	 so	 ubiquitous	 in	 human	physiology	would	exhibit	a	simple	relation	with	such	a	complex	problem.					The	final	aim	of	this	work	was	to	study	the	role	of	cytokines	in	NO	production;	cytokines	 are	 produced	 in	 varying	 quantities	 depending	 on	 genetic	predisposition	within	the	population,	previously	our	group	had	shown	that	 the	UK	 population	 may	 be	 either	 high	 or	 low	 producers	 of	 IFN-γ	 depending	 on	genotype	and	subsequently	the	highest	producers	have	been	shown	to	be	more	prone	 to	 acute	 rejection.	 	 We	 were	 interested	 to	 see	 if	 cytokine	 production	correlated	 with	 any	 changes	 in	 NO	 metabolites	 in	 the	 context	 of	 renal	transplantation	 or	 if	 the	 effects	 of	 the	 induction	 immunosuppression	 would	override	any	differences.	 	 I	 saw	an	 increase	 in	all	 of	 the	quantifiable	 cytokines	after	reperfusion,	although	 in	the	case	of	TNF-α	the	change	was	not	significant.	At	30	minutes	and	2	hours	post	reperfusion	I	found	changes	in	IL-6	and	10	were	significant	 and	 whilst	 this	 could	 be	 an	 effect	 of	 the	 surgical	 stimulus	 I	 was	
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interested	to	see	whether	induction	medication	had	an	effect	on	them.		There	are	two	 limitations	 to	my	work	 in	 chapter	 5	 and	 they	 are	 that	we	were	 unable	 to	measure	 cytokines	 in	 all	 of	 the	 samples	 and	 therefore	we	may	 be	missing	 the	peak	of	 their	production	and	also	that	when	the	 induction	 immunosuppression	sub	groups	are	analysed	the	number	of	participants	in	each	group	is	very	small	therefore	 the	 results	 should	 be	 taken	 in	 this	 context	 and	 interpreted	 with	caution.	
		This	 study	 found	 that	 cytokine	 responses	 varied	 between	 induction	immunosuppression	groups	with	the	largest	changes	seen	in	the	ATG	group	(as	would	be	expected	from	our	review	of	the	literature),	these	finding	were	evident	despite	 variation	 in	 administration	 timings	 of	 induction;	 with	 what	 is	 known	about	 the	mechanism	of	action	of	 the	 induction	therapies,	 (reviewed	 in	section	1.6.	 of	 the	 introduction)	 this	 was	 to	 be	 expected	 however	 to	 the	 best	 of	 my	knowledge,	 this	 is	 the	 first	 study	 to	 report	 this	 directly.	 	 I	 was	 not	 able	 to	establish	 any	 correlation	 between	 the	 changes	 in	 cytokine	 levels	 that	 were	measured	and	changes	of	NO2-	 and	NO3-,	 or	 any	association	between	cytokines	and	 risk	 factors	 for	 IRI.	 	We	used	 a	 Luminex	based	 assay	 to	measure	 cytokine	levels;	the	fact	that	this	proved	unreliable	for	IFN-γ	that	is	directly	related	to	the	production	 of	 NO	 is	 disappointing.	 	 Further	 information	 regarding	 eNOS/iNOS	up-regulation	may	help	answer	this	question.		Whilst	I	didn’t	find	any	specific	statistical	links	between	NO	metabolites	and	the	cytokines	measured	(as	mentioned	IFN-γ	gave	unreliable	results)	I	did	find	that	induction	 immunosuppression	 was	 influential	 on	 cytokine	 production	 and	 so	looked	to	see	if	there	was	also	any	effect	on	NO;	I	found	differences	in	change	of	NO2-	between	immunosuppression	groups	at	30	minutes	post	perfusion	and	was	surprised	 to	 see	 that	 the	 Campath	 group	 displayed	 the	 largest	 concentration	change.	 	 In	 the	 NO3-	 data,	 once	 again,	 it	 was	 within	 the	 Campath	 group	 that	differences	were	evident,	I	found	that	NO3-	concentration	rose	after	reperfusion;	in	the	samples	taken	at	24	and	72	hours	there	is	likely	to	be	a	dietary	influence	as	 the	 patients	may	well	have	 taken	 nitrates	 in	 orally	 however	 the	 increase	 in	
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concentration	 found	 in	 the	 early	 post	 reperfusion	 samples	 warrants	 further	investigation.	 	 As	 has	 been	mentioned	 previously	 these	 conclusions	 should	 be	interpreted	with	caution	due	to	the	size	of	the	groups	and	the	fact	that	the	ATG	infusion	was	on	going	for	several	of	the	post	perfusion	samples			Overall	the	findings	of	my	study	were:	changes	in	NO2-	were	influenced	by	factors	effecting	renal	IRI	and	also	by	Campath	induction.		Increasing	age	was	associated	with	dampening	of	the	NO2-	and	NO3-	response.		Cytokines	rise	after	reperfusion	of	 the	 kidney	 and	 changes	 in	 them	 were	 modified	 by	 induction	immunosuppression.	 	 A	 useful	 extension	 to	 this	 project	 would	 be	 an	investigation	of	eNOS/iNOS	up	regulation	and	peroxynitrite	production.		
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Appendices	
	
Appendix	1:		Cytokine	Families		
	
Receptor	family	 Members	 Shared	function	
Class	1	cytokine	
receptors	or	
haematopoietin	family	
receptors.	
IL-6	subfamily	GM-CSF	subfamily	IL-2	subfamily	IL-13	subfamily	and	IL-12,	G-CSF,	Erythropoietin,	Growth	hormone	and	prolactin	
T/B	cell	activation	Haemaotpoiesis	
Class	2	cytokine	or	
interferon	family	
receptors	
IFN-α/β,	IFN-ϒ,	IL-10,			IL-20,	IL-22	 Antiviral	(with	the	exception	of	IL-10)	
TNF	receptor	family	 TNF-α,	TNF-β,	TRAIL,	BAFF	 Pro	inflammatory	
IL-1/	Toll	like	
receptors	
IL-1α,	IL-1β,	IL-1RA,		IL-18	 Pro	inflammatory	
Tyrosine	kinase	
receptors	
TGF-β,	Bone	morphogenic	proteins,	Activins,	Inhibins	
Growth	factors	
Chemokine	receptors	 CXC,	CC,	CXC3	and	C	chemokines	 Chemotactic		
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Appendix	2:		Griess	Reaction	
		Reaction	diluent	was	made	up	(see	below)	and	samples	prepared	before	moving	on	to	step	2	of	the	reagent	preparation.			Sample	preparation:	1. Add	100	μl	(microlitres)	of	sample	and	100	μl	of	reaction	buffer.	2. Ultra-filtrate	 through	a	10,000	kDa	 (kilo-Daltons)	molecular	weight	 cut-off	filter	to	eliminate	protein.		Reagent	preparation:	1. Reaction	diluent	(1X)	-	dilute	30	mls	(10X)	of	reaction	diluent	concentrate	into	deionised	water	to	prepare	300ml	of	reaction	diluent	(X1).	2. Prepare	standards	using	the	appropriate	2000	μmol/l	standard	stock	and	reaction	 diluent	 (X1),	 (100	 μmol/l,	 50	 μmol/l,	 25	 μmol/l,	 12.5	 μmol/l,	6.25	 μmol/l	 and	 3.12	 μmol/l	 concentration)	 vortex	 thoroughly	 prior	 to	use.	3. Reconstitute	NADH	with	5.0ml	of	deionised	water,	allow	to	sit	for	3	min,	with	gentle	agitation	then	place	on	ice	until	needed.	4. Reconstitute	 nitrate	 reductase	 with	 1	 ml	 nitrate	 reductase	 storage	diluent,	 vortex	 and	 allow	 to	 sit	 for	 15	 minutes	 at	 room	 temperature.		Vortex	 again	 and	 allow	 to	 sit	 for	 a	 further	 15	 minutes	 then	 use	immediately	for	step	5.	5. Dilute	 Nitrate	 reductase	 immediately	 before	 use.	 Using	 following	equation:		1. Nitrate	reductase	(μl)	=	(#	wells	+	2)	x	5	μl.	2. Reaction	buffer	(μl)	=	volume	from	step	a	x	4.	3. Add	volumes	from	step	a	and	b	to	a	tube	and	vortex.	Place	in	ice	and	use	within	15	minutes.					
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Nitrite	Assay	procedure:	1. Prepare	reagents,	standards	and	samples	as	described.		2. Add	50	μl	of	 reaction	diluent	 to	any	blank	wells	of	 the	supplied	96	well	plate		3. Add	50	μl	of	nitrite	standard	or	sample	to	remaining	wells.	4. Add	50	μl	of	reaction	diluent	to	all	wells	5. Add	50	μl	of	Griess	reagent	I	to	all	wells.	6. Add	50	μl	of	Griess	 reagent	 II	 to	all	wells	 and	mix	by	 tapping	at	 side	of	plate.	7. Incubate	for	10	minutes	at	room	temp.	8. Determine	the	optical	density	for	each	well	using	a	microplate	reader	set	at	540-570	nm		Nitrate	Assay	procedure:	1. Prepare	reagents,	standards	and	samples	as	described.	2. Add	50	μl	of	reaction	diluent	to	any	blank	wells	3. Add	50	μl	of	nitrite	standard	or	sample	to	remaining	wells.	4. Add	25	μl	of	NADH	to	all	wells.	5. Add	25	μl	of	nitrate	reductase	into	all	wells,	mix	by	tapping	on	the	side	of	plate	and	cover	with	adhesive	tape.	6. Incubate	for	30	min	at	37oC.	7. Add	50	μl	of	Griess	reagent	I	to	all	wells.	8. Add	50	μl	of	Griess	 reagent	 II	 to	all	wells	 and	mix	by	 tapping	at	 side	of	plate.	9. Incubate	for	10	min	at	room	temp.	10. Determine	the	optical	density	for	each	well	using	a	microplate	reader	set	at	540-570	nm.	
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Appendix	3:		Study	Consent	Form	
		
Role	of	Nitric	Oxide	and	Interferon	Gamma	Polymorphisms	in	the	
Development	of	Delayed	Graft	Function	in	Non	Heart	Beating	Donor	
Transplants.	(IFNO)		Please	initial	box		1. 							I	confirm	that	I	have	read	and	understood	the	information	sheet	dated	14.01.2012	for	the	above	study	(Version	4)	and	have	had	the	opportunity	to	ask	questions.		2. I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to		withdraw	at	any	time,	without	giving	reason,	without	my	medical	care	or	legal	rights	being	affected.		3. I	understand	that	sections	of	any	of	my	medical	notes	may	be	looked	at	by	the	investigators	or	by	individuals	from	regulatory	authorities	where	it	is	relevant	to	my	taking	part	in	the	research.	I	give	permission	for	these	individuals	to	have	access	to	my	records.		4.	 I	understand	that	samples	will	be	taken	to	test	my	genetic	material	that	affects	the	production	of	cytokines	in	relation	to	the	study	.		5.	 I	understand	that	I	will	not	benefit	financially	if	this	research		leads	to	the	development	of	new	treatment	or	test.			6.	 I	agree	to	take	part	in	the	above	study.							7.	 I	agree	to	my	GP	being	informed	of	my	taking	part	in	this	study.																																																																																																																												Name	of	Patient																																					Date																																Signature			Name	of	Person	taking	consent													Date																																Signature	(If	different	from	researcher)			Researcher																																														Date																																Signature		(1	for	patient;			1	for	researcher;			1	to	be	kept	with	hospital	notes)	
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Appendix	4:		Luminex	Assay	
	Reagent	preparation	1. Wash	 buffer.	 	 Add	 20	 ml	 of	 wash	 buffer	 concentrate	 to	 480	 ml	 of	deionized	water.	2. Make	up	the	standards	using	3	fold	dilutions	of	calibrator	diluent.		Leave	to	sit	for	15	minutes.	3. Reconstitute	 standard	 cocktails	 1	 and	 2	with	 calibrator	 diluent	RD6-40.		Referring	 to	 the	 standard	 value	 cards	 supplied	 with	 the	 kits	 (varies	according	to	lot.	and	analyte).		Assay	procedure	1. Pre	wet	the	plate	with	100	μl	of	wash	buffer	and	take	the	liquid	off	using	a	vacuum	manifold.	2. Prepare	 the	 micro-particle	 cocktail	 by	 adding	 microparticles	 to	 the	microparticle	diluent.		Volumes	used	will	depend	on	the	number	of	wells	on	 the	 plate	 being	 utilised	 on	 a	 particular	 run	 according	 to	 the	manufacturer’s	instructions.	3. Vortex	the	diluted	micropartlcle	cocktail	and	add	50μl	to	each	plate	4. Add	 standard	 or	 samples	 to	 the	 plate	 (this	 must	 be	 done	 within	 15	minutes	to	avoid	degradation	of	the	light	sensitive	micro-particle	cocktail.	5. Cover	 the	 plate	 with	 foil	 and	 incubate	 for	 3	 hours	 on	 the	 microplate	shaker	at	room	temperature.	6. Use	the	vacuum	manifold	to	remove	the	liquid	and	wash	a	further	3	times	using	100	μl	of	wash	buffer	each	time,	taking	the	buffer	off	at	the	end.	7. Prepare	 the	 biotin	 antibody	 cocktail	 by	 diluting	 biotin	 antibodies	 in	 the	biotin	 antibody	diluent	 2.	 	 Volumes	used	will	depend	 on	 the	 number	 of	wells	 on	 the	 plate	 being	 utilised	 on	 a	 particular	 run	 according	 to	 the	manufacturers	instructions.	8. Add	50	μl	of	diluted	biotin	antibody	cocktail	to	each	well,	cover	with	foil	and	incubate	for	1	hour	on	the	microplate	shaker.	9. Repeat	wash	step	6.	
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10. Dilute	the	100x	Streptavidin	PE	to	a	1X	concentration	using	wash	buffer.		Volumes	 used	 will	 depend	 on	 the	 number	 of	 wells	 on	 the	 plate	 being	utilised	on	a	particular	run	according	to	the	manufacturers	instructions.	11. Add	 50	 μl	 of	 diluted	 Streptavidin	 PE	 to	 each	well.	 	 Cover	with	 foil	 and	incubate	for	30	minutes	at	room	temperature	on	the	microplate	shaker.	12. Repeat	wash	step	6.	13. Add	 100	 μl	 to	 each	 well	 and	 Incubate	 on	 the	 microplate	 shaker	 for	 a	further	2	minutes.	14. Read	within	90	minutes	using	Bio-Rad®	analyser.																									
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Appendix	5:		ELISA	Assay	
	Reagent	preparation	All	reagents	should	be	brought	to	room	temperature	before	use.	1. Reconstitute	 the	 IFN-γ	 standard	 using	 calibrator	 diluent	 RD6-21,	referring	to	the	standard	value	cards	supplied	with	the	kits	for	the	volume	required,	 as	 this	 varies	 according	 to	 lot.	 Allow	 to	 stand	 with	 gentle	agitation	for	15	minutes.	2. Wash	buffer.	 	Add	20	ml	of	wash	buffer	concentrate	to	480	ml	deionized	water	to	prepare	500	ml	of	wash	buffer.	3. Make	 up	 the	 standards	 using	 serial	 dilutions	 of	 the	 prepared	 IFN-γ	standard,	 undiluted	 this	 serves	 as	 the	 highest	 standard,	 to	 produce	 a	dilution	series.	4. Substrate	 solution.	 	This	should	not	be	prepared	until	 immediately	before	
use	 in	 step	 x	 below.	 Equal	 amounts	 of	 colour	 reagents	 A+B	 should	 be	mixed	 together.	 	 The	 absolute	 amount	 should	 be	 calculated	 on	 the	 day	depending	on	the	number	of	wells	being	used	on	the	plate.		Assay	procedure	1. Add	100	μl	of	assay	diluent	RD1-51	to	each	well	of	the	plate.	2. Add	100	μl	of	standard	or	sample	to	the	wells,	after	this	point	the	reagent	MUST	be	added	to	the	plate	within	15	minutes.	3. Cover	the	plate	and	incubate	at	room	temperature	for	2	hours	with	gentle	agitation.	4. Wash	 step.	 	 Aspirate	 the	 contents	 of	 the	wells	 and	 add	 400	 μl	 of	 wash	buffer.		Repeat	the	aspiration	and	wash	for	a	total	of	4	washes.	5. Add	200	μl	IFN-γ	conjugate	to	each	well,	cover	and	incubate	for	a	further	2	hours,	with	gentle	agitation	at	room	temperature.	6. Repeat	the	wash	as	in	step	4.	7. Add	 200	 μl	 of	 the	 substrate	 solution	 (which	 should	 be	 made	 up	immediately	before	use)	8. The	plate	must	now	be	protected	from	the	light.		Incubate	the	plate	for	30	min	at	room	temperature	in	a	dark	cupboard.	
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9. Add	50	μl	stop	solution	to	each	well.		N.B.		The	colour	should	now	change	from	blue	to	yellow.	10. Using	 the	 Bio-Rad®	 analyser,	 determine	 the	 optical	 density	within	 each	well.	 	 The	wavelength	 frequency	 should	 be	 set	 to	 540nm	 and	 the	 plate	should	be	read	within	30	min.		
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